EGFR inhibitors in treatment of cancer

Abstract

The present invention relates to compounds of formula (A), i.e., inhibitors of EGFR. The inhibitors described herein are useful in the treatment of diseases or conditions associated with EGFR, such as lung cancer. In particular, the present invention relates to compounds and pharmaceutical compositions that inhibit EGFR kinase activity in cells, methods of treating diseases or conditions associated with EGFR, and methods of synthesizing these compounds. # imgabs0 #

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority and benefit to U.S. Provisional Patent Application Serial No. 63 / 332835, entitled “EGFR Inhibitors in Cancer Treatment,” filed April 20, 2022, the disclosure of which is incorporated herein by reference in its entirety for all purposes. Technical Field

[0003] This invention relates to inhibitors of epidermal growth factor receptor (EGFR or EGF receptor) – a family of tyrosine kinases. The inhibitors described herein can be used to treat EGFR-related diseases or conditions, such as cancer. Specifically, this invention relates to compounds and pharmaceutical compositions that inhibit EGFR, methods for treating EGFR-related diseases or conditions, and methods for synthesizing these compounds. Background Technology

[0004] The physiological function of the epidermal growth factor receptor (EGFR) is to regulate epithelial tissue development and homeostasis. EGFR is a tyrosine kinase receptor for various growth factors, including EGF (epidermal growth factor), TGF-α (transforming growth factor-α), and other EGF-like ligands. The EGFR pathway plays a crucial role in lung physiology, particularly in the function of epithelial cells through signal transduction, regulating key cellular processes such as self-renewal, wound healing, proliferation, survival, adhesion, migration, and differentiation. EGFR is a transmembrane protein with cytoplasmic kinase activity that transduces important growth factor signals from the extracellular environment to the cell.

[0005] EGFR gene amplification, overexpression, and mutation are frequently observed in various cancer indications and are associated with poor prognosis. Epidermal growth factor receptor (EGFR) overactivation has been observed in a large number of cancers.

[0006] In pathological settings, primarily in lung and breast cancer, and glioblastoma, EGFR is a driver of tumorigenesis. Inappropriate activation of EGFR in cancer is mainly due to amplification and point mutations at genomic loci, but transcriptional upregulation or ligand overproduction due to autocrine / paracrine mechanisms has also been described. Furthermore, EGFR is increasingly considered a biomarker of drug resistance in tumors, as its amplification or secondary mutations have been found to occur under drug stress. This evidence, in addition to the receptor's prominent function in normal epithelial cells, has spurred further investigation into the physiological and pathological roles of EGFR.

[0007] High abundance of EGFR and large internal deletions are frequently observed in brain tumors, while point mutations and small insertions within the kinase domain are common in lung cancer.

[0008] Given that over 60% of non-small cell lung cancer (NSCLC) expresses EGFR, EGFR has become an important therapeutic target for these tumors. EGFR inhibitors are widely used to treat NSCLC.

[0009] Several recent reports have shown that epidermal growth factor receptor (EGFR) inhibitors have beneficial effects on improving pathological and behavioral conditions in neurodegenerative diseases (NDDs) such as Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS), as well as brain and spinal cord injuries (SCIs).

[0010] In summary, EGFR is a promising drug target for cancer treatment. Targeting EGFR and its downstream signaling cascades is considered a rational and valuable approach in cancer therapy. In recent years, various synthetic EGFR tyrosine kinase inhibitors (TKIs) have been evaluated, most of which have demonstrated clinical efficacy in relevant models and are classified into first-, second-, third-, and fourth-generation inhibitors. However, given resistance to current inhibitors, research continues to seek more potent EGFR inhibitors.

[0011] EGFR inhibitors have produced impressive therapeutic effects on responsive types of cancer. Unfortunately, however, patients who initially respond to anti-EGFR drugs almost inevitably develop resistance. Addressing the resistance mechanisms translates into a more granular mapping of signaling pathways and holds promise for prolonging patient responses. A novel targeted therapy specifically targeting the EGFR-C797S acquired resistance mutation would be highly beneficial for these patients.

[0012] In particular, patients with primary resistance to approved anti-EGFR therapies due to EGFR exon 20 insertion have had very limited treatment options to date, making new alternative and / or improved therapies essential to provide these patients with effective and well-tolerated treatment options. Therefore, potent inhibitors of mutant EGFR that exhibit higher selectivity compared to wild-type EGFR, especially potent inhibitors of mutant EGFR with exon 20 insertion mutations, represent valuable compounds that should be used as monotherapy or in combination with other drugs to supplement treatment options. Summary of the Invention

[0013] The first aspect of the present invention relates to compounds of formula (A):

[0014]

[0015] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein...

[0016] R a Selected from H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C 10 Cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein the alkyl, alkenyl, ynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally and independently selected from halogen, OH, =O, NR. 3 R 4 CN, NO2, COOR 1 CONR 3 R 4 One or more substituents are substituted in the sample;

[0017] R b 、R c 、R d Each is independently selected from H, halogen, OH, NH2, CN, NO2, C1-C6 alkyl and C1-C6 alkoxy, wherein the alkyl or alkoxy group is optionally substituted by one or more halogens or CN; X is selected from bond, O, NR. 1 C(R) 2 )2, S, S(O), S(O)2, C(O), C(O)O, C(O)NR 1 ,OC(O)O,N(R) 2 )C(O)NR 2 , arenediyl;

[0018] R 1 Selected from H, C1-C6 alkyl, C3-C 10 Cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 acyl, heterocyclic, aryl, heteroaryl and S(O)2R 2 The alkyl, alkenyl, alkynyl, heterocyclic, cycloalkyl, aryl, or heteroaryl groups are optionally and independently selected from halogens, OH, NH2, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10 One or more substituents selected from cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocyclic, aryl, and heteroaryl are used for substitution;

[0019] Each R 2 Independently selected from H, C1-C6 alkyl, C3-C 10 Cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocyclic, aryl, and heteroaryl, wherein the alkyl, alkenyl, alkynyl, heterocyclic, cycloalkyl, aryl, or heteroaryl group is optionally and independently selected from halogen, OH, NH2, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10One or more substituents selected from cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocyclic, aryl, and heteroaryl are used for substitution;

[0020] Y is selected from bond, O, NR 1 C(R) 2 )2, S, S(O), S(O)2, C(O), C(O)O, C(O)NR 1 ,OC(O)O,N(R) 2 )C(O)NR 2 ;

[0021] Z is selected from bonds, O, C(R) 2 )2;

[0022] L 1 Selected from heterocyclic dimethyl-C1-C 10 -alkyldiyl, C1-C 10 Alkyl, C2-C 10 alkendiyl, C2-C 10 acetylide diol, C3-C 10 -cycloalkyldiyl, C3-C 10 -cycloalkyldiyl-C1-C 10 -alkyldiyl, aryldiyl, aryldiyl-C1-C 10 -alkyldiyl, heterocyclic diyl, heterocyclic diyl-C(O), heteroaryl, heteroaryl-C1-C 10 Alkyl, C1-C6 alkyldiyl-O-C1-C6 alkyldiyl, C1-C6 alkyldiyl-NR 1 -C1-C6 alkyldiyl, C1-C6 alkyldiyl-C(O)NR 1 -C1-C6 alkyldiyl, wherein the alkyldiyl, alkenyldiyl, alkynyldiyl, aryldiyl, heterocyclic diyl or heteroaryl-heteroaryl group is optionally independently selected from halogen, OH, oxy, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 Substitution with one or more substituents from aryl and -S(O)2C1-C6 alkyl groups;

[0023] L 2 Selected from C1-C 10 Alkyl, C2-C 10 alkendiyl, C2-C 10 acetylide diol, C3-C 10-cycloalkyldiyl, C3-C 10 -cycloalkyldiyl-C1-C 10 -alkyldiyl, aryldiyl, aryldiyl-C1-C 10 -alkyldiyl, heterocyclic diyl, heterocyclic diyl-C1-C 10 -alkyldiyl, heterocyclic diyl-C(O), heteroaryl, heteroaryl-C1-C 10 Alkyl, C1-C6 alkyldiyl-O-C1-C6 alkyldiyl, C1-C6 alkyldiyl-NR 1 -C1-C6 alkyldiyl, C1-C6 alkyldiyl-C(O)NR 1 -C1-C6 alkyldiyl, wherein the alkyldiyl, alkenyldiyl, alkynyldiyl, aryldiyl, heterocyclic diyl or heteroaryl-heteroaryl group is optionally independently selected from halogen, OH, oxy, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 Substitution with one or more substituents from aryl and -S(O)2C1-C6 alkyl groups;

[0024] R 3 and R 4 Each is independently selected from H, C1-C6 alkyl, C1-C6 acyl and C3-C 10 cycloalkyl; or R 3 and R 4 Together with the atoms to which they are attached and any intervening atoms, they form 5-14 membered heterocycles, wherein the heterocycle is optionally substituted by one or more substituents independently selected from halogens, OH, =O, CN, NO2, C1-C6 alkyl, and C1-C6 alkoxy groups;

[0025] in,

[0026] Aryl groups are cyclic, aromatic hydrocarbon groups having one to three aromatic rings;

[0027] Aryl dimethyl groups are organic groups derived from aromatic divalent groups by removing two hydrogens;

[0028] Heterocyclic groups are 3-10 member monocyclic, 7-12 member bicyclic (fused, bridged, or spirocyclic), or 11-14 member tricyclic (fused, bridged, or spirocyclic) systems with one or more heteroatoms selected from O, N, S, P, Se, or B, and are either saturated or partially unsaturated.

[0029] Heterocyclic dimethyl groups are divalent functional groups derived from heterocycles by removing two hydrogen atoms from the ring atoms; heteroaryl groups are monovalent monocyclic or polycyclic aromatic groups containing 5 to 24 ring atoms selected from N, O, S, P or B and the remaining ring atoms are C.

[0030] The heteroaryl dimethyl group is a divalent functional group derived from heteroaryl hydrocarbons by removing two hydrogen atoms from the ring atom.

[0031] Another aspect of the present invention relates to compounds of formula (I):

[0032]

[0033] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof.

[0034] Another aspect of the present invention relates to compounds of formula (II):

[0035]

[0036] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof.

[0037] Another aspect of the invention relates to pharmaceutical compositions comprising a compound of formula (A) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may further comprise an excipient, a diluent, or a surfactant.

[0038] Another aspect of the invention relates to pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may further comprise an excipient, a diluent, or a surfactant.

[0039] Another aspect of the invention relates to pharmaceutical compositions comprising a compound of formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may further comprise an excipient, a diluent, or a surfactant.

[0040] Another aspect of the invention relates to a method for treating EGFR-related diseases or conditions. The method comprises administering to a patient requiring treatment for an EGFR-related disease or condition an effective amount of a compound of formula (A) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0041] Another aspect of the invention relates to a method for treating EGFR-related diseases or conditions. The method comprises administering to a patient requiring treatment for an EGFR-related disease or condition an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0042] Another aspect of the invention relates to a method for treating EGFR-related diseases or conditions. The method comprises administering to a patient requiring treatment for an EGFR-related disease or condition an effective amount of a compound of formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0043] Another aspect of the invention relates to a method for inhibiting EGFR. The method comprises administering to a patient in need an effective amount of a compound of formula (A) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0044] Another aspect of the invention relates to a method for inhibiting EGFR. The method comprises administering to a patient in need an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0045] Another aspect of the invention relates to a method for inhibiting EGFR. The method comprises administering to a patient in need an effective amount of a compound of formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0046] Another aspect of the present invention relates to a compound of formula (A) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer or pharmaceutical composition thereof for use in the manufacture of a medicament for inhibiting EGFR.

[0047] Another aspect of the present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, tautomers or pharmaceutical compositions thereof, for use in the manufacture of a medicament for inhibiting EGFR.

[0048] Another aspect of the present invention relates to compounds of formula (II) or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, tautomers or pharmaceutical compositions thereof, for use in the manufacture of a medicament for inhibiting EGFR.

[0049] Another aspect of the invention relates to the use of a compound of formula (A) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer or pharmaceutical composition thereof in the treatment of diseases and conditions associated with EGFR.

[0050] Another aspect of the invention relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer or pharmaceutical composition thereof in the treatment of diseases and conditions associated with EGFR.

[0051] Another aspect of the invention relates to the use of a compound of formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer or pharmaceutical composition thereof in the treatment of diseases and conditions associated with EGFR.

[0052] Another aspect of the present invention relates to compounds of formula (A) or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, tautomers or pharmaceutical compositions thereof, for use in the manufacture of medicaments for the treatment or prevention of the diseases or conditions disclosed herein.

[0053] Another aspect of the present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, tautomers or pharmaceutical compositions thereof, for use in the manufacture of medicaments for the treatment or prevention of the diseases or conditions disclosed herein.

[0054] Another aspect of the present invention relates to compounds of formula (II) or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, tautomers or pharmaceutical compositions thereof, for use in the manufacture of medicaments for the treatment or prevention of the diseases or conditions disclosed herein.

[0055] Another aspect of the invention relates to a method of treating or preventing the diseases or conditions disclosed herein in a subject in need. The method comprises administering to a patient in need of treatment an effective amount of a compound of formula (A) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0056] Another aspect of the invention relates to a method for treating or preventing the diseases or conditions disclosed herein in a subject in need. The method comprises administering to a patient in need an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0057] Another aspect of the invention relates to a method of treating or preventing the diseases or conditions disclosed herein in a subject in need. The method comprises administering to a patient in need an effective amount of a compound of formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0058] Another aspect of the invention relates to the use of a compound of formula (A) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer or pharmaceutical composition thereof in the treatment of the diseases or conditions disclosed herein.

[0059] Another aspect of the invention relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer or pharmaceutical composition thereof in the treatment of the diseases or conditions disclosed herein.

[0060] Another aspect of the invention relates to the use of a compound of formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer or pharmaceutical composition thereof in the treatment of the diseases or conditions disclosed herein.

[0061] The present invention further provides a method for treating diseases or conditions associated with EGFR, comprising administering to a patient suffering from at least one of said diseases or conditions a compound of formula (A) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0062] The present invention further provides a method for treating diseases or conditions associated with EGFR, comprising administering to a patient suffering from at least one of said diseases or conditions a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0063] The present invention further provides a method for treating diseases or conditions associated with EGFR, comprising administering to a patient suffering from at least one of said diseases or conditions a compound of formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0064] This invention provides an inhibitor of EGFR, which is a therapeutic agent in the treatment of diseases and conditions.

[0065] This invention further provides compounds and compositions that have improved efficacy and safety compared to known EGFR inhibitors. This disclosure also provides medicaments with novel mechanisms of action against EGFR for the treatment of various types of diseases.

[0066] The present invention further provides a method for treating diseases or conditions associated with EGFR, comprising administering to a patient suffering from at least one of said diseases or conditions a compound of formula (A) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0067] The present invention further provides a method for treating diseases or conditions associated with EGFR, comprising administering to a patient suffering from at least one of said diseases or conditions a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0068] The present invention further provides a method for treating diseases or conditions associated with EGFR, comprising administering to a patient suffering from at least one of said diseases or conditions a compound of formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0069] This invention provides an inhibitor of EGFR, which is a therapeutic agent in the treatment of diseases and conditions.

[0070] The present invention further provides a method for treating diseases, symptoms, or conditions selected from the following: Neonatal Inflammatory Skin and Intestinal Disease 2 (NISBD2); Lung cancer; Lung Cancer Susceptibility 3 (LNCR3); Squamous cell carcinoma of the lung; Gliosarcoma; Brainstem glioma; Adenocarcinoma; Colorectal cancer; Glioblastoma; Breast cancer; Squamous cell carcinoma; Small cell lung cancer; Squamous cell carcinoma of the lung; Neonatal Inflammatory Skin and Intestinal Disease 2; Gastric cancer; Prostate cancer; Squamous cell carcinoma of the head and neck; Pancreatic cancer; Brain cancer; Ovarian cancer; Esophageal cancer; Giant cell glioblastoma; Gliosarcoma; Benign lung tumor; Glioma; Herpes simplex; Uterine fibroids; Endometrial cancer; adenoid cystic carcinoma; bladder cancer; Cowden syndrome 1; bronchioloalveolar adenocarcinoma; oligodendroglioma; hepatocellular carcinoma; non-squamous non-small cell lung cancer; high-grade glioma; glial tumor; laryngeal squamous cell carcinoma; non-papillary renal cell carcinoma; chronic kidney disease; nasopharyngeal carcinoma; oral squamous cell carcinoma; lung disease; interstitial lung disease; adenosquamous lung cancer; bile duct carcinoma; familial meningioma; small cell carcinoma; tumor susceptibility syndrome; pancreatic adenocarcinoma; diarrhea; mammary ductal carcinoma.

[0071] In some aspects, this disclosure provides a compound that can be obtained by or through methods for preparing the compound described herein (e.g., methods including one or more steps described in the general procedure).

[0072] In some aspects, this disclosure provides an intermediate as described herein, which is suitable for use in methods for preparing the compounds described herein (e.g., the intermediate is selected from the intermediates described in preparation sections - P1-P79).

[0073] In some aspects, this disclosure provides a method for preparing the compounds of this disclosure.

[0074] In some aspects, this disclosure provides a method for preparing the compounds of this disclosure, comprising one or more steps described herein.

[0075] In some specific non-limiting aspects, this disclosure provides methods for preparing the compounds of this disclosure, as described in Examples 1-20.

[0076] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. In this specification, singular forms also include plural forms unless the context clearly indicates otherwise. Although similar or equivalent methods and materials to those described herein may be used in the practice or testing of this disclosure, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference. References cited herein are not considered prior art to the claimed invention. In case of conflict, this specification (including definitions) shall prevail. Furthermore, materials, methods, and examples are illustrative only and not intended to be limiting. In case of conflict between the chemical structures and names of compounds disclosed herein, the chemical structure shall prevail.

[0077] Other features and advantages of this disclosure will become apparent from the following detailed description and claims. Detailed Implementation

[0078] This disclosure provides a method for treating, preventing, or improving diseases or conditions associated with the inhibition of EGFR by administering a therapeutically effective amount of the disclosed compound to a subject in need.

[0079] Details of this disclosure are set forth in the accompanying description. Although methods and materials similar to or equivalent to those described herein may be used in the practice or testing of this disclosure, illustrative methods and materials are described hereafter. Other features, objects, and advantages of this disclosure will become apparent from the specification and claims. In the specification and appended claims, the singular form also includes the plural form unless the context clearly indicates otherwise. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. All patents and publications referenced in this specification are incorporated herein by reference in their entirety.

[0080] definition

[0081] The articles “a” and “an” are used in this disclosure to refer to one or more (i.e., at least one) grammatical objects of the article. For example, “an element” refers to one element or more elements.

[0082] The term “and / or” is used in this disclosure to mean “and” or “or” unless otherwise stated.

[0083] The term "optionally substituted" should be understood to mean that a given chemical moiety (e.g., an alkyl group) may (but is not required to) be bonded to other substituents (e.g., heteroatoms). For example, an optionally substituted alkyl group may be a fully saturated alkyl chain (i.e., a pure hydrocarbon). Alternatively, the same optionally substituted alkyl group may have one or more substituents other than hydrogen. For example, it may be bonded to a halogen atom, a hydroxyl group, or any other substituent described herein at any point along the chain. Thus, the term "optionally substituted" means that a given chemical moiety may contain other functional groups, but does not necessarily have any further functional groups. Suitable substituents for optional substitutions of the said group include, but are not limited to, halogens, oxy groups, -OH, -CN, -COOH, -CH2CN, -O-(C1-C6)alkyl, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, -O-(C2-C6)alkenyl, -O-(C2-C6)ynyl, (C2-C6)alkenyl, (C2-C6)ynyl, -OH, and -OP(O)(OH). 2. -OC(O)(C1-C6)alkyl, -C(O)(C1-C6)alkyl, -OC(O)O(C1-C6)alkyl, -NH2, -NH((C1-C6)alkyl), -N((C1-C6)alkyl)2, -NHC(O)(C1-C6)alkyl, -C(O)NH(C1-C6)alkyl, -S(O)2(C1-C6)alkyl, -S(O)NH(C1-C6)alkyl, and -S(O)N((C1-C6)alkyl)2. The substituent itself may be optionally substituted. As used herein, "optionally substituted" also refers to substituted or unsubstituted, as defined below.

[0084] As used herein, the term “substituted” means a specified group or portion having one or more suitable substituents, wherein the substituents may be attached to the specified group or portion at one or more positions. For example, an aryl group substituted with a cycloalkyl group may mean that the cycloalkyl group is attached to an atom of the aryl group by a bond or by fusion with the aryl group and sharing two or more common atoms.

[0085] As used herein, the term “unsubstituted” means that the specified group does not contain substituents.

[0086] Unless otherwise specifically defined, the term "aryl" refers to a cyclic aromatic hydrocarbon group having one to three aromatic rings, including monocyclic or bicyclic groups such as phenyl, biphenyl, or naphthyl. When containing two aromatic rings (bicyclic, etc.), the aromatic rings of the aryl group may be connected at a single point (e.g., biphenyl) or fused (e.g., naphthyl). The aryl group may optionally be substituted at any connection point with one or more substituents (e.g., one to five substituents). Exemplary substituents include, but are not limited to, -H, -halogen, -O-(C1-C6)alkyl, (C1-C6)alkyl, -O-(C2-C6)alkenyl, -O-(C2-C6)ynyl, (C2-C6)alkenyl, (C2-C6)ynyl, -OH, -OP(O)(OH)2, -OC(O)(C1-C6)alkyl, -C(O)(C1-C6)alkyl, -OC(O)O(C1-C6)alkyl, -NH2, -NH((C1-C6)alkyl), -N((C1-C6)alkyl)2, -S(O)2-(C1-C6)alkyl, -S(O)NH(C1-C6)alkyl, and -S(O)N((C1-C6)alkyl)2. The substituent itself may optionally be substituted. Furthermore, when containing two fused rings, the aryl group defined herein may have one or more saturated or partially unsaturated rings fused to a fully unsaturated aromatic ring. Exemplary ring systems of these aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, anthracene, phenatenyl, phenanthyl, indanyl, indenyl, tetrahydronaphthyl, tetrahydrobenzocycloalkenyl, etc.

[0087] "Arandibralyl," "arylene," or "arylene" refers to an organic group derived from an aromatic divalent group by removing at least two hydrogens from a group such as phenyl, naphthyl, indenyl, indanyl, and fluorenyl. Arylene groups typically exist as bridging or linking groups between two other groups. Non-exclusive examples of such arylene groups include 1,2-disubstituted phenyl, 1,3-disubstituted phenyl, and 1,4-disubstituted phenyl.

[0088] Unless otherwise specifically defined, a "heteroaryl" refers to a monovalent monocyclic or polycyclic aromatic group having 5 to 24 ring atoms, containing one or more cyclic heteroatoms selected from N, O, S, P, or B, with the remaining ring atoms being C. Polycyclic aromatic groups include two or more fused rings and may further include two or more spirofused rings, such as bicyclic, tricyclic, tetracyclic, etc. Unless otherwise specifically defined, "fused" refers to two rings sharing two ring atoms. Unless otherwise specifically defined, "spirofused" refers to two rings sharing one ring atom. The heteroaryl defined herein also refers to a bicyclic heteroaryl group, wherein the heteroatom is selected from N, O, S, P, or B. The heteroaryl defined herein also refers to a tricyclic heteroaryl group containing one or more cyclic heteroatoms selected from N, O, S, P, or B. The heteroaryl defined herein also refers to a tetracyclic heteroaryl group containing one or more cyclic heteroatoms selected from N, O, S, P, or B. Aromatic groups may optionally be independently substituted by one or more substituents described herein.Examples include, but are not limited to, furanyl, thiophene, pyrrolyl, pyridyl, pyrazolyl, pyrimidinyl, imidazoleyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazinyl, indoleyl, thiophene-2-yl, quinolinyl, benzopyranyl, isothiazolyl, thiazolyl, thiadiazole, indazole, benzimidazolyl, thieno[3,2-b]thiophene, triazolyl, triazinyl, imidozolo[1,2-b]pyrazolyl, furan[2,3-c]pyridyl, imidozolo[1,2-a]pyridyl, indazoleyl, pyrrolo[2,3-c]pyridyl, pyrrolo[3,2-c]pyridyl, pyrazolo[3,4-c]pyridyl, thieno[3,2-c]pyridyl, thieno[3,2-c]pyridyl, thieno[ [2,3-c]pyridyl, thieno[2,3-b]pyridyl, benzothiazolyl, indole, indolinyl, indoleketone, dihydrobenzothiaphenyl, dihydrobenzofuranyl, benzofuran, benzodihydropyranyl, thiobenzodihydropyranyl, tetrahydroquinolinyl, dihydrobenzothiazine, quinolinyl, isoquinolinyl, 1,6-naphthidyl, benzo[de]isoquinolinyl, pyrido[4,3-b][1,6]naphthidyl, thieno[2,3-b]pyrazinyl, quinazolinyl, tetrazo[1,5-a]pyridyl, [1,2,4]triazo[4,3-a]pyridyl, isoindolyl, pyrrolo[2,3-b]pyridyl, pyrrolo[3,4]pyridyl -b]pyridyl, pyrrolo[3,2-b]pyridyl, imidazo[5,4-b]pyridyl, pyrrolo[1,2-a]pyrimidinyl, tetrahydropyrrolo[1,2-a]pyrimidinyl, 3,4-dihydro-2H-1-pyrrolo[2,1-b]pyrimidinyl, dibenzo[b,d]thiophene, pyridin-2-one, furan[3,2-c]pyridyl, furan[2,3-c]pyridyl, 1H-pyrido[3,4-b][1,4]thiazinyl, benzoxazoleyl, benzoisoxazoleyl, furan[2,3-b]pyridyl, benzothiopheneyl, 1,5-naphthidyl, furan[3,2-b]pyridine, [1,2,4]triazol[1 [,5-a]pyridyl, benzo[1,2,3]triazolyl, imidazo[1,2-a]pyrimidinyl, [1,2,4]triazol[4,3-b]pyridazinyl, benzo[1,2,5]thiadiazolyl, benzo[c][1,2,5]oxadiazole, 1,3-dihydro-2H-benzo[d]imidazol-2-one, 3,4-dihydro-2H-pyrazolo[1,5-b][1,2]oxazinyl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridyl, thiazo[5,4-d]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, thieno[2,3-b]pyrroleyl, 3H-indolyl and their derivatives. Furthermore, when containing two or more fused rings, the heteroaryl group defined herein may have one or more saturated or partially unsaturated rings fused with one or more fully unsaturated aromatic rings.In heteroaryl ring systems containing more than two fused rings, a saturated or partially unsaturated ring may be further fused with a saturated or partially unsaturated ring as described herein. Furthermore, when three or more fused rings are present, the heteroaryl group as defined herein may have one or more saturated or partially unsaturated spirofused rings. Any saturated or partially unsaturated ring described herein may optionally be substituted with one or more oxygen groups. Exemplary ring systems of these heteroaryl groups include, for example, indololinyl, indololinone, dihydrobenzothiophene, dihydrobenzofuran, benzodihydropyranyl, thiobenzodihydrothiophene, tetrahydroquinolinyl, dihydrobenzothiazine, 3,4-dihydro-1H-isoquinolinyl, 2,3-dihydrobenzofuranyl, benzofuranone, indololinyl, hydroxyindolyl, indolyl, 1,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one, 7,8-dihydro-6H-pyrido[3,2-b]pyrrolazinyl, 8H-pyrido[3,2-b]pyrrolazinyl, 1,5,6,7-tetrahydrocyclopentane[b]pyrazolo[4,3- e]pyridyl, 7,8-dihydro-6H-pyrido[3,2-b]pyrrolizine, pyrazolo[1,5-a]pyrimidin-7(4H)-keto, 3,4-dihydropyrazolo[1,2-a]indole-1(2H)-keto, benzo[c][1,2]oxaborol-1(3H)-ol, 6,6a,7,8-tetrahydro-9H-pyrido|2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-keto or 6a',7'-dihydro-6'H,9'H-spiro[cyclopropane-1,8'-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin]-9'-keto.

[0089] As used in this article, the term "heteroary dimethyl" refers to a divalent functional group derived from heteroaryl hydrocarbons by removing two hydrogen atoms from a ring atom.

[0090] "Halogen" or "halogenated" refers to fluorine, chlorine, bromine, or iodine.

[0091] "Alkyl" refers to a straight-chain or branched saturated hydrocarbon containing 1 to 12 carbon atoms. Examples of (C1-C6) alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, and isohexyl.

[0092] "Alkyl", "alkylene", or "alkylenyl" refers to a straight-chain or branched saturated hydrocarbon bimethyl group containing 1 to 12 carbon atoms. Unless otherwise stated, such alkylides include substituted alkylides. Typical alkylene groups include, but are not limited to, -CH2-, -CH(CH3)-, -C(CH3)2-, -CH2CH2-, -CH2CH(CH3)-, -CH2C(CH3)2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, etc.

[0093] "Alkoxy" refers to a straight-chain or branched saturated hydrocarbon containing 1-12 carbon atoms, with a terminal "O", i.e., -O (alkyl). Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, tert-butoxy, or pentoxy.

[0094] "Alkenyl" refers to a straight-chain or branched unsaturated hydrocarbon containing 2 to 12 carbon atoms. An "alkenyl" group contains at least one double bond in the chain. The double bond in an alkenyl group can be non-conjugated or conjugated with another unsaturated group. Examples of alkenyl groups include vinyl, propenyl, n-butenyl, isobutenyl, pentenyl, or hexenyl. Alkenyl groups can be unsubstituted or substituted. Alkenyl groups as defined herein can be straight-chain or branched.

[0095] "Alkenadiyl" refers to a straight-chain or branched alkenadiyl containing 2 to 12 carbon atoms. Unless otherwise specified, such alkenadiyl includes substituted alkenadiyl. An alkenadiyl contains at least one double bond in its chain. The double bond in an alkenadiyl can be non-conjugated or conjugated with another unsaturated group. Examples of alkenyl groups include ethylenediyl, propylenediyl, n-butenediyl, isobutenediyl, pentenediyl, or hexenediyl.

[0096] "Alynyl" refers to a straight-chain or branched unsaturated hydrocarbon containing 2 to 12 carbon atoms. An alkynyl group contains at least one triple bond in its chain. Examples of alynyl groups include ethynyl, propynyl, n-butynyl, isobutynyl, pentyynyl, or hexynyl. Alynyl groups can be unsubstituted or substituted.

[0097] "Alyndiyl" refers to a straight-chain or branched unsaturated hydrocarbon dimethyl group containing 2-12 carbon atoms. An alkyndiyl contains at least one triple bond in its chain. Examples of alyndiyl groups include ethyndiyl, propyndiyl, n-butyndiyl, isobutyndiyl, pentyyndiyl, or hexyndiyl. Alyndiyl groups can be unsubstituted or substituted.

[0098] “Cycloalkyl” refers to a monocyclic or polycyclic saturated carbon ring containing 3 to 18 carbon atoms. Polycyclic cycloalkyl groups can be fused bicyclic cycloalkyl groups, bridged bicyclic cycloalkyl groups, or spiro-fused bicyclic cycloalkyl groups. Polycyclic cycloalkyl groups contain at least one non-aromatic ring. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, norbornenyl, 1,2,3,4-tetrahydronaphthyl, 2,3-dihydro-1H-indenyl, spiro[3.5]nonyl, spiro[5.5]undecyl, bicyclic[1.1.1]pentyl, bicyclic[2.2.2]octyl, or bicyclic[2.2.2]octenyl.

[0099] "Cycloalkyldiyl" refers to a divalent functional group derived from cycloalkanes by removing two hydrogen atoms from a ring atom. Cycloalkyldiyl groups can be monocyclic or polycyclic saturated carbon rings containing 3-18 carbon atoms. Polycyclic cycloalkyldiyl groups can be fused bicyclic cycloalkyl groups, bridged bicyclic cycloalkyl groups, or spiro-fused bicyclic cycloalkyldiyl groups. Polycyclic cycloalkyldiyl groups contain at least one non-aromatic ring.

[0100] "Heterocyclic group," "heterocycle," or "heterocyclic alkyl" is a monocyclic or polycyclic compound containing 3 to 24 atoms, comprising a carbon atom and one or more heteroatoms selected from N, O, S, P, or B, wherein said ring is not aromatic. Heterocyclic alkyl ring structures may be substituted with one or more substituents. The substituent itself may optionally be substituted. Examples of heterocyclic rings include, but are not limited to, oxacyclobutyl, azacyclobutyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl, dioxolinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, piperazine, azaheptanyl, oxepinyl, diazaheptanyl, tropanyl, oxazolidinone, and isotropinyl.

[0101] As used in this article, the term "heterocyclic dimer" refers to a divalent functional group derived from a heterocycle by removing two hydrogen atoms from the ring atom.

[0102] The term "aromatic" refers to a planar ring with 4n+2 electrons in a conjugated system. As used herein, a "conjugated system" refers to a system with connected p orbitals containing delocalized electrons, and this system may include lone pairs.

[0103] As used herein, the term "haloalkyl" refers to an alkyl group as defined herein that has been substituted with one or more halogens. Examples of haloalkyl groups include, but are not limited to, trifluoromethyl, difluoromethyl, pentafluoroethyl, trichloromethyl, etc.

[0104] As used herein, the term "haloalkoxy" refers to an alkoxy group substituted with one or more halogens as defined herein. Examples of halogenated alkyl groups include, but are not limited to, trifluoromethoxy, difluoromethoxy, pentafluoroethoxy, trichloromethoxy, etc.

[0105] As used in this article, the term "cyano" refers to a substituent group in which a carbon atom is bonded to a nitrogen atom via a triple bond, i.e., C≡N.

[0106] The term "solvent" refers to a complex of variable stoichiometry formed by a solute and a solvent. Such solvents used for the purposes of this disclosure may not interfere with the biological activity of the solute. Examples of suitable solvents include, but are not limited to, water, MeOH, EtOH, and AcOH. Solvents in which water is the solvent molecule are generally referred to as hydrates. Hydrates include compositions containing a stoichiometric amount of water, as well as compositions containing a variable amount of water.

[0107] The term "isomer" refers to compounds that have the same composition and molecular weight but differ in physical and / or chemical properties. Structural differences may lie in their ability to form (geometric isomers) or rotate the plane of polarization (stereoisomers). For stereoisomers, compounds of formula (A) may have one or more asymmetric carbon atoms and may appear as racemates, racemic mixtures, and individual enantiomers or diastereomers.

[0108] The term "stereoisomer" refers to compounds that have the same molecular formula and bonded atomic sequence (composition) but whose atoms have different three-dimensional orientations in space.

[0109] This disclosure also considers isotopically labeled compounds of formula I (e.g., using...). 2 H and 14 Those marked with C). Deuteration (i.e. 2 H or D) and carbon-14 (i.e., H or D) and carbon-14 14 C) Isotopes are particularly preferred due to their ease of preparation and detectability. Furthermore, substitution with a heavier isotope (e.g., deuterium) can provide certain therapeutic advantages due to greater metabolic stability (e.g., increased in vivo half-life or reduced dose requirement), and may therefore be preferred in some cases. Isotopically labeled compounds of Formula I can generally be prepared by following procedures similar to those disclosed in the schemes and / or examples below, by replacing non-isotopically labeled reagents with appropriately isotopically labeled reagents.

[0110] This disclosure also includes pharmaceutical compositions comprising a therapeutically effective amount of the disclosed compound and a pharmaceutically acceptable carrier. Representative “pharmaceutically acceptable salts” include, for example, water-soluble and water-insoluble salts such as acetates, 4,4-diaminostilbene-2,2-disulfonate, benzenesulfonate, benzoate, bicarbonate, bisulfate, tartrate, borate, bromide, butyrate, calcium, calcium edetate, camphorsulfonate, carbonate, chloride, citrate, clavulanate, dihydrochloride, edetate, ethanedisulfonate, etolate, ethanesulfonate, fumarate, gluconate, gluconate, glutamate, glycolylarsanilate, hexafluorophosphate, hexyl isophthalate, and hydrabami. (ne), hydrobromide, hydrochloride, hydroxynaphthylcarboxylate, iodide, isothiosulfate, lactate, lacturonate, laurate, magnesium, malate, maleate, mandelate, methanesulfonate, methyl bromide, methyl nitrate, methyl sulfate, acetal, naphthalene sulfonate, nitrate, N-methylglucosamine ammonium salt, 3-hydroxy-2-naphthylcarboxylate, oleate, oxalate, palmitate, dihydroxynaphthylcarboxylate, pantothenate, phosphate / hydrogen phosphate, picrate, polygalacturonate, propionate, p-toluenesulfonate, salicylate, stearate, basic acetate, succinate, sulfate, sulfosalicylate, tannate, tartrate, theochloroate, toluenesulfonate, triethyliodide, and valerate.

[0111] "Patient" or "subject" is a mammal, such as a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or a non-human primate, such as a monkey, chimpanzee, baboon, or rhesus monkey.

[0112] When used in combination with a compound, an “effective amount” is an amount that is effective in treating or preventing the disease in the subjects described herein.

[0113] As used in this disclosure, the term "carrier" encompasses carriers, excipients, and diluents, and refers to materials, compositions, or vehicles involved in carrying or transporting a pharmaceutical agent from one organ or part of a subject to another organ or part of the body, such as liquid or solid fillers, diluents, excipients, solvents, or encapsulating materials.

[0114] The term "treatment" in relation to a subject refers to the improvement of at least one symptom of the subject's condition. Treatment includes cure, improvement, or at least partial improvement of the condition.

[0115] Unless otherwise stated, the term “symptom” is used in this disclosure to mean the term disease, condition or discomfort, and may be used interchangeably with the terms disease, condition or discomfort.

[0116] As used in this disclosure, the terms “administer,” “administering,” or “administration” mean the direct administration of the disclosed compound or a pharmaceutically acceptable salt or composition of the disclosed compound to a subject, or the administration of a prodrug derivative or analog of the compound or a pharmaceutically acceptable salt of the compound or composition to a subject, which may form an equivalent amount of the active compound in the subject’s body.

[0117] As used in this disclosure, the term "prodrug" refers to a compound that can be converted into the disclosed compound in vivo through metabolism (e.g., through hydrolysis).

[0118] The term "salt" refers to a pharmaceutically acceptable salt.

[0119] The term "pharmaceutically acceptable salt" also refers to the salts of the compositions and bases of this disclosure that have acidic functional groups (e.g., carboxylic acid functional groups).

[0120] Symbols used in this disclosure It refers to a double bond with E- or Z- configuration or a double bond with a mixture of E- and Z- configurations.

[0121] As used in this article, "EGFR inhibitor" refers to a compound of formula I that inhibits EGFR and / or a composition containing a compound of formula I.

[0122] The amount of compounds of the composition described herein required to achieve a therapeutic effect can be empirically determined based on routine procedures for a particular purpose. Generally, for therapeutic agents administered for therapeutic purposes (e.g., compounds or compositions of Formula I described herein (and / or adjunct agents)), the therapeutic agent is administered at a pharmacologically effective dose. "Pharmacologically effective dose," "therapeuticly effective dose," or "effective dose" means an amount sufficient to produce the desired physiological effect or to achieve the desired result, particularly for the treatment of a symptom or disease. Effective doses as used herein can include amounts sufficient, for example, to delay the development of symptoms of a symptom or disease, to alter the course of symptoms of a symptom or disease (e.g., to slow the progression of disease symptoms), to reduce or eliminate one or more symptoms or clinical manifestations of a symptom or disease, and to reverse the symptoms of a symptom or disease. For example, administering a therapeutic agent to a subject with cancer provides a therapeutic benefit not only when the underlying condition is eradicated or improved, but also when the subject reports a reduction in the severity or duration of disease-related symptoms, such as a reduction in tumor burden, a reduction in circulating tumor cells, or an increase in progression-free survival. Therapeutic benefits also include stopping or slowing the progression of the underlying disease or symptom, regardless of whether improvement is achieved.

[0123] Compounds of the present disclosure

[0124] In one aspect, this disclosure provides compounds of formula (A) and their salts, stereoisomers, solvates, prodrugs, isotope derivatives, and tautomers:

[0125]

[0126] where R a 、R b 、R c 、R d X, L 1 Y, L 2 And Z as described in this article.

[0127] It should be understood that, for compounds of formula (A), R a 、R b 、R c 、R d X, L 1 Y, L 2 Z and R can each be selected from the groups described herein, where applicable, and this document applies to any R. a 、R b 、R c 、R d X, L 1 Y, L 2 And any group described in Z can be used with the remaining R in this document, where applicable. a 、R b 、R c 、R d X, L 1 Y, L 2 And any combination of one or more of the groups described in Z.

[0128] In some embodiments, the compound is a compound of formula (A):

[0129]

[0130] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein...

[0131] R a Selected from H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C 10 Cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein the alkyl, alkenyl, ynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally independently selected from halogen, OH, =O, NR. 3 R 4 CN, NO2, COOR 1 CONR 3 R 4One or more substituents are substituted in the sample;

[0132] R b 、R c 、R d Each is independently selected from H, halogen, OH, NH2, CN, NO2, C1-C6 alkyl and C1-C6 alkoxy, wherein the alkyl or alkoxy group is optionally substituted by one or more halogens or CN; X is selected from bond, O, NR. 1 C(R) 2 )2, S, S(O), S(O)2, C(O), C(O)O, C(O)NR 1 ,OC(O)O,N(R) 2 )C(O)NR 2 Arandibular;

[0133] R 1 Selected from H, C1-C6 alkyl, C3-C 10 Cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 acyl, heterocyclic, aryl, heteroaryl and S(O)2R 2 The alkyl, alkenyl, alkynyl, heterocyclic, cycloalkyl, aryl, or heteroaryl groups are optionally independently selected from halogens, OH, NH2, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10 One or more substituents selected from cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocyclic, aryl, and heteroaryl are used for substitution;

[0134] Each R 2 Independently selected from H, C1-C6 alkyl, C3-C 10 Cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocyclic, aryl, and heteroaryl, wherein the alkyl, alkenyl, alkynyl, heterocyclic, cycloalkyl, aryl, or heteroaryl group is optionally independently selected from halogen, OH, NH2, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10 One or more substituents selected from cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocyclic, aryl, and heteroaryl are used for substitution;

[0135] Y is selected from bond, O, NR 1 C(R) 2 )2, S, S(O), S(O)2, C(O), C(O)O, C(O)NR 1 ,OC(O)O,N(R) 2 )C(O)NR 2 ;

[0136] Z is selected from bonds, O, C(R) 2 )2;

[0137] L1 Selected from heterocyclic dimethyl-C1-C 10 -alkyldiyl, C1-C 10 Alkyl, C2-C 10 alkendiyl, C2-C 10 acetylide diol, C3-C 10 -cycloalkyldiyl, C3-C 10 -cycloalkyldiyl-C1-C 10 -alkyldiyl, aryldiyl, aryldiyl-C1-C 10 -alkyldiyl, heterocyclic diyl, heterocyclic diyl-C(O), heteroaryl, heteroaryl-C1-C 10 Alkyl, C1-C6 alkyldiyl-O-C1-C6 alkyldiyl, C1-C6 alkyldiyl-NR 1 -C1-C6 alkyldiyl, C1-C6 alkyldiyl-C(O)NR 1 -C1-C6 alkyldiyl, wherein the alkyldiyl, alkenyldiyl, alkynyldiyl, aryldiyl, heterocyclic diyl or heteroaryl-heteroaryl group is optionally independently selected from halogen, OH, oxy, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 Substitution with one or more substituents from aryl and -S(O)2C1-C6 alkyl groups;

[0138] L 2 Selected from C1-C 10 Alkyl, C2-C 10 alkendiyl, C2-C 10 acetylide diol, C3-C 10 -cycloalkyldiyl, C3-C 10 -cycloalkyldiyl-C1-C 10 -alkyldiyl, aryldiyl, aryldiyl-C1-C 10 -alkyldiyl, heterocyclic diyl, heterocyclic diyl-C1-C 10 -alkyldiyl, heterocyclic diyl-C(O), heteroaryl, heteroaryl-C1-C 10 Alkyl, C1-C6 alkyldiyl-O-C1-C6 alkyldiyl, C1-C6 alkyldiyl-NR 1 -C1-C6 alkyldiyl, C1-C6 alkyldiyl-C(O)NR 1-C1-C6 alkyldiyl, wherein the alkyldiyl, alkenyldiyl, alkynyldiyl, aryldiyl, heterocyclic diyl or heteroaryl-heteroaryl group is optionally independently selected from halogen, OH, oxy, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 Substitution with one or more substituents from aryl and -S(O)2C1-C6 alkyl groups;

[0139] R 3 and R 4 Each is independently selected from H, C1-C6 alkyl, C1-C6 acyl and C3-C 10 cycloalkyl; or R 3 and R 4 Together with the atoms to which they are attached and any intervening atoms, they form 5-14 membered heterocycles, wherein the heterocycle is optionally substituted by one or more substituents independently selected from halogens, OH, =O, CN, NO2, C1-C6 alkyl, and C1-C6 alkoxy.

[0140] In some embodiments, the compound is a compound of formula (A-1):

[0141]

[0142] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof.

[0143] In some embodiments, the compound is a compound of formula (A-1-a):

[0144]

[0145] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof.

[0146] In some embodiments, the compound is a compound of formula (A-1-b):

[0147]

[0148] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof.

[0149] In some embodiments, the compound is a compound of formula (A-1-bH):

[0150]

[0151] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof.

[0152] In some embodiments, the compound is a compound of formula (AA):

[0153]

[0154] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein ring A is selected from C3-C 10 - Cycloalkanes, aromatics, heterocyclic compounds, heteroaromatics; W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl and all other variables as defined herein.

[0155] In some embodiments, the compound is a compound of formula (AAA):

[0156]

[0157] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein i is an integer selected from 0, 1, and 2; j is an integer selected from 0, 1, and 2; and W is (CH2). w w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; Q is selected from bond, CH2, NH, O, S, S(O), S(O)2, and all other variables are as defined herein.

[0158] In some embodiments, the compound is a compound of formula (AAAI):

[0159]

[0160] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein i is an integer selected from 0, 1, and 2; j is an integer selected from 0, 1, and 2; and W is (CH2). w w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; Q is selected from bond, CH2, NH, O, S, S(O), S(O)2, and all other variables are as defined herein.

[0161] In some embodiments, the compound is a compound of formula (AAA-II):

[0162]

[0163] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein i is an integer selected from 0, 1, and 2; j is an integer selected from 0, 1, and 2; and W is (CH2). w w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; Q is selected from bond, CH2, NH, O, S, S(O), S(O)2, and all other variables are as defined herein.

[0164] In some embodiments, the compound is a compound of formula (AAA-1):

[0165]

[0166] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein i is an integer selected from 0, 1, and 2; j is an integer selected from 0, 1, and 2; and W is (CH2). w w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; Q is selected from bond, CH2, NH, O, S, S(O), S(O)2, and all other variables are as defined herein.

[0167] In some embodiments, the compound is a compound of formula (AAA-1-I):

[0168]

[0169] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein i is an integer selected from 0, 1, and 2; j is an integer selected from 0, 1, and 2; and W is (CH2). w w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; Q is selected from bond, CH2, NH, O, S, S(O), S(O)2, and all other variables are as defined herein.

[0170] In some embodiments, the compound is a compound of formula (AAA-1-II):

[0171]

[0172] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein i is an integer selected from 0, 1, and 2; j is an integer selected from 0, 1, and 2; and W is (CH2). w w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; Q is selected from bond, CH2, NH, O, S, S(O), S(O)2, and all other variables are as defined herein.

[0173] In some embodiments, the compound is a compound of formula (A-1-aI):

[0174]

[0175] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein ring A is selected from C3-C 10 - Cycloalkanes, aromatics, heterocyclic compounds, heteroaromatics; W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl and all other variables as defined herein.

[0176] In some embodiments, the compound is a compound of formula (A-1-aIA):

[0177]

[0178] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; v is an integer selected from 0, 1, 2, 3, 4, and 5; R 5Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0179] In some embodiments, the compound is a compound of formula (A-1-aIA-1):

[0180]

[0181] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein v is an integer selected from 0, 1, 2, 3, 4, and 5; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0182] In some embodiments, the compound is a compound of formula (A-1-aIB):

[0183]

[0184] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 And -S(O)2C1-C6 alkyl and all other variables are as defined herein.

[0185] In some embodiments, the compound is a compound of formula (A-1-aIB-0):

[0186]

[0187] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 And -S(O)2C1-C6 alkyl and all other variables are as defined herein.

[0188] In some embodiments, the compound is a compound of formula (A-1-aIB-1):

[0189]

[0190] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 And -S(O)2C1-C6 alkyl and all other variables are as defined herein.

[0191] In some embodiments, the compound is a compound of formula (A-1-aIB-2):

[0192]

[0193] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 And -S(O)2C1-C6 alkyl and all other variables are as defined herein.

[0194] In some embodiments, the compound is a compound of formula (A-1-aIB-3):

[0195]

[0196] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 And -S(O)2C1-C6 alkyl and all other variables are as defined herein.

[0197] In some embodiments, the compound is a compound of formula (A-1-aIC):

[0198]

[0199] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein ring H is a 3-10 membered monocyclic or bicyclic heterocycle containing 1-3 heteroatoms selected from N, O, and S; W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 And -S(O)2C1-C6 alkyl and all other variables are as defined herein.

[0200] In some embodiments, the compound is a compound of formula (A-1-aIC-1):

[0201]

[0202] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; v is an integer selected from 0, 1, 2, 3, 4, and 5; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0203] In some embodiments, the compound is a compound of formula (A-1-aIC-1-a):

[0204]

[0205] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2).w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0206] In some embodiments, the compound is a compound of the formula (A-1-aIC-1-aI):

[0207]

[0208] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0209] In some embodiments, the compound is a compound of formula (A-1-aIC-1-a-II):

[0210]

[0211] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0212] In some embodiments, the compound is a compound of formula (A-1-aIC-1-b):

[0213]

[0214] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0215] In some embodiments, the compound is a compound of the formula (A-1-aIC-1-bI):

[0216]

[0217] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0218] In some embodiments, the compound is a compound of formula (A-1-aIC-1-b-II):

[0219]

[0220] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w W is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0221] In some embodiments, the compound is a compound of formula (A-1-aIC-1-c):

[0222]

[0223] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0224] In some embodiments, the compound is a compound of the formula (A-1-aIC-1-cI):

[0225]

[0226] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0227] In some embodiments, the compound is a compound of formula (A-1-aIC-1-c-II):

[0228]

[0229] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0230] In some embodiments, the compound is a compound of formula (A-1-aIC-1-c-III):

[0231]

[0232] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0233] In some embodiments, the compound is a compound of formula (A-1-aIC-2):

[0234]

[0235] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; f is an integer selected from 1, 2, and 3; g is an integer selected from 1, 2, and 3; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0236] In some embodiments, the compound is a compound of formula (A-1-aIC-2-a):

[0237]

[0238] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0239] In some embodiments, the compound is a compound of the formula (A-1-aIC-2-aI):

[0240]

[0241] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0242] In some embodiments, the compound is a compound of formula (A-1-aIC-2-a-II):

[0243]

[0244] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0245] In some embodiments, the compound is a compound of formula (A-1-aIC-2-a-III):

[0246]

[0247] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0248] In some embodiments, the compound is a compound of formula (A-1-aIC-3):

[0249]

[0250] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; f is an integer selected from 1, 2, and 3; g is an integer selected from 1, 2, and 3; R 5Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0251] In some embodiments, the compound is a compound of formula (A-1-aIC-3-a):

[0252]

[0253] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0254] In some embodiments, the compound is a compound of the formula (A-1-aIC-3-aI):

[0255]

[0256] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0257] In some embodiments, the compound is a compound of formula (A-1-aIC-3-a-II):

[0258]

[0259] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0260] In some embodiments, the compound is a compound of formula (A-1-aID):

[0261]

[0262] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein ring D is a 5-10 membered monocyclic or bicyclic heteroaryl group containing 1-3 heteroatoms selected from N, O, and S; W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4-S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 And -S(O)2C1-C6 alkyl, and none of the other variables are as defined herein.

[0263] In some embodiments, the compound is a compound of formula (A-1-aID-1):

[0264]

[0265] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 And -S(O)2C1-C6 alkyl, and all other variables are as defined herein.

[0266] In some embodiments, the compound is a compound of formula (A-1-aID-1-a):

[0267]

[0268] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 And -S(O)2C1-C6 alkyl, and all other variables are as defined herein.

[0269] In some embodiments, the compound is a compound of formula (A-1-aID-1-b):

[0270]

[0271] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 And -S(O)2C1-C6 alkyl, and all other variables are as defined herein.

[0272] In some embodiments, the compound is a compound of formula (A-1-bI):

[0273]

[0274] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein ring A is selected from C3-C 10 - Cycloalkanes, aromatics, heterocyclic compounds, heteroaromatics; W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 And -S(O)2C1-C6 alkyl, and all other variables are as defined herein.

[0275] In some embodiments, the compound is a compound of formula (A-1-bIA):

[0276]

[0277] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; v is an integer selected from 0, 1, 2, 3, 4, and 5; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0278] In some embodiments, the compound is a compound of formula (A-1-bIA-1):

[0279]

[0280] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein v is an integer selected from 0, 1, 2, 3, 4, and 5; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0281] In some embodiments, the compound is a compound of formula (A-1-bIB):

[0282]

[0283] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 And -S(O)2C1-C6 alkyl, and all other variables are as defined herein.

[0284] In some embodiments, the compound is a compound of formula (A-1-bIB-0):

[0285]

[0286] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 And -S(O)2C1-C6 alkyl, and all other variables are as defined herein.

[0287] In some embodiments, the compound is a compound of formula (A-1-bIB-1):

[0288]

[0289] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 And -S(O)2C1-C6 alkyl, and all other variables are as defined herein.

[0290] In some embodiments, the compound is a compound of formula (A-1-bIB-2):

[0291]

[0292] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 And -S(O)2C1-C6 alkyl, and all other variables are as defined herein.

[0293] In some embodiments, the compound is a compound of formula (A-1-bIB-3):

[0294]

[0295] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4And -S(O)2C1-C6 alkyl, and all other variables are as defined herein.

[0296] In some embodiments, the compound is a compound of formula (A-1-bIC):

[0297]

[0298] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein ring H is a 3-10 membered monocyclic or bicyclic heterocycle containing 1-3 heteroatoms selected from N, O, and S; W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 And -S(O)2C1-C6 alkyl, and all other variables are as defined herein.

[0299] In some embodiments, the compound is a compound of formula (A-1-bIC-1):

[0300]

[0301] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; v is an integer selected from 0, 1, 2, 3, 4, and 5; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0302] In some embodiments, the compound is a compound of formula (A-1-bIC-1-a):

[0303]

[0304] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0305] In some embodiments, the compound is a compound of the formula (A-1-bIC-1-aI):

[0306]

[0307] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0308] In some embodiments, the compound is a compound of formula (A-1-bIC-1-a-II):

[0309]

[0310] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0311] In some embodiments, the compound is a compound of formula (A-1-bIC-1-b):

[0312]

[0313] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0314] In some embodiments, the compound is a compound of the formula (A-1-bIC-1-bI):

[0315]

[0316] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0317] In some embodiments, the compound is a compound of formula (A-1-bIC-1-b-II):

[0318]

[0319] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0320] In some embodiments, the compound is a compound of formula (A-1-bIC-1-c):

[0321]

[0322] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0323] In some embodiments, the compound is a compound of the formula (A-1-bIC-1-cI):

[0324]

[0325] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0326] In some embodiments, the compound is a compound of formula (A-1-bIC-1-c-II):

[0327]

[0328] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0329] In some embodiments, the compound is a compound of formula (A-1-bIC-1-c-III):

[0330]

[0331] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0332] In some embodiments, the compound is a compound of formula (A-1-bIC-2):

[0333]

[0334] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; f is an integer selected from 1, 2, and 3; g is an integer selected from 1, 2, and 3; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4-S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0335] In some embodiments, the compound is a compound of formula (A-1-bIC-2-a):

[0336]

[0337] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0338] In some embodiments, the compound is a compound of the formula (A-1-bIC-2-aI):

[0339]

[0340] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0341] In some embodiments, the compound is a compound of formula (A-1-bIC-2-a-II):

[0342]

[0343] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0344] In some embodiments, the compound is a compound of formula (A-1-bIC-2-a-III):

[0345]

[0346] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0347] In some embodiments, the compound is a compound of formula (A-1-bIC-3):

[0348]

[0349] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; f is an integer selected from 1, 2, and 3; g is an integer selected from 1, 2, and 3; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0350] In some embodiments, the compound is a compound of formula (A-1-bIC-3-a):

[0351]

[0352] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0353] In some embodiments, the compound is a compound of the formula (A-1-bIC-3-aI):

[0354]

[0355] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2).w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0356] In some embodiments, the compound is a compound of formula (A-1-bIC-3-a-II):

[0357]

[0358] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w W is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl; and all other variables are as defined herein.

[0359] In some embodiments, the compound is a compound of formula (A-1-bID):

[0360]

[0361] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein ring D is a 5-10 membered monocyclic or bicyclic heteroaryl group containing 1-3 heteroatoms selected from N, O, and S; W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 And -S(O)2C1-C6 alkyl, and all other variables are as defined herein.

[0362] In some embodiments, the compound is a compound of formula (A-1-bID-1):

[0363]

[0364] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 And -S(O)2C1-C6 alkyl, and all other variables are as defined herein.

[0365] In some embodiments, the compound is a compound of formula (A-1-bID-1-a):

[0366]

[0367] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 And -S(O)2C1-C6 alkyl, and all other variables are as defined herein.

[0368] In some embodiments, the compound is a compound of formula (A-1-bID-1-b):

[0369]

[0370] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein W is (CH2). w W is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 And -S(O)2C1-C6 alkyl, and all other variables are as defined herein.

[0371] In some embodiments, the compound is a compound of formula (AB):

[0372]

[0373] Or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein ring A is selected from C3-C 10 - Cycloalkanes, aromatics, heterocyclic compounds, heteroaromatics; W is (CH2). w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR3 R 4 And -S(O)2C1-C6 alkyl; u is an integer selected from 0 and 1; and all other variables are as defined herein.

[0374] In a more specific sense, this disclosure provides compounds of formula (I) and their salts, stereoisomers, solvates, prodrugs, isotope derivatives, and tautomers:

[0375]

[0376] where R a 、R b 、R c 、R d X, L 1 Y, L 2 And Z as described in this article.

[0377] It should be understood that, for compounds of formula (I), R a 、R b 、R c 、R d X, L 1 Y, L 2 Z and R can each be selected from the groups described herein, where applicable, and this document applies to any R. a 、R b 、R c 、R d X, L 1 Y, L 2 And any group described in Z can be used with respect to R where applicable. a 、R b 、R c 、R d X, L 1 Y, L 2 And any combination of one or more of the groups described in the remaining part of Z.

[0378] In some embodiments, the compound is a compound of formula (I).

[0379]

[0380] in,

[0381] R a Selected from H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C 10 Cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally independently selected from halogen, OH, =O, NR. 3 R4 CN, NO2, COOR 1 CONR 3 R 4 One or more substituents are substituted in the sample;

[0382] R b 、R c 、R d Each is independently selected from H, halogen, OH, NH2, CN, NO2, C1-C6 alkyl and C1-C6 alkoxy, wherein the alkyl or alkoxy group is optionally substituted by one or more halogens or CN; X is selected from bond, O, NR. 1 C(R) 2 )2, S, S(O), S(O)2, C(O), C(O)O, C(O)NR 1 ,OC(O)O,N(R) 2 )C(O)NR 2 Arandibular;

[0383] R 1 Selected from H, C1-C6 alkyl, C3-C 10 Cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 acyl, heterocyclic, aryl, heteroaryl and S(O)2R 2 The alkyl, alkenyl, alkynyl, heterocyclic, cycloalkyl, aryl, or heteroaryl groups are optionally independently selected from halogens, OH, NH2, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10 One or more substituents selected from cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocyclic, aryl, and heteroaryl are used for substitution;

[0384] Each R 2 Independently selected from H, C1-C6 alkyl, C3-C 10 Cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocyclic, aryl, and heteroaryl, wherein the alkyl, alkenyl, alkynyl, heterocyclic, cycloalkyl, aryl, or heteroaryl group is optionally independently selected from halogen, OH, NH2, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10 One or more substituents selected from cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocyclic, aryl, and heteroaryl are used for substitution;

[0385] Y is selected from bond, O, NR 1 C(R) 2 )2, S, S(O), S(O)2, C(O), C(O)O, C(O)NR 1 ,OC(O)O,N(R) 2 )C(O)NR 2 ;

[0386] Z is selected from bonds, O, C(R) 2 )2;

[0387] L 1 Selected from heterocyclic dimethyl-C1-C 10 -alkyldiyl, C1-C 10 Alkyl, C2-C 10 alkendiyl, C2-C 10 acetylide diol, C3-C 10 -cycloalkyldiyl, C3-C 10 -cycloalkyldiyl-C1-C 10 -alkyldiyl, aryldiyl, aryldiyl-C1-C 10 -alkyldiyl, heterocyclic diyl, heterocyclic diyl-C(O), heteroaryl, heteroaryl-C1-C 10 Alkyl, C1-C6 alkyldiyl-O-C1-C6 alkyldiyl, C1-C6 alkyldiyl-NR 1 -C1-C6 alkyldiyl, C1-C6 alkyldiyl-C(O)NR 1 -C1-C6 alkyldiyl, wherein the alkyldiyl, alkenyldiyl, alkynyldiyl, aryldiyl, heterocyclic diyl or heteroaryl-heteroaryl group is optionally independently selected from halogen, OH, oxy, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 Substitution with one or more substituents from aryl and -S(O)2C1-C6 alkyl groups;

[0388] L 2 Selected from C1-C 10 Alkyl, C2-C 10 alkendiyl, C2-C 10 acetylide diol, C3-C 10 -cycloalkyldiyl, C3-C 10 -cycloalkyldiyl-C1-C 10 -alkyldiyl, aryldiyl, aryldiyl-C1-C 10 -alkyldiyl, heterocyclic diyl, heterocyclic diyl-C1-C 10 -alkyldiyl, heterocyclic diyl-C(O), heteroaryl, heteroaryl-C1-C 10 Alkyl, C1-C6 alkyldiyl-O-C1-C6 alkyldiyl, C1-C6 alkyldiyl-NR 1-C1-C6 alkyldiyl, C1-C6 alkyldiyl-C(O)NR 1 -C1-C6 alkyldiyl, wherein the alkyldiyl, alkenyldiyl, alkynyldiyl, aryldiyl, heterocyclic diyl or heteroaryl-heteroaryl group is optionally independently selected from halogen, OH, oxy, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 Substitution with one or more substituents from aryl and -S(O)2C1-C6 alkyl groups;

[0389] R 3 and R 4 Each is independently selected from H, C1-C6 alkyl, C1-C6 acyl and C3-C 10 cycloalkyl; or R 3 and R 4 Together with the atoms to which they are attached and any intervening atoms, they form 5-14 membered heterocycles, wherein the heterocycle is optionally substituted by one or more substituents independently selected from halogens, OH, =O, CN, NO2, C1-C6 alkyl, and C1-C6 alkoxy.

[0390] In another, more specific aspect, this disclosure provides compounds of formula (II) and their salts, stereoisomers, solvates, prodrugs, isotope derivatives, and tautomers:

[0391]

[0392] where R a 、R b 、R c 、R d X, L 1 Y, L 2 And Z as described in this article.

[0393] It should be understood that, for compounds of formula (I), R a 、R b 、R c 、R d X, L 1 Y, L 2 Z and R can each be selected from the groups described herein, where applicable, and this document applies to any R. a 、R b 、R c 、Rd X, L 1 Y, L 2 And any group described in Z can be used in conjunction with the group described herein for R, where applicable. a 、R b 、R c 、R d X, L 1 Y, L 2 And any combination of one or more of the described groups in the remaining part of Z.

[0394] In some embodiments, the compound is a compound of formula (II).

[0395]

[0396] in,

[0397] R a Selected from H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C 10 Cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally independently selected from halogen, OH, =O, NR. 3 R 4 CN, NO2, COOR 1 CONR 3 R 4 One or more substituents are substituted in the sample;

[0398] R b 、R c 、R d Each is independently selected from H, halogen, OH, NH2, CN, NO2, C1-C6 alkyl and C1-C6 alkoxy, wherein the alkyl or alkoxy group is optionally substituted by one or more halogens or CN; X is selected from bond, O, NR. 1 C(R) 2 )2, S, S(O), S(O)2, C(O), C(O)O, C(O)NR 1 ,OC(O)O,N(R) 2 )C(O)NR 2 Arandibular;

[0399] R 1 Selected from H, C1-C6 alkyl, C3-C 10 Cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 acyl, heterocyclic, aryl, heteroaryl and S(O)2R 2The alkyl, alkenyl, alkynyl, heterocyclic, cycloalkyl, aryl, or heteroaryl groups are optionally independently selected from halogens, OH, NH2, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10 One or more substituents selected from cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocyclic, aryl, and heteroaryl are used for substitution;

[0400] Each R 2 Independently selected from H, C1-C6 alkyl, C3-C 10 Cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocyclic, aryl, and heteroaryl, wherein the alkyl, alkenyl, alkynyl, heterocyclic, cycloalkyl, aryl, or heteroaryl group is optionally independently selected from halogen, OH, NH2, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10 One or more substituents selected from cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocyclic, aryl, and heteroaryl are used for substitution;

[0401] Y is selected from bond, O, NR 1 C(R) 2 )2, S, S(O), S(O)2, C(O), C(O)O, C(O)NR 1 ,OC(O)O,N(R) 2 )C(O)NR 2 ;

[0402] Z is selected from bonds, O, C(R) 2 )2;

[0403] L 1 Selected from heterocyclic dimethyl-C1-C 10 -alkyldiyl, C1-C 10 Alkyl, C2-C 10 alkendiyl, C2-C 10 acetylide diol, C3-C 10 -cycloalkyldiyl, C3-C 10 -cycloalkyldiyl-C1-C 10 -alkyldiyl, aryldiyl, aryldiyl-C1-C 10 -alkyldiyl, heterocyclic diyl, heterocyclic diyl-C(O), heteroaryl, heteroaryl-C1-C 10 Alkyl, C1-C6 alkyldiyl-O-C1-C6 alkyldiyl, C1-C6 alkyldiyl-NR 1 -C1-C6 alkyldiyl, C1-C6 alkyldiyl-C(O)NR 1-C1-C6 alkyldiyl, wherein the alkyldiyl, alkenyldiyl, alkynyldiyl, aryldiyl, heterocyclic diyl or heteroaryl-heteroaryl group is optionally independently selected from halogen, OH, oxy, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 Substitution with one or more substituents from aryl and -S(O)2C1-C6 alkyl groups;

[0404] L 2 Selected from C1-C 10 Alkyl, C2-C 10 alkendiyl, C2-C 10 acetylide diol, C3-C 10 -cycloalkyldiyl, C3-C 10 -cycloalkyldiyl-C1-C 10 -alkyldiyl, aryldiyl, aryldiyl-C1-C 10 -alkyldiyl, heterocyclic diyl, heterocyclic diyl-C1-C 10 -alkyldiyl, heterocyclic diyl-C(O), heteroaryl, heteroaryl-C1-C 10 Alkyl, C1-C6 alkyldiyl-O-C1-C6 alkyldiyl, C1-C6 alkyldiyl-NR 1 -C1-C6 alkyldiyl, C1-C6 alkyldiyl-C(O)NR 1 -C1-C6 alkyldiyl, wherein the alkyldiyl, alkenyldiyl, alkynyldiyl, aryldiyl, heterocyclic diyl or heteroaryl-heteroaryl group is optionally independently selected from halogen, OH, oxy, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 Substitution with one or more substituents from aryl and -S(O)2C1-C6 alkyl groups;

[0405] R 3 and R 4 Each is independently selected from H, C1-C6 alkyl, C1-C6 acyl and C3-C 10 cycloalkyl; or R3 and R 4 Together with the atoms to which they are attached and any intervening atoms, they form 5-14 membered heterocycles, wherein the heterocycle is optionally substituted by one or more substituents independently selected from halogens, OH, =O, CN, NO2, C1-C6 alkyl, and C1-C6 alkoxy.

[0406] In some implementations, R a Selected from H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C 10 Cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally independently selected from halogen, OH, =O, NR. 3 R 4 CN, NO2, COOR 1 CONR 3 R 4 One or more substituents are substituted in the sample.

[0407] In some implementations, R a It's H.

[0408] In some implementations, R a It is a C1-C6 alkyl group.

[0409] In some implementations, R a It is a C1-C6 alkyl group substituted with one or more halogens.

[0410] In some implementations, R a It is a C1-C6 alkyl group substituted with one or more F atoms.

[0411] In some implementations, R a It is -CH3.

[0412] In some implementations, R a It is -CH2CH3.

[0413] In some implementations, R a It is -CH2F.

[0414] In some implementations, R a It is -CHF2.

[0415] In some implementations, R a It is -CF3.

[0416] In some implementations, R a It is -CH2CHF2.

[0417] In some implementations, R aIt is a C2-C6 alkenyl group.

[0418] In some implementations, R a It is -CH2CH=CH2.

[0419] In some implementations, R b It is selected from H, halogen, OH, NH2, CN, NO2, C1-C6 alkyl and C1-C6 alkoxy, wherein the alkyl or alkoxy is optionally substituted by one or more halogens or CN.

[0420] In some implementations, R b It's H.

[0421] In some implementations, R b It is halogen.

[0422] In some implementations, R b It is F.

[0423] In some implementations, R b It is Cl.

[0424] In some implementations, R b It is Br.

[0425] In some implementations, R b It is OH.

[0426] In some implementations, R b It's CN.

[0427] In some implementations, R b It's CF3.

[0428] In some implementations, R c It is selected from H, halogen, OH, NH2, CN, NO2, C1-C6 alkyl and C1-C6 alkoxy, wherein the alkyl or alkoxy is optionally substituted by one or more halogens or CN.

[0429] In some implementations, R c It's H.

[0430] In some implementations, R c It is halogen.

[0431] In some implementations, R c It is F.

[0432] In some implementations, R c It is Cl.

[0433] In some implementations, R c It is Br.

[0434] In some implementations, R c It is OH.

[0435] In some implementations, R c It's CN.

[0436] In some implementations, R c It's CF3.

[0437] In some implementations, R d It is selected from H, halogen, OH, NH2, CN, NO2, C1-C6 alkyl and C1-C6 alkoxy, wherein the alkyl or alkoxy is optionally substituted by one or more halogens or CN.

[0438] In some implementations, R d It's H.

[0439] In some implementations, R d It is halogen.

[0440] In some implementations, R d It is F.

[0441] In some implementations, R d It is Cl.

[0442] In some implementations, R d It is Br.

[0443] In some implementations, R d It is OH.

[0444] In some implementations, R d It's CN.

[0445] In some implementations, R d It's CF3.

[0446] In some embodiments, the compound is a compound of formula (IA):

[0447]

[0448] in,

[0449] X is selected from O, bond, NR 1 C(R) 2 )2, S, S(O), S(O)2, C(O), C(O)O, C(O)NR 1 ,OC(O)O,N(R) 2 )C(O)NR 2 Arandibular;

[0450] R 1Selected from H, C1-C6 alkyl, C3-C 10 Cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 acyl, heterocyclic, aryl, heteroaryl and S(O)2R 2 The alkyl, alkenyl, alkynyl, heterocyclic, cycloalkyl, aryl, or heteroaryl groups are independently selected from halogens, OH, NH2, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10 One or more substituents selected from cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocyclic, aryl, and heteroaryl are used for substitution;

[0451] Each R 2 Independently selected from H, C1-C6 alkyl, C3-C 10 Cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocyclic, aryl, and heteroaryl, wherein the alkyl, alkenyl, alkynyl, heterocyclic, cycloalkyl, aryl, or heteroaryl group is optionally independently selected from halogen, OH, NH2, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10 One or more substituents selected from cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocyclic, aryl, and heteroaryl are used for substitution;

[0452] Y is selected from bond, O, NR 1 C(R) 2 )2, S, S(O), S(O)2, C(O), C(O)O, C(O)NR 1 ,OC(O)O,N(R) 2 )C(O)NR 2 ;

[0453] Z is selected from bonds, O, C(R) 2 )2;

[0454] L 1 Selected from heterocyclic dimethyl-C1-C 10 -alkyldiyl, C1-C 10 Alkyl, C2-C 10 alkendiyl, C2-C 10 acetylide diol, C3-C 10 -cycloalkyldiyl, C3-C 10 -cycloalkyldiyl-C1-C 10 -alkyldiyl, aryldiyl, aryldiyl-C1-C 10 -alkyldiyl, heterocyclic diyl, heterocyclic diyl-C(O), heteroaryl, heteroaryl-C1-C 10 Alkyl, C1-C6 alkyldiyl-O-C1-C6 alkyldiyl, C1-C6 alkyldiyl-NR 1 -C1-C6 alkyldiyl, C1-C6 alkyldiyl-C(O)NR 1-C1-C6 alkyldiyl, wherein the alkyldiyl, alkenyldiyl, alkynyldiyl, aryldiyl, heterocyclic diyl or heteroaryl-heteroaryl group is optionally independently selected from halogen, OH, oxy, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 Substitution with one or more substituents from aryl and -S(O)2C1-C6 alkyl groups;

[0455] L 2 Selected from C1-C 10 Alkyl, C2-C 10 alkendiyl, C2-C 10 acetylide diol, C3-C 10 -cycloalkyldiyl, C3-C 10 -cycloalkyldiyl-C1-C 10 -alkyldiyl, aryldiyl, aryldiyl-C1-C 10 -alkyldiyl, heterocyclic diyl, heterocyclic diyl-C1-C 10 -alkyldiyl, heterocyclic diyl-C(O), heteroaryl, heteroaryl-C1-C 10 Alkyl, C1-C6 alkyldiyl-O-C1-C6 alkyldiyl, C1-C6 alkyldiyl-NR 1 -C1-C6 alkyldiyl, C1-C6 alkyldiyl-C(O)NR 1 -C1-C6 alkyldiyl, wherein the alkyldiyl, alkenyldiyl, alkynyldiyl, aryldiyl, heterocyclic diyl or heteroaryl-heteroaryl group is optionally independently selected from halogen, OH, oxy, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 Substitution with one or more substituents from aryl and -S(O)2C1-C6 alkyl groups;

[0456] R 3 and R 4 Each is independently selected from H, C1-C6 alkyl, C1-C6 acyl and C3-C 10 cycloalkyl; or R3 and R 4 Together with the atoms to which they are attached and any intervening atoms, they form 5-14 membered heterocycles, wherein the heterocycle is optionally substituted by one or more substituents independently selected from halogens, OH, =O, CN, NO2, C1-C6 alkyl, and C1-C6 alkoxy.

[0457] In some embodiments, the compound is a compound of formula (II-A):

[0458]

[0459] in

[0460] X is selected from O, bond, NR 1 C(R) 2 )2, S, S(O), S(O)2, C(O), C(O)O, C(O)NR 1 ,OC(O)O,N(R) 2 )C(O)NR 2 Arandibular;

[0461] R 1 Selected from H, C1-C6 alkyl, C3-C 10 Cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 acyl, heterocyclic, aryl, heteroaryl and S(O)2R 2 The alkyl, alkenyl, alkynyl, heterocyclic, cycloalkyl, aryl, or heteroaryl groups are optionally independently selected from halogens, OH, NH2, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10 One or more substituents selected from cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocyclic, aryl, and heteroaryl are used for substitution;

[0462] Each R 2 Independently selected from H, C1-C6 alkyl, C3-C 10 Cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocyclic, aryl, and heteroaryl, wherein the alkyl, alkenyl, alkynyl, heterocyclic, cycloalkyl, aryl, or heteroaryl group is optionally independently selected from halogen, OH, NH2, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10 One or more substituents selected from cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocyclic, aryl, and heteroaryl are used for substitution;

[0463] Y is selected from bond, O, NR 1 C(R) 2 )2, S, S(O), S(O)2, C(O), C(O)O, C(O)NR 1 ,OC(O)O,N(R)2 )C(O)NR 2 ;

[0464] Z is selected from bonds, O, C(R) 2 )2;

[0465] L 1 Selected from heterocyclic dimethyl-C1-C 10 -alkyldiyl, C1-C 10 Alkyl, C2-C 10 alkendiyl, C2-C 10 acetylide diol, C3-C 10 -cycloalkyldiyl, C3-C 10 -cycloalkyldiyl-C1-C 10 -alkyldiyl, aryldiyl, aryldiyl-C1-C 10 -alkyldiyl, heterocyclic diyl, heterocyclic diyl-C(O), heteroaryl, heteroaryl-C1-C 10 Alkyl, C1-C6 alkyldiyl-O-C1-C6 alkyldiyl, C1-C6 alkyldiyl-NR 1 -C1-C6 alkyldiyl, C1-C6 alkyldiyl-C(O)NR 1 -C1-C6 alkyldiyl, wherein the alkyldiyl, alkenyldiyl, alkynyldiyl, aryldiyl, heterocyclic diyl or heteroaryl-heteroaryl group is optionally independently selected from halogen, OH, oxy, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 Substitution with one or more substituents from aryl and -S(O)2C1-C6 alkyl groups;

[0466] L 2 Selected from C1-C 10 Alkyl, C2-C 10 alkendiyl, C2-C 10 acetylide diol, C3-C 10 -cycloalkyldiyl, C3-C 10 -cycloalkyldiyl-C1-C 10 -alkyldiyl, aryldiyl, aryldiyl-C1-C 10 -alkyldiyl, heterocyclic diyl, heterocyclic diyl-C1-C 10 -alkyldiyl, heterocyclic diyl-C(O), heteroaryl, heteroaryl-C1-C 10Alkyl, C1-C6 alkyldiyl-O-C1-C6 alkyldiyl, C1-C6 alkyldiyl-NR 1 -C1-C6 alkyldiyl, C1-C6 alkyldiyl-C(O)NR 1 -C1-C6 alkyldiyl, wherein the alkyldiyl, alkenyldiyl, alkynyldiyl, aryldiyl, heterocyclic diyl or heteroaryl-heteroaryl group is optionally independently selected from halogen, OH, oxy, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 Substitution with one or more substituents from aryl and -S(O)2C1-C6 alkyl groups;

[0467] R 3 and R 4 Each is independently selected from H, C1-C6 alkyl, C1-C6 acyl and C3-C 10 cycloalkyl; or R 3 and R 4 Together with the atoms to which they are attached and any intervening atoms, they form 5-14 membered heterocycles, wherein the heterocycle is optionally substituted by one or more substituents independently selected from halogens, OH, =O, CN, NO2, C1-C6 alkyl, and C1-C6 alkoxy.

[0468] In some implementations, X is selected from bond, O, NR 1 C(R) 2 )2, S, S(O), S(O)2, C(O), C(O)O, C(O)NR 1 , OC(O)O or N(R 2 )C(O)NR 2 .

[0469] In some implementations, X is a key.

[0470] In some implementations, X is a single bond.

[0471] In some implementations, X is -O-.

[0472] In some implementations, X is

[0473] In some implementations, X is

[0474] In some implementations, X is

[0475] In some implementations, X is

[0476] In some implementations, X is

[0477] In some implementations, X is

[0478] In some implementations, X is

[0479] In some implementations, X is -S-.

[0480] In some implementations, X is

[0481] In some implementations, X is

[0482] In some implementations, X is

[0483] In some implementations, X is

[0484] In some implementations, X is

[0485] In some implementations, X is

[0486] In some implementations, X is

[0487] In some implementations, X is

[0488] In some implementations, X is

[0489] In some implementations, X is

[0490] In some implementations, X is

[0491] In some implementations, R 1 Selected from H, C1-C6 alkyl, C3-C 10 Cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 acyl, heterocyclic, aryl, heteroaryl, or S(O)2R 2The alkyl, alkenyl, alkynyl, heterocyclic, cycloalkyl, aryl, or heteroaryl groups are optionally independently selected from halogens, OH, NH2, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10 One or more of the following substituents are used: cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocyclic, aryl, and heteroaryl.

[0492] In some implementations, R 1 For H.

[0493] In some implementations, R 1 It is CH3.

[0494] In some implementations, R 2 Selected from H, C1-C6 alkyl, C3-C 10 Cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocyclic, aryl, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, heterocyclic, cycloalkyl, aryl, or heteroaryl group is optionally independently selected from halogen, OH, NH2, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10 One or more of the following substituents are used: cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocyclic, aryl, and heteroaryl.

[0495] In some implementations, R 2 For H.

[0496] In some implementations, R 2 It is CH3.

[0497] In some implementations, Y represents bond, O, NR. 1 C(R) 2 )2, S, S(O), S(O)2; C(O); C(O)O, C(O)NR 1 ,OC(O)O,N(R) 2 )C(O)NR 2 Aranediol.

[0498] In some implementations, Y is a key.

[0499] In some implementations, Y is a single bond.

[0500] In some implementations, Y is -O-.

[0501] In some implementations, Y is

[0502] In some implementations, Y is

[0503] In some implementations, Y is

[0504] In some implementations, Y is

[0505] In some implementations, Y is

[0506] In some implementations, Y is

[0507] In some implementations, Y is

[0508] In some implementations, Y is

[0509] In some implementations, Y is

[0510] In some implementations, Y is -S-.

[0511] In some implementations, Y is

[0512] In some implementations, Y is

[0513] In some implementations, Y is

[0514] In some implementations, Y is

[0515] In some implementations, Y is

[0516] In some implementations, Y is

[0517] In some implementations, Y is

[0518] In some implementations, Y is

[0519] In some implementations, Y is -OC(O)O-.

[0520] In some implementations, Y is N(R) 2 )C(O)NR 2 .

[0521] In some implementations, Y is

[0522] In some implementations, Y is

[0523] In some implementations, Y is

[0524] In some implementations, Y is

[0525] In some implementations, Z is selected from bond, O, or C(R) 2 )2.

[0526] In some implementations, Z is a key.

[0527] In some implementations, Z is a single bond.

[0528] In some implementations, Z is -O-.

[0529] In some implementations, Z is C(R) 2 )2.

[0530] In some implementations, Z is CH2.

[0531] In some implementations, L 1 Selected from C1-C 10 Alkyl, C2-C 10 alkendiyl, C2-C 10 acetylide diol, C3-C 10 -cycloalkyldiyl, C3-C 10 -cycloalkyldiyl-C1-C 10 -alkyldiyl, aryldiyl, aryldiyl-C1-C 10 -alkyldiyl, heterocyclic diyl, heterocyclic diyl-C1-C 10 -alkyldiyl, heterocyclic diyl-C(O), heteroaryl, heteroaryl-C1-C 10 Alkyl, C1-C6 alkyldiyl-O-C1-C6 alkyldiyl, C1-C6 alkyldiyl-NR 1 -C1-C6 alkyldiyl, C1-C6 alkyldiyl-C(O)NR 1 -C1-C6 alkyldiyl, wherein the alkyldiyl, alkenyldiyl, alkynyldiyl, aryldiyl, heterocyclic diyl or heteroaryl-heteroaryl group is optionally independently selected from halogen, OH, oxy, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 It is substituted with one or more of the following: aryl and -S(O)2C1-C6 alkyl groups.

[0532] In some implementations, L 1 It is C1-C 10 Alkyl.

[0533] In some implementations, L 1 It is optionally and independently selected from halogen, OH, oxy, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 C1-C6 alkyl groups substituted with one or more of the following: aryl and -S(O)2C1-C6 alkyl groups. 10 Alkyl.

[0534] In some implementations, L 1 It is a dimethylamine.

[0535] In some implementations, L 1 It is ethylenedimethylamine.

[0536] In some implementations, L 1 It is 1,1-ethadiyl.

[0537] In some implementations, L 1 It is 1,2-ethylenedimethyl.

[0538] In some implementations, L 1 It is propanediol.

[0539] In some implementations, L 1 It is 1,3-propanediol.

[0540] In some implementations, L 1 It is 1-methylpropyldiyl-1,3-methylpropanediol.

[0541] In some implementations, L 1 It is 2-methylpropyldiyl-1,3-methylpropanediol.

[0542] In some implementations, L 1 It is butylene glycol.

[0543] In some implementations, L 1 It is 1,4-butadiyl.

[0544] In some implementations, L 1 It is 2-methylbutadiene-1,4-methyl.

[0545] In some implementations, L 1 It is pentylene dimethylbenzene.

[0546] In some implementations, L 1 It is 1,5-pentadiyl.

[0547] In some implementations, L 1 It is 3-methylpentadiyl-1,5-methyl.

[0548] In some implementations, L 1 It is 2,3-dimethylpentadiyl-1,5-.

[0549] In some implementations, L 1 It is the two basic elements.

[0550] In some implementations, L 1 It is 1,6-hexadiyl.

[0551] In some implementations, L 1 It is 3-methylhexanediol-1,6.

[0552] In some implementations, L 1 It is 3,4-dimethylhexamethylene-1,6-dimethylhexadiyl-1,6-dimethylhexamethylene ...

[0553] In some implementations, L 1 It is C2-C 10 alkenadiyl.

[0554] In some implementations, L 1 It is E-C2-C 10 alkenadiyl.

[0555] In some implementations, L 1 It is Z-C2-C 10 alkenadiyl.

[0556] In some implementations, L 1 It is ethylenedimethyl.

[0557] In some implementations, L 1 It is vinylidene-1,2.

[0558] In some implementations, L 1 It is propylene dimethyl.

[0559] In some implementations, L 1 It is propylene diene-1,3-propene.

[0560] In some implementations, L 1 It is 2-methylpropenyl-1,3 ...

[0561] In some implementations, L 1 It is butenyldiyl.

[0562] In some implementations, L 1 It is butene-1-diyl-1,4.

[0563] In some implementations, L 1 It is E-butene-1-diyl-1,4.

[0564] In some implementations, L 1 It is Z-butene-1-diyl-1,4.

[0565] In some implementations, L 1 It is butene-2-diyl-1,4-butene.

[0566] In some implementations, L 1 It is E-butene-2-diyl-1,4-butene.

[0567] In some implementations, L 1 It is Z-butene-2-diyl-1,4-butene.

[0568] In some implementations, L 1 It is 2-methylbutene-2-diyl-1,4 ...

[0569] In some implementations, L 1 It is E-2-methylbutene-2-diyl-1,4 ...

[0570] In some implementations, L 1 It is Z-2-methylbutene-2-diyl-1,4-.

[0571] In some implementations, L 1 It is pentenyldiyl.

[0572] In some implementations, L 1 It is pentene-2-diyl-1,5-.

[0573] In some implementations, L 1 It is E-pentene-2-diyl-1,5-.

[0574] In some implementations, L 1 It is Z-penten-2-diyl-1,5-.

[0575] In some implementations, L 1 It is 2-methylpentene-2-diyl-1,5 ...

[0576] In some implementations, L 1 It is E-2-methylpenten-2-diyl-1,5-methyl.

[0577] In some implementations, L 1 It is Z-2-methylpenten-2-diyl-1,5-methyl.

[0578] In some implementations, L 1 It is 3-methylpentene-2-diyl-1,5 ...

[0579] In some implementations, L 1 It is E-3-methylpentene-2-diyl-1,5 ...

[0580] In some implementations, L 1 It is Z-3-methylpenten-2-diyl-1,5-methyl.

[0581] In some implementations, L 1 It is 2,3-dimethylpentene-2-diyl-1,5 ...

[0582] In some implementations, L 1 It is E-2,3-dimethylpentene-2-diyl-1,5-.

[0583] In some implementations, L 1 It is Z-2,3-dimethylpentene-2-diyl-1,5 ...

[0584] In some implementations, L 1 It is hexenyldiyl.

[0585] In some implementations, L 1 It is hexene-2-diyl-1,6.

[0586] In some implementations, L 1 It is hexene-3-diyl-1,6.

[0587] In some implementations, L 1 It is 3-methylhexene-3-diyl-1,6.

[0588] In some implementations, L 1 It is E-3-methylhexene-3-diyl-1,6.

[0589] In some implementations, L 1 It is Z-3-methylhexene-3-diyl-1,6.

[0590] In some implementations, L 1 It is 3,4-dimethylhexene-3-diyl-1,6.

[0591] In some implementations, L 1 It is E-3,4-dimethylhexene-3-diyl-1,6.

[0592] In some implementations, L 1 It is Z-3,4-dimethylhexene-3-diyl-1,6.

[0593] In some implementations, L 1 It is C2-C 10 Diyne.

[0594] In some implementations, L 1 It is acetylene dimethyl.

[0595] In some implementations, L 1 It is propyne dimethyl.

[0596] In some implementations, L 1 It is propyne-1-diyl-1,3.

[0597] In some implementations, L 1 It is 3-methylpropyn-1-diyl-1,3-methylpropynyl-1-diyl-1,3-diyl-1 ...2-diyl-3-methyl-propynyl-1-diyl-2-diyl-3-diyl-2-diyl-3-diyl-2-diyl

[0598] In some implementations, L 1 It is C3-C 10 -Cycloalkyldiyl.

[0599] In some implementations, L 1 yes

[0600] In some implementations, L 1 yes

[0601] In some implementations, L 1 yes

[0602] In some implementations, L 1 yes

[0603] In some implementations, L 1 yes

[0604] In some implementations, L 1 yes

[0605] In some implementations, L 1 yes

[0606] In some implementations, L 1 yes

[0607] In some implementations, L1 yes

[0608] In some implementations, L 1 yes

[0609] In some implementations, L 1 yes

[0610] In some implementations, L 1 yes

[0611] In some implementations, L 1 yes

[0612] In some implementations, L 1 yes

[0613] In some implementations, L 1 yes

[0614] In some implementations, L 1 It is C3-C 10 -cycloalkyldiyl-C1-C 10 -alkyldiyl.

[0615] In some implementations, L 1 yes

[0616] In some implementations, L 1 yes

[0617] In some implementations, L 1 yes

[0618] In some implementations, L 1 yes

[0619] In some implementations, L 1 yes

[0620] In some implementations, L 1 It is aryl dimethyl benzoate.

[0621] In some implementations, L 1 yes

[0622] In some implementations, L 1 yes

[0623] In some implementations, L 1 yes

[0624] In some implementations, L 1 It is aryl-C1-C 10 -alkyldiyl.

[0625] In some implementations, L 1 It is aryldiyl-methyldiyl.

[0626] In some implementations, L 1 It is aryldimethyl-ethylenedimethyl.

[0627] In some implementations, L 1 It is aryldiyl-1,2-ethylenediyl.

[0628] In some implementations, L 1 It is aryldimethyl-propyldimethyl.

[0629] In some implementations, L 1 It is aryldiyl-1,3-propadiyl.

[0630] In some implementations, L 1 It is aryldiyl-butadiyl.

[0631] In some implementations, L 1 It is aryldiyl-1,4-butadiyl.

[0632] In some implementations, L 1 It is aryldiyl-pentadiyl.

[0633] In some implementations, L 1 It is aryl-hexadiyl.

[0634] In some implementations, L 1 It is aryl-heptyl-heptyl.

[0635] In some implementations, L 1 It is aryldiyl-octadiyl.

[0636] In some implementations, L 1 It is aryl-nonadiyl.

[0637] In some implementations, L 1 It is aryl-decyldiyl.

[0638] In some implementations, L 1 It is phenylene-C1-C 10 -alkyldiyl.

[0639] In some implementations, L 1 yes

[0640] In some implementations, L 1 yes

[0641] In some implementations, L 1 yes

[0642] In some implementations, L 1 It is a heterocyclic dimethyl group.

[0643] In some implementations, L 1 It is a 3-membered heterocyclic dimethyl group.

[0644] In some implementations, L 1 It is a 3-membered heterocyclic dimethyl group containing N as a heteroatom.

[0645] In some implementations, L 1 It is a 4-membered heterocyclic dimethyl group.

[0646] In some implementations, L 1 It is a 4-membered heterocyclic dimethyl group containing N as a heteroatom.

[0647] In some implementations, L 1 yes

[0648] In some implementations, L 1 yes

[0649] In some implementations, L 1 yes

[0650] In some implementations, L 1 yes

[0651] In some implementations, L 1 It is a 5-membered heterocyclic dimethyl group.

[0652] In some implementations, L 1 It is a 5-membered heterocyclic dimethyl group containing N as a heteroatom.

[0653] In some implementations, L 1 yes

[0654] In some implementations, L 1 yes

[0655] In some implementations, L 1 It is a 6-membered heterocyclic dimethyl group.

[0656] In some implementations, L 1 It is a 6-membered heterocyclic dimethyl group containing N as a heteroatom.

[0657] In some implementations, L 1 It is piperidine dimethyl.

[0658] In some implementations, L 1 yes

[0659] In some implementations, L 1 yes

[0660] In some implementations, L 1 yes

[0661] In some implementations, L 1 yes

[0662] In some implementations, L 1 yes

[0663] In some implementations, L 1 yes

[0664] In some implementations, L 1 It is a 7-membered heterocyclic dimethyl group.

[0665] In some implementations, L 1 It is a 7-membered heterocyclic dimethyl group containing N as a heteroatom.

[0666] In some implementations, L 1 It is a heterocyclic dimethyl-C1-C 10 -alkyldiyl.

[0667] In some implementations, L 1 It is a heterocyclic dimethyl-methyldimethyl.

[0668] In some implementations, L 1 It is a heterocyclic dimethyl-ethylenedimethyl.

[0669] In some implementations, L 1 It is a heterocyclic dimethyl-1,2-ethylenedimethyl.

[0670] In some implementations, L 1 It is a heterocyclic dimethyl-propyldimethyl.

[0671] In some implementations, L 1 It is a heterocyclic dimethyl-1,3-propyldimethyl.

[0672] In some implementations, L 1 It is a heterocyclic dimethyl-butyldimethyl.

[0673] In some implementations, L 1 It is a heterocyclic dimethyl-1,4-butadiyl.

[0674] In some implementations, L 1 It is a heterocyclic dimethyl-pentadiyl.

[0675] In some implementations, L 1 It is a heterocyclic dimethyl-hexadiyl.

[0676] In some implementations, L 1 It is a heterocyclic dimethyl-heptadiyl.

[0677] In some implementations, L 1 It is a heterocyclic dimethyl-octadiyl.

[0678] In some implementations, L 1 It is a heterocyclic dimethyl-nonadimethyl.

[0679] In some implementations, L 1 It is a heterocyclic dimethyl-decyldimethyl.

[0680] In some implementations, L 1 It is a 3-membered heterocyclic dimethyl-C1-C 10 -alkyldiyl.

[0681] In some implementations, L 1 It is a 4-membered heterocyclic dimethyl-C1-C 10 -alkyldiyl.

[0682] In some implementations, L 1 yes

[0683] In some implementations, L 1 yes

[0684] In some implementations, L 1 yes

[0685] In some implementations, L 1 yes

[0686] In some implementations, L 1 yes

[0687] In some implementations, L 1 yes

[0688] In some implementations, L 1 yes

[0689] In some implementations, L 1 yes

[0690] In some implementations, L 1 It is a 5-membered heterocyclic dimethyl-C1-C 10 -alkyldiyl.

[0691] In some implementations, L 1 yes

[0692] In some implementations, L 1 yes

[0693] In some implementations, L 1 It is a 6-membered heterocyclic dimethyl-C1-C 10 -alkyldiyl.

[0694] In some implementations, L 1 yes

[0695] In some implementations, L 1 yes

[0696] In some implementations, L 1 yes

[0697] In some implementations, L 1 yes

[0698] In some implementations, L 1 yes

[0699] In some implementations, L 1 yes

[0700] In some implementations, L 1 yes

[0701] In some implementations, L 1 yes

[0702] In some implementations, L1 yes

[0703] In some implementations, L 1 yes

[0704] In some implementations, L 1 yes

[0705] In some implementations, L 1 yes

[0706] In some implementations, L 1 yes

[0707] In some implementations, L 1 It is a 7-membered heterocyclic dimethyl-C1-C 10 -alkyldiyl.

[0708] In some implementations, L 1 It is a mixed aromatic dibasic.

[0709] In some implementations, L 1 It is a 5-membered heteroaryl aromatic dimethyl.

[0710] In some implementations, L 1 yes

[0711] In some implementations, L 1 yes

[0712] In some implementations, L 1 yes

[0713] In some implementations, L 1 It is a 6-membered heteroaryl aromatic dimethyl.

[0714] In some implementations, L 1 yes

[0715] In some implementations, L 1 yes

[0716] In some implementations, L 1 yes

[0717] In some implementations, L 1 yes

[0718] In some implementations, L 1 It is a heteroaryl-C1-C 10 Alkyl.

[0719] In some implementations, L 1 It is a heteroaryl-methyldiyl.

[0720] In some implementations, L 1 It is a heteroaryl-ethylenedimethyl.

[0721] In some implementations, L 1 It is a heteroaryl-1,2-ethadiyl.

[0722] In some implementations, L 1 It is a heteroaryl-propyldiyl.

[0723] In some implementations, L 1 It is a heteroaryl-1,3-propanediyl.

[0724] In some implementations, L 1 It is a heteroaryl-butadiyl.

[0725] In some implementations, L 1 It is a heteroaryl-1,4-butadiyl.

[0726] In some implementations, L 1 It is a heteroaryl-pentadiyl.

[0727] In some implementations, L 1 It is a heteroaryl-hexyldiyl.

[0728] In some implementations, L 1 It is a heteroaryl-heptyldimethyl ...

[0729] In some implementations, L 1 It is a mixed aromatic dimethyl-octyl dimethyl.

[0730] In some implementations, L 1 It is a diarylene-nonadiyl.

[0731] In some implementations, L 1 It is a heteroaryl-decyldiyl.

[0732] In some implementations, L 1 It is a 5-membered heteroaryl-C1-C 10 Alkyl.

[0733] In some implementations, L 1 yes

[0734] In some implementations, L 1 yes

[0735] In some implementations, L 1 yes

[0736] In some implementations, L 1 yes

[0737] In some implementations, L 1 yes

[0738] In some implementations, L 1 It is a 6-membered heteroaryl-C1-C 10 Alkyl.

[0739] In some implementations, L 1 yes

[0740] In some implementations, L 1 yes

[0741] In some implementations, L 1 yes

[0742] In some implementations, L 1 yes

[0743] In some implementations, L 1 yes

[0744] In some implementations, L 1 yes

[0745] In some implementations, L 1 yes

[0746] In some implementations, L 1 yes

[0747] In some implementations, L 1 It is C1-C6 alkyldiyl-O-C1-C6 alkyldiyl.

[0748] In some implementations, L 1 It is -CH2-O-CH2-.

[0749] In some implementations, L 1It is -CH2-O-CH2CH2-.

[0750] In some implementations, L 1 It is -CH2-O-CH2CH2CH2-.

[0751] In some implementations, L 1 It is -CH2CH2-O-CH2CH2-.

[0752] In some implementations, L 1 It is -CH2CH2-O-CH2CH2CH2-.

[0753] In some implementations, L 1 It's -CH2CH2CH2-O-CH2CH2CH2-.

[0754] In some implementations, L 1 It is C1-C6 alkyldiyl-NR 1 -C1-C6 alkyldiyl.

[0755] In some implementations, L 1 It is C1-C6 alkyldiyl-NH-C1-C6 alkyldiyl.

[0756] In some implementations, L 1 It is C1-C6 alkyldiyl-N(CH3)-C1-C6 alkyldiyl.

[0757] In some implementations, L 1 yes

[0758] In some implementations, L 1 yes

[0759] In some implementations, L 1 yes

[0760] In some implementations, L 1 It is a C1-C6 alkyldiyl-C(O)NR 1 -C1-C6 alkyldiyl, wherein each alkyldiyl is independently and optionally selected independently from halogen, OH, oxy, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R4 It is substituted with one or more of the following: aryl and -S(O)2C1-C6 alkyl groups.

[0761] In some implementations, L 1 It is -CH2CH2CH2NHC(O)CH2-.

[0762] In some implementations, L 1 yes

[0763] In some implementations, L 1 yes

[0764] In some implementations, L 1 yes

[0765] In some implementations, L 1 It is -CH2CH2CH2NHC(O)C(CH3)H-.

[0766] In some implementations, L 1 yes

[0767] In some implementations, L 1 yes

[0768] In some implementations, L 1 Independently selected from halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 It is substituted with one or more of the following: aryl and -S(O)2C1-C6 alkyl groups.

[0769] In some implementations, L 2 Selected from C1-C 10 Alkyl, C2-C 10 alkendiyl, C2-C 10 acetylide diol, C3-C 10 -cycloalkyldiyl, C3-C 10 -cycloalkyldiyl-C1-C 10 -alkyldiyl, aryldiyl, aryldiyl-C1-C 10-alkyldiyl, heterocyclic diyl, heterocyclic diyl-C1-C 10 -alkyldiyl, heterocyclic diyl-C(O), heteroaryl, heteroaryl-C1-C 10 Alkyl, C1-C6 alkyldiyl-O-C1-C6 alkyldiyl, C1-C6 alkyldiyl-NR 1 -C1-C6 alkyldiyl, C1-C6 alkyldiyl-C(O)NR 1 -C1-C6 alkyldiyl, wherein the alkyldiyl, alkenyldiyl, alkynyldiyl, aryldiyl, heterocyclic diyl or heteroaryl-heteroaryl group is optionally independently selected from halogen, OH, oxy, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 It is substituted with one or more of the following: aryl and -S(O)2C1-C6 alkyl groups.

[0770] In some implementations, L 2 It is C1-C 10 Alkyl.

[0771] In some implementations, L 2 It is a dimethylamine.

[0772] In some implementations, L 2 It is ethylenedimethylamine.

[0773] In some implementations, L 2 It is 1,1-ethadiyl.

[0774] In some implementations, L 2 It is 1,2-ethylenedimethyl.

[0775] In some implementations, L 2 It is propanediol.

[0776] In some implementations, L 2 It is 1,3-propanediol.

[0777] In some implementations, L 2 It is 1-methylpropyldiyl-1,3-methylpropanediol.

[0778] In some implementations, L 2 It is 2-methylpropyldiyl-1,3-methylpropanediol.

[0779] In some implementations, L2 It is butylene glycol.

[0780] In some implementations, L 2 It is 1,3-butadiyl.

[0781] In some implementations, L 2 It is 1,4-butadiyl.

[0782] In some implementations, L 2 It is 2-methylbutadiene-1,4-methyl.

[0783] In some implementations, L 2 It is pentylene dimethylbenzene.

[0784] In some implementations, L 2 It is 1,5-pentadiyl.

[0785] In some implementations, L 2 It is 3-methylpentadiyl-1,5-methyl.

[0786] In some implementations, L 2 It is 2,3-dimethylpentadiyl-1,5-.

[0787] In some implementations, L 2 It is the two basic elements.

[0788] In some implementations, L 2 It is 1,6-hexadiyl.

[0789] In some implementations, L 2 It is 3-methylhexanediol-1,6.

[0790] In some implementations, L 2 It is 3,4-dimethylhexamethylene-1,6-dimethylhexadiyl-1,6-dimethylhexamethylene ...

[0791] In some implementations, L 2 It is C2-C 10 alkenadiyl.

[0792] In some implementations, L 2 It is ethylenedimethyl.

[0793] In some implementations, L 2 It is vinylidene-1,2.

[0794] In some implementations, L 2 It is propylene dimethyl.

[0795] In some implementations, L 2 It is propylene diene-1,3-propene.

[0796] In some implementations, L 2 It is 2-methylpropenyl-1,3 ...

[0797] In some implementations, L 2 It is butenyldiyl.

[0798] In some implementations, L 2 It is butene-1-diyl-1,4.

[0799] In some implementations, L 2 It is E-butene-1-diyl-1,4.

[0800] In some implementations, L 2 It is Z-butene-1-diyl-1,4.

[0801] In some implementations, L 2 It is butene-2-diyl-1,4-butene.

[0802] In some implementations, L 2 It is E-butene-2-diyl-1,4-butene.

[0803] In some implementations, L 2 It is Z-butene-2-diyl-1,4-butene.

[0804] In some implementations, L 2 It is 2-methylbutene-2-diyl-1,4 ...

[0805] In some implementations, L 2 It is E-2-methylbutene-2-diyl-1,4 ...

[0806] In some implementations, L 2 It is Z-2-methylbutene-2-diyl-1,4-.

[0807] In some implementations, L 2 It is pentenyldiyl.

[0808] In some implementations, L 2 It is pentene-2-diyl-1,5-.

[0809] In some implementations, L 2 It is E-pentene-2-diyl-1,5-.

[0810] In some implementations, L 2 It is Z-penten-2-diyl-1,5-.

[0811] In some implementations, L 2 It is 2-methylpentene-2-diyl-1,5 ...

[0812] In some implementations, L 2 It is E-2-methylpenten-2-diyl-1,5-methyl.

[0813] In some implementations, L 2 It is Z-2-methylpenten-2-diyl-1,5-methyl.

[0814] In some implementations, L 2 It is 3-methylpentene-2-diyl-1,5 ...

[0815] In some implementations, L 2 It is E-3-methylpentene-2-diyl-1,5 ...

[0816] In some implementations, L 2 It is Z-3-methylpenten-2-diyl-1,5-methyl.

[0817] In some implementations, L 2 It is 2,3-dimethylpentene-2-diyl-1,5 ...

[0818] In some implementations, L 2 It is E-2,3-dimethylpentene-2-diyl-1,5-.

[0819] In some implementations, L 2 It is Z-2,3-dimethylpentene-2-diyl-1,5 ...

[0820] In some implementations, L 2 It is hexenyldiyl.

[0821] In some implementations, L 2 It is hexene-2-diyl-1,6.

[0822] In some implementations, L 2 It is hexene-3-diyl-1,6.

[0823] In some implementations, L 2 It is 3-methylhexene-3-diyl-1,6.

[0824] In some implementations, L 2 It is E-3-methylhexene-3-diyl-1,6.

[0825] In some implementations, L 2 It is Z-3-methylhexene-3-diyl-1,6.

[0826] In some implementations, L 2 It is 3,4-dimethylhexene-3-diyl-1,6.

[0827] In some implementations, L 2 It is E-3,4-dimethylhexene-3-diyl-1,6.

[0828] In some implementations, L 2 It is Z-3,4-dimethylhexene-3-diyl-1,6.

[0829] In some implementations, L 2 It is C2-C 10 Diyne.

[0830] In some implementations, L 2 It is acetylene dimethyl.

[0831] In some implementations, L 2 It is propyne dimethyl.

[0832] In some implementations, L 2 It is propyne-1-diyl-1,3.

[0833] In some implementations, L 2 It is 3-methylpropyn-1-diyl-1,3-methylpropynyl-1-diyl-1,3-diyl-1 ...2-diyl-3-methyl-propynyl-1-diyl-2-diyl-3-diyl-2-diyl-3-diyl-2-diyl

[0834] In some implementations, L 2 It is C3-C 10 -Cycloalkyldiyl.

[0835] In some implementations, L 2 yes

[0836] In some implementations, L 2 yes

[0837] In some implementations, L 2 yes

[0838] In some implementations, L 2 yes

[0839] In some implementations, L 2 yes

[0840] In some implementations, L 2 It is C3-C 10 -cycloalkyldiyl-C1-C 10 -alkyldiyl.

[0841] In some implementations, L 2 yes

[0842] In some implementations, L 2 yes

[0843] In some implementations, L 2 yes

[0844] In some implementations, L 2 yes

[0845] In some implementations, L 2 It is aryl dimethyl benzoate.

[0846] In some implementations, L 2 yes

[0847] In some implementations, L 2 yes

[0848] In some implementations, L 2 yes

[0849] In some implementations, L 2 It is aryl-C1-C 10 -alkyldiyl.

[0850] In some implementations, L 2 It is aryldiyl-methyldiyl.

[0851] In some implementations, L 2 It is aryldimethyl-ethylenedimethyl.

[0852] In some implementations, L 2 It is aryldiyl-1,2-ethylenediyl.

[0853] In some implementations, L 2 It is aryldimethyl-propyldimethyl.

[0854] In some implementations, L 2 It is aryldiyl-1,3-propadiyl.

[0855] In some implementations, L 2 It is aryldiyl-butadiyl.

[0856] In some implementations, L 2 It is aryldiyl-1,4-butadiyl.

[0857] In some implementations, L 2 It is aryldiyl-pentadiyl.

[0858] In some implementations, L 2 It is aryl-hexadiyl.

[0859] In some implementations, L 2 It is aryl-heptyl-heptyl.

[0860] In some implementations, L 2 It is aryldiyl-octadiyl.

[0861] In some implementations, L 2 It is aryl-nonadiyl.

[0862] In some implementations, L 2 It is aryl-decyldiyl.

[0863] In some implementations, L 2 It is phenylene-C1-C 10 -alkyldiyl.

[0864] In some implementations, L 2 yes

[0865] In some implementations, L 2 yes

[0866] In some implementations, L 2 yes

[0867] In some implementations, L 2 It is a heterocyclic dimethyl group.

[0868] In some implementations, L 2 It is a 3-membered heterocyclic dimethyl group.

[0869] In some implementations, L 2 It is a 3-membered heterocyclic dimethyl group containing N as a heteroatom.

[0870] In some implementations, L 2 It is a 4-membered heterocyclic dimethyl group.

[0871] In some implementations, L 2 It is a 4-membered heterocyclic dimethyl group containing N as a heteroatom.

[0872] In some implementations, L 2 It is a 5-membered heterocyclic dimethyl group.

[0873] In some implementations, L 2 It is a 5-membered heterocyclic dimethyl group containing N as a heteroatom.

[0874] In some implementations, L 2It is a 6-membered heterocyclic dimethyl group.

[0875] In some implementations, L 2 It is a 6-membered heterocyclic dimethyl group containing N as a heteroatom.

[0876] In some implementations, L 2 It is piperidine dimethyl.

[0877] In some implementations, L 2 yes

[0878] In some implementations, L 2 yes

[0879] In some implementations, L 2 yes

[0880] In some implementations, L 2 yes

[0881] In some implementations, L 2 It is a 7-membered heterocyclic dimethyl group.

[0882] In some implementations, L 2 It is a 7-membered heterocyclic dimethyl group containing N as a heteroatom.

[0883] In some implementations, L 2 It is a heterocyclic dimethyl-C1-C 10 -alkyldiyl.

[0884] In some implementations, L 2 It is a heterocyclic dimethyl-methyldimethyl.

[0885] In some implementations, L 2 It is a heterocyclic dimethyl-ethylenedimethyl.

[0886] In some implementations, L 2 It is a heterocyclic dimethyl-1,2-ethylenedimethyl.

[0887] In some implementations, L 2 It is a heterocyclic dimethyl-propyldimethyl.

[0888] In some implementations, L 2 It is a heterocyclic dimethyl-1,3-propyldimethyl.

[0889] In some implementations, L 2 It is a heterocyclic dimethyl-butyldimethyl.

[0890] In some implementations, L 2It is a heterocyclic dimethyl-1,4-butadiyl.

[0891] In some implementations, L 2 It is a heterocyclic dimethyl-pentadiyl.

[0892] In some implementations, L 2 It is a heterocyclic dimethyl-hexadiyl.

[0893] In some implementations, L 2 It is a heterocyclic dimethyl-heptadiyl.

[0894] In some implementations, L 2 It is a heterocyclic dimethyl-octadiyl.

[0895] In some implementations, L 2 It is a heterocyclic dimethyl-nonadimethyl.

[0896] In some implementations, L 2 It is a heterocyclic dimethyl-decyldimethyl.

[0897] In some implementations, L 2 It is a 3-membered heterocyclic dimethyl-C1-C 10 -alkyldiyl.

[0898] In some implementations, L 2 It is a 4-membered heterocyclic dimethyl-C1-C 10 -alkyldiyl.

[0899] In some implementations, L 2 It is a 5-membered heterocyclic dimethyl-C1-C 10 -alkyldiyl.

[0900] In some implementations, L 2 It is a 6-membered heterocyclic dimethyl-C1-C 10 -alkyldiyl.

[0901] In some implementations, L 2 yes

[0902] In some implementations, L 2 yes

[0903] In some implementations, L 2 yes

[0904] In some implementations, L 2 yes

[0905] In some implementations, L 2 yes

[0906] In some implementations, L 2 yes

[0907] In some implementations, L 2 It is a 7-membered heterocyclic dimethyl-C1-C 10 -alkyldiyl.

[0908] In some implementations, L 2 It is a heterocyclic dimethyl-C(O).

[0909] In some implementations, L 2 yes

[0910] In some implementations, L 2 yes

[0911] In some implementations, L 2 yes

[0912] In some implementations, L 2 yes

[0913] In some implementations, L 2 yes

[0914] In some implementations, L 2 yes

[0915] In some implementations, L 2 It is a mixed aromatic dibasic.

[0916] In some implementations, L 2 It is a 5-membered heteroaryl aromatic dimethyl.

[0917] In some implementations, L 2 yes

[0918] In some implementations, L 2 yes

[0919] In some implementations, L 2 yes

[0920] In some implementations, L 2 It is a 6-membered heteroaryl aromatic dimethyl.

[0921] In some implementations, L 2 yes

[0922] In some implementations, L 2 yes

[0923] In some implementations, L 2 yes

[0924] In some implementations, L 2 yes

[0925] In some implementations, L 2 It is a heteroaryl-C1-C 10 Alkyl.

[0926] In some implementations, L 2 It is a heteroaryl-methyldiyl.

[0927] In some implementations, L 2 It is a heteroaryl-ethylenedimethyl.

[0928] In some implementations, L 2 It is a heteroaryl-1,2-ethadiyl.

[0929] In some implementations, L 2 It is a heteroaryl-propyldiyl.

[0930] In some implementations, L 2 It is a heteroaryl-1,3-propanediyl.

[0931] In some implementations, L 2 It is a heteroaryl-butadiyl.

[0932] In some implementations, L 2 It is a heteroaryl-1,4-butadiyl.

[0933] In some implementations, L 2 It is a heteroaryl-pentadiyl.

[0934] In some implementations, L 2 It is a heteroaryl-hexyldiyl.

[0935] In some implementations, L 2 It is a heteroaryl-heptyldimethyl ...

[0936] In some implementations, L 2 It is a mixed aromatic dimethyl-octyl dimethyl.

[0937] In some implementations, L 2 It is a diarylene-nonadiyl.

[0938] In some implementations, L 2 It is a heteroaryl-decyldiyl.

[0939] In some implementations, L 2 It is a 5-membered heteroaryl-C1-C 10 Alkyl.

[0940] In some implementations, L 2 yes

[0941] In some implementations, L 2 yes

[0942] In some implementations, L 2 yes

[0943] In some implementations, L 2 yes

[0944] In some implementations, L 2 yes

[0945] In some implementations, L 2 It is a 6-membered heteroaryl-C1-C 10 Alkyl.

[0946] In some implementations, L 2 yes

[0947] In some implementations, L 2 yes

[0948] In some implementations, L 2 yes

[0949] In some implementations, L 2 yes

[0950] In some implementations, L 2 yes

[0951] In some implementations, L 2 yes

[0952] In some implementations, L 2 yes

[0953] In some implementations, L2 yes

[0954] In some implementations, L 2 It is C1-C6 alkyldiyl-O-C1-C6 alkyldiyl.

[0955] In some implementations, L 2 It is -CH2-O-CH2-.

[0956] In some implementations, L 2 It is -CH2-O-CH2CH2-.

[0957] In some implementations, L 2 It is -CH2-O-CH2CH2CH2-.

[0958] In some implementations, L 2 It is -CH2CH2-O-CH2CH2-.

[0959] In some implementations, L 2 It is -CH2CH2-O-CH2CH2CH2-.

[0960] In some implementations, L 2 It's -CH2CH2CH2-O-CH2CH2CH2-.

[0961] In some implementations, L 2 It is C1-C6 alkyldiyl-NR 1 -C1-C6 alkyldiyl.

[0962] In some implementations, L 2 It is C1-C6 alkyldiyl-NH-C1-C6 alkyldiyl.

[0963] In some implementations, L 2 It is C1-C6 alkyldiyl-N(CH3)-C1-C6 alkyldiyl.

[0964] In some implementations, L 2 It is a C1-C6 alkyldiyl-C(O)NR 1 -C1-C6 alkyldiyl.

[0965] In some implementations, L 2 It is -CH2-NH-C(O)-CH2-.

[0966] In some implementations, L 2 It is -CH2-N(CH3)-C(O)-CH2-.

[0967] In some implementations, L2 It is -CH2-CH2-NH-C(O)-CH2-.

[0968] In some implementations, L 2 yes

[0969] In some implementations, L 2 yes

[0970] In some implementations, L 2 yes

[0971] In some implementations, L 2 Independently selected from halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NH-C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 It is substituted with one or more substituents in the -S(O)2C1-C6 alkyl group.

[0972] In some implementations, R 3 and R 4 Each is independently selected from H, C1-C6 alkyl, C1-C6 acyl and C3-C 10 Cycloalkyl.

[0973] In some implementations, R 3 and R 4 It's H.

[0974] In some implementations, R 3 It is H and R 4 It is CH3.

[0975] In some implementations, R 3 and R 4 It is CH3.

[0976] In some implementations, R 3 and R 4 Together with the atoms to which they are attached and any intervening atoms, they form 5-14 membered heterocycles, wherein the heterocycle is optionally substituted by one or more substituents independently selected from halogens, OH, =O, CN, NO2, C1-C6 alkyl, and C1-C6 alkoxy.

[0977] In some preferred embodiments, X, Y, Z, L1 and L 2 The combinations were selected from Table 1.

[0978] Table 1. X, Y, Z, L 1 and L 2 The choice of possible values.

[0979]

[0980]

[0981]

[0982]

[0983]

[0984]

[0985]

[0986]

[0987]

[0988] Those skilled in the art will understand that any bimolecular described herein can be bonded to any bimolecular described herein according to general formula (A) using either of its two unpaired valence electrons, provided that the bond is chemically capable of being formed. Table 2 lists some examples of possible bonded bimoleculars described herein.

[0989] Table 2. Possible bonding of the bibases described in this paper (non-limiting examples).

[0990]

[0991]

[0992] In some embodiments, the compound has the formula (I'):

[0993]

[0994] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer, all of which are as defined herein.

[0995] In some embodiments, the compound has the formula (I”):

[0996]

[0997] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer, all of which are as defined herein.

[0998] In some embodiments, the compound has the formula (I-A'):

[0999]

[1000] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer, all of which are as defined herein.

[1001] In some embodiments, the compound has the formula (IA”):

[1002]

[1003] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer, all of which are as defined herein.

[1004] In some embodiments, the compound has the formula (IAI):

[1005]

[1006] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1007] In some embodiments, the compound has the formula (IA-I'):

[1008]

[1009] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1010] In some embodiments, the compound has the formula (IAI”):

[1011]

[1012] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1013] In some embodiments, the compound has the formula (IAIA):

[1014]

[1015] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1016] In some embodiments, the compound has the formula (IAI-A'):

[1017]

[1018] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1019] In some embodiments, the compound has the formula (IAIA”):

[1020]

[1021] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1022] In some embodiments, the compound has the formula (IAIB):

[1023]

[1024] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1025] In some embodiments, the compound has the formula (IAI-B'):

[1026]

[1027] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1028] In some embodiments, the compound has the formula (IAIB”):

[1029]

[1030] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1031] In some embodiments, the compound has the formula (IAIBH):

[1032]

[1033] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1034] In some embodiments, the compound has the formula (IAIB-H'):

[1035]

[1036] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1037] In some embodiments, the compound has the formula (IAIBH”):

[1038]

[1039] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1040] In some embodiments, the compound has the formula (IAIC):

[1041]

[1042] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1043] In some embodiments, the compound has the formula (IAI-C'):

[1044]

[1045] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1046] In some embodiments, the compound has the formula (IAIC”):

[1047]

[1048] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1049] In some embodiments, the compound has the formula (IAICH):

[1050]

[1051] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1052] In some embodiments, the compound has the formula (IAIC-H'):

[1053]

[1054] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1055] In some embodiments, the compound has the formula (IAICH”):

[1056]

[1057] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1058] In some embodiments, the compound has the formula (IAID):

[1059]

[1060] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1061] In some embodiments, the compound has the formula (IAI-D'):

[1062]

[1063] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1064] In some embodiments, the compound has the formula (IAID”):

[1065]

[1066] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1067] In some embodiments, the compound has the formula (IAIE):

[1068]

[1069] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1070] In some embodiments, the compound has the formula (IAI-E'):

[1071]

[1072] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1073] In some embodiments, the compound has the formula (IAIE”):

[1074]

[1075] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1076] In some embodiments, the compound has the formula (IAIF):

[1077]

[1078] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1079] In some embodiments, the compound has the formula (IAI-F'):

[1080]

[1081] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1082] In some embodiments, the compound has the formula (IAIF”):

[1083]

[1084] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1085] In some embodiments, the compound has the formula (IAIG):

[1086]

[1087] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1088] In some embodiments, the compound has the formula (IAI-G'):

[1089]

[1090] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1091] In some embodiments, the compound has the formula (IAIG”):

[1092]

[1093] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1094] In some embodiments, the compound has the formula (IAIAa):

[1095]

[1096] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1097] In some embodiments, the compound has the formula (IAIA-a'):

[1098]

[1099] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1100] In some embodiments, the compound has the formula (IAIAa”):

[1101]

[1102] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1103] In some embodiments, the compound has the formula (IAIAb):

[1104]

[1105] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1106] In some embodiments, the compound has the formula (IAIA-b'):

[1107]

[1108] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1109] In some embodiments, the compound has the formula (IAIAb”):

[1110]

[1111] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1112] In some embodiments, the compound has the formula (IAIAc):

[1113]

[1114] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1115] In some embodiments, the compound has the formula (IAIA-c'):

[1116]

[1117] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1118] In some embodiments, the compound has the formula (IAIAc”):

[1119]

[1120] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1121] In some embodiments, the compound has the formula (IAIAcH):

[1122]

[1123] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1124] In some embodiments, the compound has the formula (IAIAc-H'):

[1125]

[1126] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1127] In some embodiments, the compound has the formula (IAIAcH”):

[1128]

[1129] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1130] In some embodiments, the compound has the formula (IAIAcM):

[1131]

[1132] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1133] In some embodiments, the compound has the formula (IAIAc-M'):

[1134]

[1135] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1136] In some embodiments, the compound has the formula (IAIAcM”):

[1137]

[1138] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1139] In some embodiments, the compound has the formula (IAIAc-IP):

[1140]

[1141] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1142] In some embodiments, the compound has the formula (IAIAc-IP'):

[1143]

[1144] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1145] In some embodiments, the compound has the formula (IAIAc-IP”):

[1146]

[1147] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1148] In some embodiments, the compound has the formula (IAIAc-Ar):

[1149]

[1150] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1151] In some embodiments, the compound has the formula (IAIAc-Ar'):

[1152]

[1153] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1154] In some embodiments, the compound has the formula (IAIAc-Ar”):

[1155]

[1156] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1157] In some embodiments, the compound has the formula (IAIAd):

[1158]

[1159] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1160] In some embodiments, the compound has the formula (IAIA-d'):

[1161]

[1162] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1163] In some embodiments, the compound has the formula (IAIAd”):

[1164]

[1165] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1166] In some embodiments, the compound has the formula (IAIAe):

[1167]

[1168] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1169] In some embodiments, the compound has the formula (IAIA-e'):

[1170]

[1171] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1172] In some embodiments, the compound has the formula (IAIAe”):

[1173]

[1174] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1175] In some embodiments, the compound has the formula (IAIAf):

[1176]

[1177] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1178] In some embodiments, the compound has the formula (IAIA-f'):

[1179]

[1180] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1181] In some embodiments, the compound has the formula (IAIAf”):

[1182]

[1183] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1184] In some embodiments, the compound has the formula (IAIAg):

[1185]

[1186] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1187] In some embodiments, the compound has the formula (IAIA-g'):

[1188]

[1189] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1190] In some embodiments, the compound has the formula (IAIAg”):

[1191]

[1192] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1193] In some embodiments, the compound has the formula (IAIAh):

[1194]

[1195] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1196] In some embodiments, the compound has the formula (IAIA-h'):

[1197]

[1198] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1199] In some embodiments, the compound has the formula (IAIAh”):

[1200]

[1201] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1202] In some embodiments, the compound has the formula (IAIAi):

[1203]

[1204] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1205] In some embodiments, the compound has the formula (IAIA-i'):

[1206]

[1207] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1208] In some embodiments, the compound has the formula (IAIAi”):

[1209]

[1210] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1211] In some embodiments, the compound has the formula (IAIAj):

[1212]

[1213] Or its pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer, where t is 0, 1 or 2 and all other variables are as defined herein.

[1214] In some embodiments, the compound has the formula (IAIA-i'):

[1215]

[1216] Or its pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer, where t is 0, 1 or 2 and all other variables are as defined herein.

[1217] In some embodiments, the compound has the formula (IAIAi”):

[1218]

[1219] Or its pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer, where t is 0, 1 or 2 and all other variables are as defined herein.

[1220] In some embodiments, the compound has the formula (IAIAk):

[1221]

[1222] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1223] In some embodiments, the compound has the formula (IAIA-k'):

[1224]

[1225] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1226] In some embodiments, the compound has the formula (IAIAk”):

[1227]

[1228] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1229] In some embodiments, the compound has the formula (IAIBa):

[1230]

[1231] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1232] In some embodiments, the compound has the formula (IAIB-a'):

[1233]

[1234] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1235] In some embodiments, the compound has the formula (IAIB-1-a”):

[1236]

[1237] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1238] In some embodiments, the compound has the formula (IAIBb):

[1239]

[1240] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1241] In some embodiments, the compound has the formula (IAIB-b'):

[1242]

[1243] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1244] In some embodiments, the compound has the formula (IAIBb”):

[1245]

[1246] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1247] In some embodiments, the compound has the formula (IAIBc):

[1248]

[1249] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1250] In some embodiments, the compound has the formula (IAIB-c'):

[1251]

[1252] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1253] In some embodiments, the compound has the formula (IAIBc”):

[1254]

[1255] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1256] In some embodiments, the compound has the formula (IAIBcH):

[1257]

[1258] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1259] In some embodiments, the compound has the formula (IAIBc-H'):

[1260]

[1261] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1262] In some embodiments, the compound has the formula (IAIBcH”):

[1263]

[1264] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1265] In some embodiments, the compound has the formula (IAIBcM):

[1266]

[1267] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1268] In some embodiments, the compound has the formula (IAIBc-M'):

[1269]

[1270] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1271] In some embodiments, the compound has the formula (IAIBcM”):

[1272]

[1273] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1274] In some embodiments, the compound has the formula (IAIBd):

[1275]

[1276] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1277] In some embodiments, the compound has the formula (IAIB-d'):

[1278]

[1279] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1280] In some embodiments, the compound has the formula (IAIBd”):

[1281]

[1282] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1283] In some embodiments, the compound has the formula (IAIBe):

[1284]

[1285] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1286] In some embodiments, the compound has the formula (IAIB-e'):

[1287]

[1288] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1289] In some embodiments, the compound has the formula (IAIBe”):

[1290]

[1291] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1292] In some embodiments, the compound has the formula (IAIBf):

[1293]

[1294] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1295] In some embodiments, the compound has the formula (IAIB-f'):

[1296]

[1297] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1298] In some embodiments, the compound has the formula (IAIBf”):

[1299]

[1300] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1301] In some embodiments, the compound has the formula (IAIBg):

[1302]

[1303] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1304] In some embodiments, the compound has the formula (IAIB-g'):

[1305]

[1306] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1307] In some embodiments, the compound has the formula (IAIBg”):

[1308]

[1309] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1310] In some embodiments, the compound has the formula (IAIBh):

[1311]

[1312] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1313] In some embodiments, the compound has the formula (IAIB-h'):

[1314]

[1315] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1316] In some embodiments, the compound has the formula (IAIB-1-h”):

[1317]

[1318] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1319] In some embodiments, the compound has the formula (IAIBi):

[1320]

[1321] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1322] In some embodiments, the compound has the formula (IAIB-i'):

[1323]

[1324] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1325] In some embodiments, the compound has the formula (IAIBi”):

[1326]

[1327] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1328] In some embodiments, the compound has the formula (IAIBj):

[1329]

[1330] Or its pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer, where t is 0, 1 or 2 and all other variables are as defined herein.

[1331] In some embodiments, the compound has the formula (IAIB-i'):

[1332]

[1333] Or its pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer, where t is 0, 1 or 2 and all other variables are as defined herein.

[1334] In some embodiments, the compound has the formula (IAIBi”):

[1335]

[1336] Or its pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer, where t is 0, 1 or 2 and all other variables are as defined herein.

[1337] In some embodiments, the compound has the formula (IAIBk):

[1338]

[1339] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1340] In some embodiments, the compound has the formula (IAIB-k'):

[1341]

[1342] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1343] In some embodiments, the compound has the formula (IAIBk”):

[1344]

[1345] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1346] In some embodiments, the compound has the formula (IAIAa-1):

[1347]

[1348] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1349] In some embodiments, the compound has the formula (IAIAa-1') or (IAIAa-1”):

[1350]

[1351] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1352] In some embodiments, the compound has the formula (IAIAa-2):

[1353]

[1354] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1355] In some embodiments, the compound has the formula (IAIAa-2') or (IAIAa-2”):

[1356]

[1357] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1358] In some embodiments, the compound has the formula (IAIAa-3):

[1359]

[1360] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1361] In some embodiments, the compound has the formula (IAIAa-3') or (IAIAa-3”):

[1362]

[1363] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1364] In some embodiments, the compound has the formula (IAIAa-4):

[1365]

[1366] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1367] In some embodiments, the compound has the formula (IAIAa-4') or (IAIAa-4”):

[1368]

[1369] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1370] In some embodiments, the compound has the formula (IAIAa-5):

[1371]

[1372] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1373] In some embodiments, the compound has the formula (IAIAa-5') or (IAIAa-5”):

[1374]

[1375] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1376] In some embodiments, the compound has the formula (IAIAa-6):

[1377]

[1378] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1379] In some embodiments, the compound has the formula (IAIAa-6') or (IAIAa-6”):

[1380]

[1381] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1382] In some embodiments, the compound has the formula (IAIAa-7):

[1383]

[1384] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1385] In some embodiments, the compound has the formula (IAIAa-7') or (IAIAa-7”):

[1386]

[1387] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1388] In some embodiments, the compound has the formula (IAIAa-8):

[1389]

[1390] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1391] In some embodiments, the compound has the formula (IAIAa-8') or (IAIAa-8”):

[1392]

[1393] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1394] In some embodiments, the compound has the formula (IAIAa-9):

[1395]

[1396] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1397] In some embodiments, the compound has the formula (IAIAa-9') or (IAIAa-9”):

[1398]

[1399] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1400] In some embodiments, the compound has the formula (IAIAa-10):

[1401]

[1402] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1403] In some embodiments, the compound has the formula (IAIAa-10') or (IAIAa-10”):

[1404]

[1405] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1406] In some embodiments, the compound has the formula (IAIAa-11):

[1407]

[1408] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1409] In some embodiments, the compound has the formula (EIAIAa-11) or (ZIAIAa-11):

[1410]

[1411] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1412] In some embodiments, the compound has the formula (EIAIAa-11'), (ZIAIAa-11'), (EIAIAa-11”), or (ZIAIAa-11”):

[1413]

[1414] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1415] In some embodiments, the compound has the formula (IAIAa-12):

[1416]

[1417] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1418] In some embodiments, the compound has the formula (EIAIAa-12) or (ZIAIAa-12):

[1419]

[1420] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1421] In some embodiments, the compound has the formula (EIAIAa-12'), (EIAIAa-12”), (ZIAIAa-12'), or (ZIAIAa-12”):

[1422]

[1423] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1424] In some embodiments, the compound has the formula (IAIAa-13):

[1425]

[1426] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1427] In some embodiments, the compound has the formula (EIAIAa-13) or (ZIAIAa-13):

[1428]

[1429] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1430] In some embodiments, the compound has the formula (EIAIAa-13'), (EIAIAa-13”), (ZIAIAa-13'), or (ZIAIAa-13”):

[1431]

[1432] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1433] In some embodiments, the compound has the formula (IAIAa-14):

[1434]

[1435] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1436] In some embodiments, the compound has the formula (EIAIAa-14) or (ZIAIAa-14):

[1437]

[1438] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1439] In some embodiments, the compound has the formula (EIAIAa-14'), (EIAIAa-14”), (ZIAIAa-14'), or (ZIAIAa-14”):

[1440]

[1441] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1442] In some embodiments, the compound has the formula (IAIAa-15):

[1443]

[1444] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1445] In some embodiments, the compound has the formula (EIAIAa-15) or (ZIAIAa-15):

[1446]

[1447] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1448] In some embodiments, the compound has the formula (EIAIAa-15'), (EIAIAa-15”), (ZIAIAa-15'), or (ZIAIAa-15”):

[1449]

[1450] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1451] In some embodiments, the compound has the formula (IAIAa-16):

[1452]

[1453] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1454] In some embodiments, the compound has the formula (EIAIAa-16) or (ZIAIAa-16):

[1455]

[1456] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1457] In some embodiments, the compound has the formula (EIAIAa-16'), (EIAIAa-16”), (ZIAIAa-16'), or (ZIAIAa-16”):

[1458]

[1459] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1460] In some embodiments, the compound has the formula (IAIAa-17):

[1461]

[1462] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1463] In some embodiments, the compound has the formula (EIAIAa-17) or (EIAIAa-17):

[1464]

[1465] Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[1466] In some embodiments, the compound has the formula (EIAIAa-17'), (EIAIAa-17”), (ZIAIAa-17'), or (ZIAIAa-17”):

[1467]

[1468] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1469] In some embodiments, the compound has the formula (IAIAa-18):

[1470]

[1471] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1472] In some embodiments, the compound has the formula (IAIAa-18') or (IAIAa-18”):

[1473]

[1474] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1475] In some embodiments, the compound has the formula (IAIAa-19):

[1476]

[1477] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1478] In some embodiments, the compound has the formula (IAIAa-19') or (IAIAa-19”):

[1479]

[1480] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1481] In some embodiments, the compound has the formula (IAIAa-20):

[1482]

[1483] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1484] In some embodiments, the compound has the formula (IAIAa-20') or (IAIAa-20”):

[1485]

[1486] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1487] In some embodiments, the compound has the formula (IAIAa-21):

[1488]

[1489] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1490] In some embodiments, the compound has the formula (IAIAa-21') or (IAIAa-21”):

[1491]

[1492] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1493] In some embodiments, the compound has the formula (IAIAa-22):

[1494]

[1495] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1496] In some embodiments, the compound has the formula (IAIAa-22') or (IAIAa-22”):

[1497]

[1498] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1499] In some embodiments, the compound has the formula (IAIAa-23):

[1500]

[1501] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1502] In some embodiments, the compound has the formula (IAIAa-23') or (IAIAa-23”):

[1503]

[1504] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1505] In some embodiments, the compound has the formula (IAIAa-24):

[1506]

[1507] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1508] In some embodiments, the compound has the formula (IAIAa-24'), (IAIAa-24”), (IAIAa-24'”), or (IAIAa-24””):

[1509]

[1510] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1511] In some embodiments, the compound has the formula (IAIAa-25):

[1512]

[1513] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1514] In some embodiments, the compound has the formula (IAIAa-25'), (IAIAa-25”), (IAIAa-25'”), or (IAIAa-25””):

[1515]

[1516] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1517] In some embodiments, the compound has the formula (IAIAa-26):

[1518]

[1519] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1520] In some embodiments, the compound has the formula (IAIAa-26'), (IAIAa-26”), (IAIAa-26'”), or (IAIAa-26””):

[1521]

[1522] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1523] In some embodiments, the compound has the formula (IAIAa-27):

[1524]

[1525] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1526] In some embodiments, the compound has the formula (IAIAa-27'), (IAIAa-27”), (IAIAa-27'”), or (IAIAa-27””):

[1527]

[1528] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1529] In some embodiments, the compound has the formula (IAIAa-28):

[1530]

[1531] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1532] In some embodiments, the compound has the formula (IAIAa-28'), (IAIAa-28”), (IAIAa-28'”), or (IAIAa-28””):

[1533]

[1534] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1535] In some embodiments, the compound has the formula (IAIAa-29):

[1536]

[1537] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1538] In some embodiments, the compound has the formula (IAIAa-29'), (IAIAa-29”), (IAIAa-29'”), or (IAIAa-29””):

[1539]

[1540] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1541] In some embodiments, the compound has the formula (IAIAa-30):

[1542]

[1543] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1544] In some embodiments, the compound has the formula (IAIAa-30'), (IAIAa-30”), (IAIAa-30'”), or (IAIAa-30””):

[1545]

[1546] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1547] In some embodiments, the compound has the formula (IAIAb-1):

[1548]

[1549] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1550] In some embodiments, the compound has the formula (IAIAb-1') or (IAIAb-1”):

[1551]

[1552] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1553] In some embodiments, the compound has the formula (IAIAb-2):

[1554]

[1555] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1556] In some embodiments, the compound has the formula (IAIAb-2') or (IAIAb-2”):

[1557]

[1558] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1559] In some embodiments, the compound has the formula (IAIAb-3):

[1560]

[1561] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1562] In some embodiments, the compound has the formula (IAIAa-3') or (IAIAa-3”):

[1563]

[1564] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1565] In some embodiments, the compound has the formula (IAIAb-4):

[1566]

[1567] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1568] In some embodiments, the compound has the formula (IAIAb-4') or (IAIAb-4”):

[1569]

[1570] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1571] In some embodiments, the compound has the formula (IAIAb-5):

[1572]

[1573] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1574] In some embodiments, the compound has the formula (IAIAb-5') or (IAIAb-5”):

[1575]

[1576] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1577] In some embodiments, the compound has the formula (IAIAb-6):

[1578]

[1579] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1580] In some embodiments, the compound has the formula (IAIAa-6') or (IAIAa-6”):

[1581]

[1582] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1583] In some embodiments, the compound has the formula (IAIAb-7):

[1584]

[1585] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1586] In some embodiments, the compound has the formula (IAIAb-7') or (IAIAb-7”):

[1587]

[1588] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1589] In some embodiments, the compound has the formula (IAIAb-8):

[1590]

[1591] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1592] In some embodiments, the compound has the formula (IAIAb-8') or (IAIAb-8”):

[1593]

[1594] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1595] In some embodiments, the compound has the formula (IAIAb-9):

[1596]

[1597] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1598] In some embodiments, the compound has the formula (EIAIAb-9) or (ZIAIAb-9):

[1599]

[1600] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1601] In some embodiments, the compound has the formula (EIAIAb-9'), (EIAIAb-9”), (ZIAIAb-9'), and (ZIAIAb-9”):

[1602]

[1603] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1604] In some embodiments, the compound has the formula (IAIAb-10):

[1605]

[1606] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1607] In some embodiments, the compound has the formula (EIAIAb-10) or (ZIAIAb-10):

[1608]

[1609] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1610] In some embodiments, the compound has the formula (EIAIAb-10'), (EIAIAb-10”), (ZIAIAb-10'), or (ZIAIAb-10”):

[1611]

[1612] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1613] In some embodiments, the compound has the formula (IAIAb-11):

[1614]

[1615] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1616] In some embodiments, the compound has the formula (EIAIAb-11) or (ZIAIAb-11):

[1617]

[1618] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1619] In some embodiments, the compound has the formula (IAIAb-11'), (IAIAb-11”), (IAIAb-11'), or (IAIAb-11”):

[1620]

[1621] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1622] In some embodiments, the compound has the formula (IAIAb-12):

[1623]

[1624] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1625] In some embodiments, the compound has the formula (EIAIAb-12) or (ZIAIAb-12):

[1626]

[1627] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1628] In some embodiments, the compound has the formula (EIAIAb-12'), (EIAIAb-12”), (ZIAIAb-12'), and (ZIAIAb-12”):

[1629]

[1630] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1631] In some embodiments, the compound has the formula (IAIAb-13):

[1632]

[1633] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1634] In some embodiments, the compound has the formula (EIAIAb-13) or (ZIAIAb-13):

[1635]

[1636] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1637] In some embodiments, the compound has the formula (EIAIAb-13'), (EIAIAb-13”), (ZIAIAb-13'), and (ZIAIAb-13”):

[1638]

[1639] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1640] In some embodiments, the compound has the formula (IAIAb-14):

[1641]

[1642] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1643] In some embodiments, the compound has the formula (IAIAb-14') or (IAIAb-14”):

[1644]

[1645] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1646] In some embodiments, the compound has the formula (IAIAb-15):

[1647]

[1648] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1649] In some embodiments, the compound has the formula (IAIAb-15') or (IAIAb-15”):

[1650]

[1651] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1652] In some embodiments, the compound has the formula (IAIAb-16):

[1653]

[1654] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1655] In some embodiments, the compound has the formula (IAIAb-16') or (IAIAb-16”):

[1656]

[1657] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1658] In some embodiments, the compound has the formula (IAIAb-17):

[1659]

[1660] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1661] In some embodiments, the compound has the formula (IAIAb-17') or (IAIAb-17”):

[1662]

[1663] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1664] In some embodiments, the compound has the formula (IAIAb-18):

[1665]

[1666] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1667] In some embodiments, the compound has the formula (IAIAb-18') or (IAIAb-18”):

[1668]

[1669] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1670] In some embodiments, the compound has the formula (IAIAb-19):

[1671]

[1672] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1673] In some embodiments, the compound has the formula (IAIAb-19') or (IAIAb-19”):

[1674]

[1675] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1676] In some embodiments, the compound has the formula (IAIAc-1):

[1677]

[1678] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1679] In some embodiments, the compound has the formula (IAIAc-1') or (IAIAc-1”):

[1680]

[1681] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1682] In some embodiments, the compound has the formula (IAIAc-2):

[1683]

[1684] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1685] In some embodiments, the compound has the formula (IAIAc-2') or (IAIAc-2”):

[1686]

[1687] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1688] In some embodiments, the compound has the formula (IAIAc-3):

[1689]

[1690] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1691] In some embodiments, the compound has the formula (IAIAc-3') or (IAIAc-3”):

[1692]

[1693] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1694] In some embodiments, the compound has the formula (IAIAc-4):

[1695]

[1696] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1697] In some embodiments, the compound has the formula (IAIAc-4') or (IAIAc-4”):

[1698]

[1699] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1700] In some embodiments, the compound has the formula (IAIAc-5):

[1701]

[1702] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1703] In some embodiments, the compound has the formula (IAIAc-5') or (IAIAc-5”):

[1704]

[1705] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1706] In some embodiments, the compound has the formula (IAIAc-6):

[1707]

[1708] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1709] In some embodiments, the compound has the formula (IAIAc-6') or (IAIAc-6”):

[1710]

[1711] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1712] In some embodiments, the compound has the formula (IAIAc-7):

[1713]

[1714] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1715] In some embodiments, the compound has the formula (IAIAc-7') or (IAIAc-7”):

[1716]

[1717] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1718] In some embodiments, the compound has the formula (IAIAd-1):

[1719]

[1720] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1721] In some embodiments, the compound has the formula (IAIAd-1') or (IAIAd-1”):

[1722]

[1723] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1724] In some embodiments, the compound has the formula (IAIAd-2):

[1725]

[1726] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1727] In some embodiments, the compound has the formula (IAIAd-2') or (IAIAd-2”):

[1728]

[1729] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1730] In some embodiments, the compound has the formula (IAIAd-3):

[1731]

[1732] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1733] In some embodiments, the compound has the formula (IAIAd-3') or (IAIAd-3”):

[1734]

[1735] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1736] In some embodiments, the compound has the formula (IAIAd-4):

[1737]

[1738] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1739] In some embodiments, the compound has the formula (IAIAd-4') or (IAIAd-4”):

[1740]

[1741] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1742] In some embodiments, the compound has the formula (IAIAd-5):

[1743]

[1744] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1745] In some embodiments, the compound has the formula (IAIAd-5') or (IAIAd-5”):

[1746]

[1747] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1748] In some embodiments, the compound has the formula (IAIAe-1):

[1749]

[1750] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1751] In some embodiments, the compound has the formula (IAIAe-1') or (IAIAe-1”):

[1752]

[1753] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1754] In some embodiments, the compound has the formula (IAIAe-2):

[1755]

[1756] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1757] In some embodiments, the compound has the formula (IAIAe-2') or (IAIAe-2”):

[1758]

[1759] Or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer thereof.

[1760] In some embodiments, the compound has the formula (IAIAf-1):

[1761]

[1762] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1763] In some embodiments, the compound has the formula (IAIAf-1') or (IAIAf-2'):

[1764]

[1765] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1766] In some embodiments, the compound has the formula (IAIAg-1):

[1767]

[1768] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1769] In some embodiments, the compound has the formula (IAIAg-1') or (IAIAg-1”):

[1770]

[1771] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1772] In some embodiments, the compound has the formula (IAIAg-2):

[1773]

[1774] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1775] In some embodiments, the compound has the formula (IAIAg-2') or (IAIAg-2”):

[1776]

[1777] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1778] In some embodiments, the compound has the formula (IAIAh-1):

[1779]

[1780] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1781] In some embodiments, the compound has the formula (IAIAh-1') or (IAIAh-1”):

[1782]

[1783] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1784] In some embodiments, the compound has the formula (IAIAh-2):

[1785]

[1786] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1787] In some embodiments, the compound has the formula (IAIAh-2') or (IAIAh-2”):

[1788]

[1789] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1790] In some embodiments, the compound has the formula (IAIA-100):

[1791]

[1792] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1793] In some embodiments, the compound has the formula (IAIA-101):

[1794]

[1795] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1796] In some embodiments, the compound has the formula (IAIA-102):

[1797]

[1798] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1799] In some embodiments, the compound has the formula (IAIA-103):

[1800]

[1801] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1802] In some embodiments, the compound has the formula (IAIA-104):

[1803]

[1804] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1805] In some embodiments, the compound has the formula (IAIA-105):

[1806]

[1807] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1808] In some embodiments, the compound has the formula (IAIA-106):

[1809]

[1810] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1811] In some embodiments, the compound has the formula (IAIA-107):

[1812]

[1813] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1814] In some embodiments, the compound has the formula (IAIA-108):

[1815]

[1816] Or its pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer, where i is an integer selected from 0, 1, 2 and 3; j is an integer selected from 1, 2, 3, 4 and 5; and all other variables are as defined herein.

[1817] In some embodiments, the compound has the formula (IAIA-109):

[1818]

[1819] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1820] In some embodiments, the compound has the formula (IAIA-110):

[1821]

[1822] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1823] In some embodiments, the compound has the formula (IAIA-110'), (IAIA-110”), (IAIA-110'”), or (IAIA-110””):

[1824]

[1825] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1826] In some embodiments, the compound has the formula (IAIA-111):

[1827]

[1828] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1829] In some embodiments, the compound has the formula (IAIBa-1):

[1830]

[1831] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1832] In some embodiments, the compound has the formula (IAIBa-1') or (IAIBa-1”):

[1833]

[1834] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1835] In some embodiments, the compound has the formula (IAIBa-2):

[1836]

[1837] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1838] In some embodiments, the compound has the formula (IAIBa-2') or (IAIBa-2”):

[1839]

[1840] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1841] In some embodiments, the compound has the formula (IAIBa-3):

[1842]

[1843] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1844] In some embodiments, the compound has the formula (IAIBa-3') or (IAIBa-3”):

[1845]

[1846] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1847] In some embodiments, the compound has the formula (IAIBa-4):

[1848]

[1849] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1850] In some embodiments, the compound has the formula (IAIBa-4') or (IAIBa-4”):

[1851]

[1852] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1853] In some embodiments, the compound has the formula (IAIBa-5):

[1854]

[1855] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1856] In some embodiments, the compound has the formula (IAIBa-5') or (IAIBa-5”):

[1857]

[1858] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1859] In some embodiments, the compound has the formula (IAIBa-6):

[1860]

[1861] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1862] In some embodiments, the compound has the formula (IAIBa-6') or (IAIBa-6”):

[1863]

[1864] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1865] In some embodiments, the compound has the formula (IAIBa-7):

[1866]

[1867] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1868] In some embodiments, the compound has the formula (IAIBa-7') or (IAIBa-7”):

[1869]

[1870] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1871] In some embodiments, the compound has the formula (IAIBa-8):

[1872]

[1873] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1874] In some embodiments, the compound has the formula (IAIBa-8') or (IAIBa-8”):

[1875]

[1876] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1877] In some embodiments, the compound has the formula (IAIBa-9):

[1878]

[1879] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1880] In some embodiments, the compound has the formula (IAIBa-9') or (IAIBa-9”):

[1881]

[1882] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1883] In some embodiments, the compound has the formula (IAIBa-10):

[1884]

[1885] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1886] In some embodiments, the compound has the formula (IAIBa-10') or (IAIBa-10”):

[1887]

[1888] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1889] In some embodiments, the compound has the formula (IAIBa-11):

[1890]

[1891] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1892] In some embodiments, the compound has the formula (EIAIBa-11) or (ZIAIBa-11):

[1893]

[1894] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1895] In some embodiments, the compound has the formula (EIAIBa-11'), (ZIAIBa-11'), (EIAIBa-11”), or (ZIAIBa-11”):

[1896]

[1897] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1898] In some embodiments, the compound has the formula (IAIBa-12):

[1899]

[1900] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1901] In some embodiments, the compound has the formula (EIAIBa-12) or (ZIAIBa-12):

[1902]

[1903] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1904] In some embodiments, the compound has the formula (EIAIBa-12'), (EIAIBa-12”), (ZIAIBa-12'), or (ZIAIBa-12”):

[1905]

[1906] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1907] In some embodiments, the compound has the formula (IAIBa-13):

[1908]

[1909] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1910] In some embodiments, the compound has the formula (EIAIBa-13) or (ZIAIBa-13):

[1911]

[1912] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1913] In some embodiments, the compound has the formula (EIAIBa-13'), (EIAIBa-13”), (ZIAIBa-13'), or (ZIAIBa-13”):

[1914]

[1915] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1916] In some embodiments, the compound has the formula (IAIBa-14):

[1917]

[1918] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1919] In some embodiments, the compound has the formula (EIAIBa-14) or (ZIAIBa-14):

[1920]

[1921] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1922] In some embodiments, the compound has the formula (EIAIBa-14'), (EIAIBa-14”), (ZIAIBa-14'), or (ZIAIBa-14”):

[1923]

[1924] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1925] In some embodiments, the compound has the formula (IAIBa-15):

[1926]

[1927] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1928] In some embodiments, the compound has the formula (EIAIBa-15) or (ZIAIBa-15):

[1929]

[1930] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1931] In some embodiments, the compound has the formula (EIAIBa-15'), (EIAIBa-15”), (ZIAIBa-15'), or (ZIAIBa-15”):

[1932]

[1933] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1934] In some embodiments, the compound has the formula (IAIBa-16):

[1935]

[1936] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1937] In some embodiments, the compound has the formula (EIAIBa-16) or (ZIAIBa-16):

[1938]

[1939] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1940] In some embodiments, the compound has the formula (EIAIBa-16'), (EIAIBa-16”), (ZIAIBa-16'), or (ZIAIBa-16”):

[1941]

[1942] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1943] In some embodiments, the compound has the formula (IAIBa-17):

[1944]

[1945] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1946] In some embodiments, the compound is of formula (EIAIBa-17) or (EIAIBa-17):

[1947]

[1948] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1949] In some embodiments, the compound has the formula (EIAIBa-17'), (EIAIBa-17”), (ZIAIBa-17'), or (ZIAIBa-17”):

[1950]

[1951] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1952] In some embodiments, the compound has the formula (IAIBa-18):

[1953]

[1954] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1955] In some embodiments, the compound has the formula (IAIBa-18') or (IAIBa-18”):

[1956]

[1957] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1958] In some embodiments, the compound has the formula (IAIBa-19):

[1959]

[1960] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1961] In some embodiments, the compound has the formula (IAIBa-19') or (IAIBa-19”):

[1962]

[1963] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1964] In some embodiments, the compound has the formula (IAIBa-20):

[1965]

[1966] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1967] In some embodiments, the compound has the formula (IAIBa-20') or (IAIBa-20”):

[1968]

[1969] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1970] In some embodiments, the compound has the formula (IAIBa-21):

[1971]

[1972] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1973] In some embodiments, the compound has the formula (IAIBa-21') or (IAIBa-21”):

[1974]

[1975] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1976] In some embodiments, the compound has the formula (IAIBa-22):

[1977]

[1978] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1979] In some embodiments, the compound has the formula (IAIBa-22') or (IAIBa-22”):

[1980]

[1981] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1982] In some embodiments, the compound has the formula (IAIBa-23):

[1983]

[1984] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1985] In some embodiments, the compound has the formula (IAIBa-23') or (IAIBa-23”):

[1986]

[1987] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1988] In some embodiments, the compound has the formula (IAIBa-24):

[1989]

[1990] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1991] In some embodiments, the compound has the formula (IAIBa-24') or (IAIBa-24”):

[1992]

[1993] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1994] In some embodiments, the compound has the formula (IAIBb-1):

[1995]

[1996] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[1997] In some embodiments, the compound has the formula (IAIBb-1') or (IAIBb-1”):

[1998]

[1999] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2000] In some embodiments, the compound has the formula (IAIBb-2):

[2001]

[2002] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2003] In some embodiments, the compound has the formula (IAIBb-2') or (IAIBb-2”):

[2004]

[2005] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2006] In some embodiments, the compound has the formula (IAIBb-3):

[2007]

[2008] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2009] In some embodiments, the compound has the formula (IAIBa-3') or (IAIBa-3”):

[2010]

[2011] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2012] In some embodiments, the compound has the formula (IAIBb-4):

[2013]

[2014] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2015] In some embodiments, the compound has the formula (IAIBb-4') or (IAIBb-4”):

[2016]

[2017] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2018] In some embodiments, the compound has the formula (IA-1-Bb-5):

[2019]

[2020] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2021] In some embodiments, the compound has the formula (IAIBb-5') or (IAIBb-5”):

[2022]

[2023] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2024] In some embodiments, the compound has the formula (IAIBb-6):

[2025]

[2026] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2027] In some embodiments, the compound has the formula (IAIBa-6') or (IAIBa-6”):

[2028]

[2029] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2030] In some embodiments, the compound has the formula (IAIBb-7):

[2031]

[2032] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2033] In some embodiments, the compound has the formula (IAIBb-7') or (IAIBb-7”):

[2034]

[2035] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2036] In some embodiments, the compound has the formula (IAIBb-8):

[2037]

[2038] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2039] In some embodiments, the compound has the formula (IAIBb-8') or (IAIBb-8”):

[2040]

[2041] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2042] In some embodiments, the compound has the formula (IAIBb-9):

[2043]

[2044] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2045] In some embodiments, the compound has the formula (EIAIBb-9) or (ZIAIBb-9):

[2046]

[2047] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2048] In some embodiments, the compound has the formula (EIAIBb-9'), (EIAIBb-9”), (ZIAIBb-9'), and (ZIAIBb-9”):

[2049]

[2050] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2051] In some embodiments, the compound has the formula (IAIBb-10):

[2052]

[2053] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2054] In some embodiments, the compound has the formula (EIAIBb-10) or (ZIAIBb-10):

[2055]

[2056] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2057] In some embodiments, the compound has the formula (EIAIBb-10'), (EIAIBb-10”), (ZIAIBb-10'), or (ZIAIBb-10”):

[2058]

[2059] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2060] In some embodiments, the compound has the formula (IAIBb-11):

[2061]

[2062] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2063] In some embodiments, the compound has the formula (EIAIBb-11) or (ZIAIBb-11):

[2064]

[2065] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2066] In some embodiments, the compound has the formula (IAIBb-11'), (IAIBb-11”), (IAIBb-11'), or (IAIBb-11”):

[2067]

[2068] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2069] In some embodiments, the compound has the formula (IAIBb-12):

[2070]

[2071] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2072] In some embodiments, the compound has the formula (EIAIBb-12) or (ZIAIBb-12):

[2073]

[2074] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2075] In some embodiments, the compound has the formula (EIAIBb-12'), (EIAIBb-12”), (ZIAIBb-12'), and (ZIAIBb-12”):

[2076]

[2077] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2078] In some embodiments, the compound has the formula (IAIBb-13):

[2079]

[2080] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2081] In some embodiments, the compound has the formula (EIAIBb-13) or (ZIAIBb-13):

[2082]

[2083] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2084] In some embodiments, the compound has the formula (EIAIBb-13'), (EIAIBb-13”), (ZIAIBb-13'), and (ZIAIBb-13”):

[2085]

[2086] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2087] In some embodiments, the compound has the formula (IAIBb-14):

[2088]

[2089] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2090] In some embodiments, the compound has the formula (IAIBb-14') or (IAIBb-14”):

[2091]

[2092] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2093] In some embodiments, the compound has the formula (IAIBb-15):

[2094]

[2095] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2096] In some embodiments, the compound has the formula (IAIBb-15') or (IAIBb-15”):

[2097]

[2098] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2099] In some embodiments, the compound has the formula (IAIBb-16):

[2100]

[2101] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2102] In some embodiments, the compound has the formula (IAIBb-16') or (IAIBb-16”):

[2103]

[2104] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2105] In some embodiments, the compound has the formula (IAIBb-17):

[2106]

[2107] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2108] In some embodiments, the compound has the formula (IAIBb-17') or (IAIBb-17”):

[2109]

[2110] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2111] In some embodiments, the compound has the formula (IAIBb-18):

[2112]

[2113] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2114] In some embodiments, the compound has the formula (IAIBb-18') or (IAIBb-18”):

[2115]

[2116] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2117] In some embodiments, the compound has the formula (IAIBb-19):

[2118]

[2119] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2120] In some embodiments, the compound has the formula (IAIBb-19') or (IAIBb-19”):

[2121]

[2122] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2123] In some embodiments, the compound has the formula (IAIBc-1):

[2124]

[2125] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2126] In some embodiments, the compound has the formula (IAIBc-1') or (IAIBc-1”):

[2127]

[2128] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2129] In some embodiments, the compound has the formula (IAIBc-2):

[2130]

[2131] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2132] In some embodiments, the compound has the formula (IAIBc-2') or (IAIBc-2”):

[2133]

[2134] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2135] In some embodiments, the compound has the formula (IAIBc-3):

[2136]

[2137] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2138] In some embodiments, the compound has the formula (IAIBc-3') or (IAIBc-3”):

[2139]

[2140] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2141] In some embodiments, the compound has the formula (IAIBc-4):

[2142]

[2143] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2144] In some embodiments, the compound has the formula (IAIBc-4') or (IAIBc-4”):

[2145]

[2146] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2147] In some embodiments, the compound has the formula (IAIBc-5):

[2148]

[2149] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2150] In some embodiments, the compound has the formula (IAIBc-5') or (IAIBc-5”):

[2151]

[2152] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2153] In some embodiments, the compound has the formula (IAIBc-6):

[2154]

[2155] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2156] In some embodiments, the compound has the formula (IAIBc-6') or (IAIBc-6”):

[2157]

[2158] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2159] In some embodiments, the compound has the formula (IAIBc-7):

[2160]

[2161] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2162] In some embodiments, the compound has the formula (IAIBc-7') or (IAIBc-7”):

[2163]

[2164] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2165] In some embodiments, the compound has the formula (IAIBd-1):

[2166]

[2167] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2168] In some embodiments, the compound has the formula (IAIBd-1') or (IAIBd-1”):

[2169]

[2170] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2171] In some embodiments, the compound has the formula (IAIBd-2):

[2172]

[2173] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2174] In some embodiments, the compound has the formula (IAIBd-2') or (IAIBd-2”):

[2175]

[2176] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2177] In some embodiments, the compound has the formula (IAIBd-3):

[2178]

[2179] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2180] In some embodiments, the compound has the formula (IAIBd-3') or (IAIBd-3”):

[2181]

[2182] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2183] In some embodiments, the compound has the formula (IAIBe-1):

[2184]

[2185] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2186] In some embodiments, the compound has the formula (IAIBe-1') or (IAIBe-1”):

[2187]

[2188] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2189] In some embodiments, the compound has the formula (IAIBe-2):

[2190]

[2191] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2192] In some embodiments, the compound has the formula (IAIBe-2') or (IAIBe-2”):

[2193]

[2194] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2195] In some embodiments, the compound has the formula (IAIBf-1):

[2196]

[2197] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2198] In some embodiments, the compound has the formula (IAIBf-1') or (IAIBf-2”):

[2199]

[2200] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2201] In some embodiments, the compound has the formula (IAIBg-1):

[2202]

[2203] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2204] In some embodiments, the compound has the formula (IAIBg-1') or (IAIBg-1”):

[2205]

[2206] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2207] In some embodiments, the compound has the formula (IAIBg-2):

[2208]

[2209] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2210] In some embodiments, the compound has the formula (IAIBg-2') or (IAIBg-2”):

[2211]

[2212] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2213] In some embodiments, the compound has the formula (IAIBh-1):

[2214]

[2215] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2216] In some embodiments, the compound has the formula (IAIBh-1') or (IAIBh-1”):

[2217]

[2218] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2219] In some embodiments, the compound has the formula (IAIBh-2):

[2220]

[2221] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2222] In some embodiments, the compound has the formula (IAIBh-2') or (IAIBh-2”):

[2223]

[2224] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2225] In some embodiments, the compound has formula (IA-II):

[2226]

[2227] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2228] In some embodiments, the compound has the formula (IA-II-A):

[2229]

[2230] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2231] In some embodiments, the compound has the formula (IA-II-B):

[2232]

[2233] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2234] In some embodiments, the compound has the formula (AB):

[2235]

[2236] Or its pharmaceutically acceptable salt, stereoisomer, solvate, or tautomer, wherein R a Selected from C1-C6 alkyl, H, C2-C6 alkenyl, C2-C6 alkynyl, C3-C 10 Cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally independently selected from halogen, OH, =O, NR. 3 R 4 CN, NO2, COOR 1 CONR 3 R 4 One or more substituents are substituted in the sample;

[2237] R b 、R c 、R d Each is independently selected from H, halogen, OH, NH2, CN, NO2, C1-C6 alkyl and C1-C6 alkoxy, wherein the alkyl or alkoxy group is optionally substituted by one or more halogens or CN; X is selected from bond, O, NR. 1 C(R) 2 )2, S, S(O), S(O)2, C(O), C(O)O, C(O)NR 1 ,OC(O)O,N(R) 2 )C(O)NR 2 Arandibular;

[2238] R 1 Selected from H, C1-C6 alkyl, C3-C 10 Cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 acyl, heterocyclic, aryl, heteroaryl and S(O)2R 2 The alkyl, alkenyl, alkynyl, heterocyclic, cycloalkyl, aryl, or heteroaryl groups are optionally independently selected from halogens, OH, NH2, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10 One or more substituents selected from cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocyclic, aryl, and heteroaryl are used for substitution;

[2239] Each R 2 Independently selected from H, C1-C6 alkyl, C3-C 10 Cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocyclic, aryl, and heteroaryl, wherein the alkyl, alkenyl, alkynyl, heterocyclic, cycloalkyl, aryl, or heteroaryl group is optionally independently selected from halogen, OH, NH2, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10One or more substituents selected from cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocyclic, aryl, and heteroaryl are used for substitution;

[2240] L 1 Selected from C1-C 10 Alkyl, C2-C 10 alkendiyl, C2-C 10 acetylide diol, C3-C 10 -cycloalkyldiyl, C3-C 10 -cycloalkyldiyl-C1-C 10 -alkyldiyl, aryldiyl, aryldiyl-C1-C 10 -alkyldiyl, heterocyclic diyl, heterocyclic diyl-C1-C 10 -alkyldiyl, heterocyclic diyl-C(O), heteroaryl, heteroaryl-C1-C 10 Alkyl, C1-C6 alkyldiyl-O-C1-C6 alkyldiyl, C1-C6 alkyldiyl-NR 1 -C1-C6 alkyldiyl, C1-C6 alkyldiyl-C(O)NR 1 -C1-C6 alkyldiyl, wherein the alkyldiyl, alkenyldiyl, alkynyldiyl, aryldiyl, heterocyclic diyl or heteroaryl-heteroaryl group is optionally independently selected from halogen, OH, oxy, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 Substitution with one or more substituents from aryl and -S(O)2C1-C6 alkyl groups;

[2241] Y is selected from bond, O, NR 1 C(R) 2 )2, S, S(O), S(O)2, C(O), C(O)O, C(O)NR 1 ,OC(O)O,N(R) 2 )C(O)NR 2 ;

[2242] Z is selected from bonds, O, C(R) 2 )2;

[2243] Ring A is selected from C3-C 10 -Cycloalkanes, aromatics, heterocyclic compounds, and heteroaromatics;

[2244] W is (CH2) w ;

[2245] w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;

[2246] u is an integer selected from 0 and 1;

[2247] R 3 and R 4 Each is independently selected from H, C1-C6 alkyl, C1-C6 acyl and C3-C 10 cycloalkyl; or R 3 and R 4 Together with the atoms to which they are attached and any intervening atoms, they form 5-14 membered heterocycles, wherein the heterocycle is optionally substituted by one or more substituents independently selected from halogens, OH, =O, CN, NO2, C1-C6 alkyl, and C1-C6 alkoxy groups;

[2248] R 5 Selected from H, halogen, OH, oxygen, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 -C(O)NR 3 R 4 -S(O)C1-C6 alkyl, -S(O)2NR 3 R 4 And -S(O)2C1-C6 alkyl.

[2249] In some embodiments, the compound has the formula (IA-II-Aa):

[2250]

[2251] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2252] In some embodiments, the compound has the formula (IA-II-Aa-1):

[2253]

[2254] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2255] In some embodiments, the compound has the formula (IA-II-Ah):

[2256]

[2257] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2258] In some embodiments, the compound has the formula (IA-II-Ah-1):

[2259]

[2260] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2261] In some embodiments, the compound has the formula (IA-II-Ah-2):

[2262]

[2263] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2264] In some embodiments, the compound has the formula (II'):

[2265]

[2266] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer, all of which are as defined herein.

[2267] In some embodiments, the compound has the formula (II”):

[2268]

[2269] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer, all of which are as defined herein.

[2270] In some embodiments, the compound has the formula (II-A'):

[2271]

[2272] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer, all of which are as defined herein.

[2273] In some embodiments, the compound has the formula (II-A”):

[2274]

[2275] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer, all of which are as defined herein.

[2276] In some embodiments, the compound has the formula (II-AI):

[2277]

[2278] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2279] In some embodiments, the compound has the formula (II-A-I'):

[2280]

[2281] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2282] In some embodiments, the compound has the formula (II-AI”):

[2283]

[2284] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2285] In some embodiments, the compound has the formula (II-AIA):

[2286]

[2287] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2288] In some embodiments, the compound has the formula (II-AI-A'):

[2289]

[2290] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2291] In some embodiments, the compound has the formula (II-AIA”):

[2292]

[2293] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2294] In some embodiments, the compound has the formula (II-AIB):

[2295]

[2296] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2297] In some embodiments, the compound has the formula (II-AI-B'):

[2298]

[2299] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2300] In some embodiments, the compound has the formula (II-AIB”):

[2301]

[2302] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2303] In some embodiments, the compound has the formula (II-AIBH):

[2304]

[2305] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2306] In some embodiments, the compound has the formula (II-AIB-H'):

[2307]

[2308] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2309] In some embodiments, the compound has the formula (II-AIBH”):

[2310]

[2311] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2312] In some embodiments, the compound has the formula (II-AIC):

[2313]

[2314] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2315] In some embodiments, the compound has the formula (II-AI-C'):

[2316]

[2317] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2318] In some embodiments, the compound has the formula (II-AIC”):

[2319]

[2320] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2321] In some embodiments, the compound has the formula (II-AICH):

[2322]

[2323] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2324] In some embodiments, the compound has the formula (II-AIC-H'):

[2325]

[2326] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2327] In some embodiments, the compound has the formula (II-AICH”):

[2328]

[2329] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2330] In some embodiments, the compound has the formula (II-AID):

[2331]

[2332] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2333] In some embodiments, the compound has the formula (II-AI-D'):

[2334]

[2335] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2336] In some embodiments, the compound has the formula (II-AID”):

[2337]

[2338] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2339] In some embodiments, the compound has the formula (II-AIE):

[2340]

[2341] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2342] In some embodiments, the compound has the formula (II-AI-E'):

[2343]

[2344] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2345] In some embodiments, the compound has the formula (II-AIE”):

[2346]

[2347] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2348] In some embodiments, the compound has the formula (II-AIF):

[2349]

[2350] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2351] In some embodiments, the compound has the formula (II-AI-F'):

[2352]

[2353] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2354] In some embodiments, the compound has the formula (II-AIF”):

[2355]

[2356] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2357] In some embodiments, the compound has the formula (II-AIG):

[2358]

[2359] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2360] In some embodiments, the compound has the formula (II-AI-G'):

[2361]

[2362] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2363] In some embodiments, the compound has the formula (II-AIG”):

[2364]

[2365] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2366] In some embodiments, the compound has the formula (II-AIAa):

[2367]

[2368] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2369] In some embodiments, the compound has the formula (II-AIA-a'):

[2370]

[2371] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2372] In some embodiments, the compound has the formula (II-AIAa”):

[2373]

[2374] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2375] In some embodiments, the compound has the formula (II-AIAb):

[2376]

[2377] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2378] In some embodiments, the compound has the formula (II-AIA-b'):

[2379]

[2380] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2381] In some embodiments, the compound has the formula (II-AIAb”):

[2382]

[2383] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2384] In some embodiments, the compound has the formula (II-AIAc):

[2385]

[2386] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2387] In some embodiments, the compound has the formula (II-AIA-c'):

[2388]

[2389] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2390] In some embodiments, the compound has the formula (II-AIAc”):

[2391]

[2392] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2393] In some embodiments, the compound has the formula (II-AIAcH):

[2394]

[2395] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2396] In some embodiments, the compound has the formula (II-AIAc-H'):

[2397]

[2398] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2399] In some embodiments, the compound has the formula (II-AIAcH”):

[2400]

[2401] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2402] In some embodiments, the compound has the formula (II-AIAcM):

[2403]

[2404] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2405] In some embodiments, the compound has the formula (II-AIAc-M'):

[2406]

[2407] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2408] In some embodiments, the compound has the formula (II-AIAcM”):

[2409]

[2410] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2411] In some embodiments, the compound has the formula (II-AIAd):

[2412]

[2413] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2414] In some embodiments, the compound has the formula (II-AIA-d'):

[2415]

[2416] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2417] In some embodiments, the compound has the formula (II-AIAd”):

[2418]

[2419] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2420] In some embodiments, the compound has the formula (II-AIAe):

[2421]

[2422] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2423] In some embodiments, the compound has the formula (II-AIA-e'):

[2424]

[2425] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2426] In some embodiments, the compound has the formula (II-AIAe”):

[2427]

[2428] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2429] In some embodiments, the compound has the formula (II-AIAf):

[2430]

[2431] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2432] In some embodiments, the compound has the formula (II-AIA-f'):

[2433]

[2434] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2435] In some embodiments, the compound has the formula (II-AIAf”):

[2436]

[2437] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2438] In some embodiments, the compound has the formula (II-AIAg):

[2439] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2440] In some embodiments, the compound has the formula (II-AIA-g'):

[2441]

[2442] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2443] In some embodiments, the compound has the formula (II-AIAg”):

[2444]

[2445] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2446] In some embodiments, the compound has the formula (II-AIAh):

[2447]

[2448] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2449] In some embodiments, the compound has the formula (II-AIA-h'):

[2450]

[2451] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2452] In some embodiments, the compound has the formula (II-AIAh”):

[2453]

[2454] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2455] In some embodiments, the compound has the formula (II-AIAi):

[2456]

[2457] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2458] In some embodiments, the compound has the formula (II-AIA-i'):

[2459]

[2460] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2461] In some embodiments, the compound has the formula (II-AIAi”):

[2462]

[2463] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2464] In some embodiments, the compound has the formula (II-AIAj):

[2465]

[2466] Or its pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer, where t is 0, 1 or 2 and all other variables are as defined herein.

[2467] In some embodiments, the compound has the formula (II-AIA-i'):

[2468]

[2469] Or its pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer, where t is 0, 1 or 2 and all other variables are as defined herein.

[2470] In some embodiments, the compound has the formula (II-AIAi”):

[2471]

[2472] Or its pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer, where t is 0, 1 or 2 and all other variables are as defined herein.

[2473] In some embodiments, the compound has the formula (II-AIAk):

[2474]

[2475] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2476] In some embodiments, the compound has the formula (II-AIA-k'):

[2477]

[2478] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2479] In some embodiments, the compound has the formula (II-AIAk”):

[2480]

[2481] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2482] In some embodiments, the compound has the formula (II-AIBa):

[2483]

[2484] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2485] In some embodiments, the compound has the formula (II-AIB-a'):

[2486]

[2487] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2488] In some embodiments, the compound has the formula (II-AIBa”):

[2489]

[2490] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2491] In some embodiments, the compound has the formula (II-AIBb):

[2492]

[2493] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2494] In some embodiments, the compound has the formula (II-AIB-b'):

[2495]

[2496] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2497] In some embodiments, the compound has the formula (II-AIBb”):

[2498]

[2499] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2500] In some embodiments, the compound has the formula (II-AIBc):

[2501]

[2502] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2503] In some embodiments, the compound has the formula (II-AIB-c'):

[2504]

[2505] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2506] In some embodiments, the compound has the formula (II-AIBc”):

[2507]

[2508] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2509] In some embodiments, the compound has the formula (II-AIBcH):

[2510]

[2511] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2512] In some embodiments, the compound has the formula (II-AIBc-H'):

[2513]

[2514] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2515] In some embodiments, the compound has the formula (II-AIBcH”):

[2516]

[2517] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2518] In some embodiments, the compound has the formula (II-AIBcM):

[2519]

[2520] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2521] In some embodiments, the compound has the formula (II-AIBc-M'):

[2522]

[2523] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2524] In some embodiments, the compound has the formula (II-AIBcM”):

[2525]

[2526] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2527] In some embodiments, the compound has the formula (II-AIBd):

[2528]

[2529] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2530] In some embodiments, the compound has the formula (II-AIB-d'):

[2531]

[2532] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2533] In some embodiments, the compound has the formula (II-AIBd”):

[2534]

[2535] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2536] In some embodiments, the compound has the formula (II-AIBe):

[2537]

[2538] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2539] In some embodiments, the compound has the formula (II-AIB-e'):

[2540]

[2541] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2542] In some embodiments, the compound has the formula (II-AIBe”):

[2543]

[2544] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2545] In some embodiments, the compound has the formula (II-AIBf):

[2546]

[2547] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2548] In some embodiments, the compound has the formula (II-AIB-f'):

[2549]

[2550] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2551] In some embodiments, the compound has the formula (II-AIBf”):

[2552]

[2553] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2554] In some embodiments, the compound has the formula (II-AIBg):

[2555]

[2556] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2557] In some embodiments, the compound has the formula (II-AIB-g'):

[2558]

[2559] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2560] In some embodiments, the compound has the formula (II-AIBg”):

[2561]

[2562] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2563] In some embodiments, the compound has the formula (II-AIBh):

[2564]

[2565] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2566] In some embodiments, the compound has the formula (II-AIB-h'):

[2567]

[2568] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2569] In some embodiments, the compound has the formula (II-AIBh”):

[2570]

[2571] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2572] In some embodiments, the compound has the formula (II-AIBi):

[2573]

[2574] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2575] In some embodiments, the compound has the formula (II-AIB-i'):

[2576]

[2577] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2578] In some embodiments, the compound has the formula (II-AIBi”):

[2579]

[2580] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2581] In some embodiments, the compound has the formula (II-AIBj):

[2582]

[2583] Or its pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer, where t is 0, 1 or 2 and all other variables are as defined herein.

[2584] In some embodiments, the compound has the formula (II-AIB-i'):

[2585]

[2586] Or its pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer, where t is 0, 1 or 2 and all other variables are as defined herein.

[2587] In some embodiments, the compound has the formula (II-AIBi”):

[2588]

[2589] Or its pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative or tautomer, where t is 0, 1 or 2 and all other variables are as defined herein.

[2590] In some embodiments, the compound has the formula (II-AIBk):

[2591]

[2592] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2593] In some embodiments, the compound has the formula (II-AIB-k'):

[2594]

[2595] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2596] In some embodiments, the compound has the formula (II-AIBk”):

[2597]

[2598] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2599] In some embodiments, the compound has the formula (II-AIAa-1):

[2600]

[2601] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2602] In some embodiments, the compound has the formula (II-AIAa-1') or (II-AIAa-1”):

[2603]

[2604] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2605] In some embodiments, the compound has the formula (II-AIAa-2):

[2606]

[2607] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2608] In some embodiments, the compound has the formula (II-AIAa-2') or (II-AIAa-2”):

[2609]

[2610] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2611] In some embodiments, the compound has the formula (II-AIAa-3):

[2612]

[2613] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2614] In some embodiments, the compound has the formula (IAIAa-3') or (IAIAa-3”):

[2615]

[2616] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2617] In some embodiments, the compound has the formula (II-AIAa-4):

[2618]

[2619] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2620] In some embodiments, the compound has the formula (II-AIAa-4') or (II-AIAa-4”):

[2621]

[2622] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2623] In some embodiments, the compound has the formula (II-AIAa-5):

[2624]

[2625] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2626] In some embodiments, the compound has the formula (II-AIAa-5') or (II-AIAa-5”):

[2627]

[2628] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2629] In some embodiments, the compound has the formula (II-AIAa-6):

[2630]

[2631] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2632] In some embodiments, the compound has the formula (II-AIAa-6') or (II-AIAa-6”):

[2633]

[2634] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2635] In some embodiments, the compound has the formula (II-AIAa-7):

[2636]

[2637] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2638] In some embodiments, the compound has the formula (II-AIAa-7') or (II-AIAa-7”):

[2639]

[2640] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2641] In some embodiments, the compound has the formula (II-AIAa-8):

[2642]

[2643] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2644] In some embodiments, the compound has the formula (II-AIAa-8') or (II-AIAa-8”):

[2645]

[2646] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2647] In some embodiments, the compound has the formula (II-AIAa-9):

[2648]

[2649] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2650] In some embodiments, the compound has the formula (II-AIAa-9') or (II-AIAa-9”):

[2651]

[2652] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2653] In some embodiments, the compound has the formula (IAIAa-10):

[2654]

[2655] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2656] In some embodiments, the compound has the formula (IAIAa-10') or (IAIAa-10”):

[2657]

[2658] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2659] In some embodiments, the compound has the formula (II-AIAa-11):

[2660]

[2661] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2662] In some embodiments, the compound has the formula (E-II-AIAa-11) or (Z-II-AIAa-11):

[2663]

[2664] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2665] In some embodiments, the compound has the formula (II-AIAa-12):

[2666]

[2667] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2668] In some embodiments, the compound has the formula (E-II-AIAa-12) or (Z-II-AIAa-12):

[2669]

[2670] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2671] In some embodiments, the compound has the formula (II-AIAa-13):

[2672]

[2673] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2674] In some embodiments, the compound has the formula (E-II-AIAa-13) or (Z-II-AIAa-13):

[2675]

[2676] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2677] In some embodiments, the compound has the formula (II-AIAa-14):

[2678]

[2679] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2680] In some embodiments, the compound has the formula (E-II-AIAa-14) or (Z-II-AIAa-14):

[2681]

[2682] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2683] In some embodiments, the compound has the formula (II-AIAa-15):

[2684]

[2685] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2686] In some embodiments, the compound has the formula (E-II-AIAa-15) or (Z-II-AIAa-15):

[2687]

[2688] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2689] In some embodiments, the compound has the formula (II-AIAa-16):

[2690]

[2691] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2692] In some embodiments, the compound has the formula (E-II-AIAa-16) or (Z-II-AIAa-16):

[2693]

[2694] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2695] In some embodiments, the compound has the formula (II-AIAa-17):

[2696]

[2697] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2698] In some embodiments, the compound has the formula (E-II-AIAa-17) or (E-II-AIAa-17):

[2699]

[2700] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2701] In some embodiments, the compound has the formula (II-AIAa-18):

[2702]

[2703] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2704] In some embodiments, the compound has the formula (II-AIAa-18') or (II-AIAa-18”):

[2705]

[2706] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2707] In some embodiments, the compound has the formula (II-AIAa-19):

[2708]

[2709] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2710] In some embodiments, the compound has the formula (II-AIAa-19') or (II-AIAa-19”):

[2711]

[2712] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2713] In some embodiments, the compound has the formula (II-AIAa-20):

[2714]

[2715] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2716] In some embodiments, the compound has the formula (II-AIAa-20') or (II-AIAa-20”):

[2717]

[2718] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2719] In some embodiments, the compound has the formula (II-AIAa-21):

[2720]

[2721] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2722] In some embodiments, the compound has the formula (II-AIAa-21') or (II-AIAa-21”):

[2723]

[2724] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2725] In some embodiments, the compound has the formula (II-AIAa-22):

[2726]

[2727] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2728] In some embodiments, the compound has the formula (II-AIAa-22') or (II-AIAa-22”):

[2729]

[2730] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2731] In some embodiments, the compound has the formula (II-AIAa-23):

[2732]

[2733] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2734] In some embodiments, the compound has the formula (II-AIAa-23') or (II-AIAa-23”):

[2735]

[2736] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2737] In some embodiments, the compound has the formula (II-AIAa-24):

[2738]

[2739] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2740] In some embodiments, the compound has the formula (II-AIAa-24'), (II-AIAa-24”), (II-AIAa-24'”), or (II-AIAa-24””):

[2741]

[2742] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2743] In some embodiments, the compound has the formula (II-AIAa-25):

[2744]

[2745] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2746] In some embodiments, the compound has the formula (II-AIAa-25'), (II-AIAa-25”), (II-AIAa-25'”), or (II-AIAa-25””):

[2747]

[2748] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2749] In some embodiments, the compound has the formula (II-AIAa-26):

[2750]

[2751] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2752] In some embodiments, the compound has the formula (II-AIAa-26'), (II-AIAa-26”), (II-AIAa-26'”), or (II-AIAa-26””):

[2753]

[2754] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2755] In some embodiments, the compound has the formula (II-AIAa-27):

[2756]

[2757] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2758] In some embodiments, the compound has the formula (II-AIAa-27'), (II-AIAa-27”), (II-AIAa-27'”), or (II-AIAa-27””):

[2759]

[2760] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2761] In some embodiments, the compound has the formula (II-AIAa-28):

[2762]

[2763] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2764] In some embodiments, the compound has the formula (II-AIAa-28'), (II-AIAa-28”), (II-AIAa-28'”), or (II-AIAa-28””):

[2765]

[2766] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2767] In some embodiments, the compound has the formula (II-AIAa-29):

[2768]

[2769] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2770] In some embodiments, the compound has the formula (II-AIAa-29'), (II-AIAa-29”), (II-AIAa-29'”), or (II-AIAa-29””):

[2771]

[2772] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2773] In some embodiments, the compound has the formula (II-AIAb-1):

[2774]

[2775] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2776] In some embodiments, the compound has the formula (II-AIAb-1') or (II-AIAb-1”):

[2777]

[2778] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2779] In some embodiments, the compound has the formula (II-AIAb-2):

[2780]

[2781] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2782] In some embodiments, the compound has the formula (II-AIAb-2') or (II-AIAb-2”):

[2783]

[2784] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2785] In some embodiments, the compound has the formula (II-AIAb-3):

[2786]

[2787] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2788] In some embodiments, the compound has the formula (II-AIAa-3') or (II-AIAa-3”):

[2789]

[2790] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2791] In some embodiments, the compound has the formula (II-AIAb-4):

[2792]

[2793] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2794] In some embodiments, the compound has the formula (II-AIAb-4') or (II-AIAb-4”):

[2795]

[2796] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2797] In some embodiments, the compound has the formula (II-AIAb-5):

[2798]

[2799] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2800] In some embodiments, the compound has the formula (II-AIAb-5') or (II-AIAb-5”):

[2801]

[2802] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2803] In some embodiments, the compound has the formula (II-AIAb-6):

[2804]

[2805] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2806] In some embodiments, the compound has the formula (II-AIAa-6') or (II-AIAa-6”):

[2807]

[2808] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2809] In some embodiments, the compound has the formula (II-AIAb-7):

[2810]

[2811] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2812] In some embodiments, the compound has the formula (II-AIAb-7') or (II-AIAb-7”):

[2813]

[2814] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2815] In some embodiments, the compound has the formula (II-AIAb-8):

[2816]

[2817] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2818] In some embodiments, the compound has the formula (II-AIAb-8') or (II-AIAb-8”):

[2819]

[2820] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2821] In some embodiments, the compound has the formula (II-AIAb-9):

[2822]

[2823] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2824] In some embodiments, the compound has the formula (EIAIAb-9) or (ZIAIAb-9):

[2825]

[2826] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2827] In some embodiments, the compound has the formula (II-AIAb-10):

[2828]

[2829] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2830] In some embodiments, the compound has the formula (E-II-AIAb-10) or (Z-II-AIAb-10):

[2831]

[2832] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2833] In some embodiments, the compound has the formula (II-AIAb-11):

[2834]

[2835] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2836] In some embodiments, the compound has the formula (E-II-AIAb-11) or (Z-II-AIAb-11):

[2837]

[2838] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2839] In some embodiments, the compound has the formula (II-AIAb-12):

[2840]

[2841] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2842] In some embodiments, the compound has the formula (E-II-AIAb-12) or (Z-II-AIAb-12):

[2843]

[2844] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2845] In some embodiments, the compound has the formula (II-AIAb-13):

[2846]

[2847] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2848] In some embodiments, the compound has the formula (E-II-AIAb-13) or (Z-II-AIAb-13):

[2849]

[2850] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2851] In some embodiments, the compound has the formula (II-AIAb-14):

[2852]

[2853] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2854] In some embodiments, the compound has the formula (II-AIAb-14') or (II-AIAb-14”):

[2855]

[2856] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2857] In some embodiments, the compound has the formula (II-AIAb-15):

[2858]

[2859] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2860] In some embodiments, the compound has the formula (II-AIAb-15') or (II-AIAb-15”):

[2861]

[2862] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2863] In some embodiments, the compound has the formula (II-AIAb-16):

[2864]

[2865] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2866] In some embodiments, the compound has the formula (II-AIAb-16') or (II-AIAb-16”):

[2867]

[2868] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2869] In some embodiments, the compound has the formula (II-AIAb-17):

[2870]

[2871] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2872] In some embodiments, the compound has the formula (II-AIAb-17') or (II-AIAb-17”):

[2873]

[2874] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2875] In some embodiments, the compound has the formula (II-AIAb-18):

[2876]

[2877] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2878] In some embodiments, the compound has the formula (II-AIAb-18') or (II-AIAb-18”):

[2879]

[2880] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2881] In some embodiments, the compound has the formula (II-AIAb-19):

[2882]

[2883] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2884] In some embodiments, the compound has the formula (II-AIAb-19') or (II-AIAb-19”):

[2885]

[2886] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2887] In some embodiments, the compound has the formula (II-AIAc-1):

[2888]

[2889] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2890] In some embodiments, the compound has the formula (II-AIAc-1') or (II-AIAc-1”):

[2891]

[2892] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2893] In some embodiments, the compound has the formula (II-AIAc-2):

[2894]

[2895] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2896] In some embodiments, the compound has the formula (II-AIAc-2') or (II-AIAc-2”):

[2897]

[2898] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2899] In some embodiments, the compound has the formula (II-AIAc-3):

[2900]

[2901] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2902] In some embodiments, the compound has the formula (II-AIAc-3') or (II-AIAc-3”):

[2903]

[2904] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2905] In some embodiments, the compound has the formula (II-AIAc-4):

[2906]

[2907] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2908] In some embodiments, the compound has the formula (II-AIAc-4') or (II-AIAc-4”):

[2909]

[2910] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2911] In some embodiments, the compound has the formula (II-AIAc-5):

[2912]

[2913] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2914] In some embodiments, the compound has the formula (II-AIAc-5') or (II-AIAc-5”):

[2915]

[2916] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2917] In some embodiments, the compound has the formula (II-AIAc-6):

[2918]

[2919] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2920] In some embodiments, the compound has the formula (II-AIAc-6') or (II-AIAc-6”):

[2921]

[2922] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2923] In some embodiments, the compound has the formula (II-AIAc-7):

[2924]

[2925] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2926] In some embodiments, the compound has the formula (II-AIAc-7') or (II-AIAc-7”):

[2927]

[2928] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2929] In some embodiments, the compound has the formula (II-AIAd-1):

[2930]

[2931] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2932] In some embodiments, the compound has the formula (II-AIAd-1') or (II-AIAd-1”):

[2933]

[2934] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2935] In some embodiments, the compound has the formula (II-AIAd-2):

[2936]

[2937] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2938] In some embodiments, the compound is of the formula (II-AIAd-2') or (II-AIAd-2”):

[2939]

[2940] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2941] In some embodiments, the compound has the formula (II-AIAd-3):

[2942]

[2943] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2944] In some embodiments, the compound has the formula (II-AIAd-3') or (II-AIAd-3”):

[2945]

[2946] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2947] In some embodiments, the compound has the formula (II-AIAd-4):

[2948]

[2949] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2950] In some embodiments, the compound has the formula (II-AIAd-4') or (II-AIAd-4”):

[2951]

[2952] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2953] In some embodiments, the compound has the formula (II-AIAd-5):

[2954]

[2955] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2956] In some embodiments, the compound has the formula (II-AIAd-5') or (II-AIAd-5”):

[2957]

[2958] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2959] In some embodiments, the compound has the formula (II-AIAe-1):

[2960]

[2961] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2962] In some embodiments, the compound has the formula (II-AIAe-1') or (II-AIAe-1”):

[2963]

[2964] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2965] In some embodiments, the compound has the formula (II-AIAe-2):

[2966]

[2967] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2968] In some embodiments, the compound has the formula (II-AIAe-2') or (II-AIAe-2”):

[2969]

[2970] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2971] In some embodiments, the compound has the formula (II-AIAf-1):

[2972]

[2973] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2974] In some embodiments, the compound has the formula (II-AIAf-1') or (II-AIAf-2'):

[2975]

[2976] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2977] In some embodiments, the compound has the formula (II-AIAg-1):

[2978] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2979] In some embodiments, the compound has the formula (II-AIAg-1') or (II-AIAg-1”):

[2980]

[2981] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2982] In some embodiments, the compound has the formula (II-AIAg-2):

[2983]

[2984] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2985] In some embodiments, the compound has the formula (II-AIAg-2') or (II-AIAg-2”):

[2986]

[2987] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2988] In some embodiments, the compound has the formula (II-AIAh-1):

[2989]

[2990] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2991] In some embodiments, the compound has the formula (IAIAh-1') or (IAIAh-1”):

[2992]

[2993] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2994] In some embodiments, the compound has the formula (II-AIAh-2):

[2995]

[2996] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope derivative, or tautomer.

[2997] In some embodiments, the compound has the formula (II-AIAh-2') or (II-AIAh-2”):

[2998]

[2999] Or it may be a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotope de...

Claims

1. A compound of formula (A): or a pharmaceutically acceptable salt, stereoisomer, solvate or tautomer thereof, wherein R a is selected from C1-C6 alkyl, H, C2-C6 alkenyl, C2-C6 alkynyl, C3-C 10 Cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally independently selected from halogen, OH, =O, NR 3 R 4 、CN、NO2、COOR 1 ,CONR 3 R 4 is substituted with one or more substituents; R b , R c , R d Each is independently selected from H, halogen, OH, NH2, CN, NO2, C1-C6 alkyl and C1-C6 alkoxy, wherein the alkyl or alkoxy is optionally substituted with one or more halogen, CN; X is selected from O, a bond, NR 1 , C(R 2 )2, S, S(O), S(O)2, C(O), C(O)O, C(O)NR 1 、OC(O)O、N(R 2 )C(O)NR 2 , aromatic diyl; R 1 Selected from H, C1-C6 alkyl, C3-C 10 Cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 acyl, heterocyclic, aryl, heteroaryl and S(O)2R 2 , wherein the alkyl, alkenyl, alkynyl, heterocycle, cycloalkyl, aryl or heteroaryl is optionally independently selected from halogen, OH, NH2, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10 Substituted by one or more substituents selected from cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocycle, aryl, heteroaryl; Each R 2 Independently selected from H, C1-C6 alkyl, C3-C 10 Cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocycle, aryl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, heterocycle, cycloalkyl, aryl or heteroaryl is optionally independently selected from halogen, OH, NH2, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10 Substituted by one or more substituents selected from cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocycle, aryl, heteroaryl; Y is selected from a bond, O, NR 1 , C(R 2 )2, S, S(O), S(O)2, C(O), C(O)O, C(O)NR 1 , OC(O)O, N(R 2 )C(O)NR 2 ; Z is selected from a bond, O, C(R 2 )2; L 1 Selected from heterocyclic diyl-C1-C 10 -alkanediyl, C1-C 10 Alkanediyl, C2-C 10 Alkenyl, C2-C 10 Alkynediyl, C3-C 10 -cycloalkanediyl, C3-C 10 -cycloalkanediyl-C1-C 10 -Alkanediyl, aryldiyl, aryldiyl-C1-C 10 -alkanediyl, heterocyclodiyl, heterocyclodiyl-C(O), heteroaryldiyl, heteroaryldiyl-C1-C 10 Alkanediyl, C1-C6 alkanediyl-O-C1-C6 alkanediyl, C1-C6 alkanediyl-NR 1 -C1-C6 alkanediyl, C1-C6 alkanediyl-C(O)NR 1 -C1-C6 alkanediyl, wherein alkanediyl, alkenediyl, alkynyl, aryldiyl, heterocyclodiyl or heteroaryldiylheteroaryl is optionally independently selected from halogen, OH, oxy, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 、-C(O)NR 3 R 4 、-S(O)C1-C6 alkyl、-S(O)2NR 3 R 4 , aryl and -S(O)2C1-C6 alkyl; L 2 Selected from C1-C 10 Alkanediyl, C2-C 10 Alkenyl, C2-C 10 Alkynediyl, C3-C 10 -cycloalkanediyl, C3-C 10 -cycloalkanediyl-C1-C 10 -Alkanediyl, aryldiyl, aryldiyl-C1-C 10 -alkanediyl, heterocyclodiyl, heterocyclodiyl-C1-C 10 -alkanediyl, heterocyclodiyl-C(O), heteroaryldiyl, heteroaryldiyl-C1-C 10 Alkanediyl, C1-C6 alkanediyl-O-C1-C6 alkanediyl, C1-C6 alkanediyl-NR 1 -C1-C6 alkanediyl, C1-C6 alkanediyl-C(O)NR 1 -C1-C6 alkanediyl, wherein alkanediyl, alkenediyl, alkynyl, aryldiyl, heterocyclodiyl or heteroaryldiylheteroaryl is optionally independently selected from halogen, OH, oxy, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 、-C(O)NR 3 R 4 、-S(O)C1-C6 alkyl、-S(O)2NR 3 R 4 , aryl and -S(O)2C1-C6 alkyl; R 3 and R 4 Each independently selected from H, C1-C6 alkyl, C1-C6 acyl and C3-C 10 Cycloalkyl; or R 3 and R 4 Together with the atoms to which they are attached and any intervening atoms, they form a 5-14 membered heterocyclic ring, wherein the heterocyclic ring is optionally substituted with one or more substituents independently selected from halogen, OH, =O, CN, NO2, C1-C6 alkyl, C1-C6 alkoxy; in, Aryl is a cyclic aromatic hydrocarbon group having 1 to 3 aromatic rings; Arylene diyl is an organic radical derived from an aromatic divalent radical by removing two hydrogens; Heterocyclyl is a saturated or partially unsaturated 3-10 membered monocyclic, 7-12 membered bicyclic (fused, bridged or spiro) or 11-14 membered tricyclic ring system (fused, bridged or spiro) having one or more heteroatoms selected from O, N, S, P, Se or B; A heterocyclodiyl radical is a divalent functional group derived from a heterocycle by removing two hydrogen atoms from the ring atoms; Heteroaryl is a monovalent monocyclic or polycyclic aromatic group of 5 to 24 ring atoms, which contains one or more ring heteroatoms selected from N, O, S, P or B, and the remaining ring atoms are C; A heteroarenediyl radical is a divalent functional group derived from a heteroarene by removing two hydrogen atoms from ring atoms.

2. The compound according to claim 1, wherein The compound has formula (I): or a pharmaceutically acceptable salt, stereoisomer, solvate or tautomer thereof.

3. The compound according to claim 2, wherein The compound has formula (I') or formula (I"): or a pharmaceutically acceptable salt, stereoisomer, solvate or tautomer thereof.

4. The compound according to claim 1, wherein The compound has formula (II): or a pharmaceutically acceptable salt, stereoisomer, solvate or tautomer thereof.

5. The compound according to claim 4, wherein The compound has formula (II') or formula (II"): or a pharmaceutically acceptable salt, stereoisomer, solvate or tautomer thereof.

6. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, stereoisomer, solvate or tautomer thereof, wherein: R a Selected from H, C1-C6 alkyl, C2-C6 alkenyl, wherein the alkyl or alkenyl is optionally substituted by one or more substituents independently selected from halogen, OH, =O, NH2, CN, NO2; R b , R c , R d Each is independently selected from H, halogen, OH, NH2, CN, NO2, C1-C6 alkyl, C1-C6 alkoxy; X is selected from a bond, -O-, -NH-, -N(CH3)-, -CH2-, -S-, -S(O)-, -S(O)2-, -C(O)-, -C(O)O-, -C(O)NH-, -OC(O)O-, -NHC(O)NH-; Y selection key, -O-, -NH-, -N(CH3)-, -N(CH(CH3)2)-, -CH2-, -S-, -S(O)-, -S(O)2-, -C(O)-, -C(O)O-, -C(O)NH-, -OC(O)O-, -NHC(O)NH-; Z is selected from a bond, -O-, -CH2-; L 1 CH2-、-(CH2)2-、-(CH2)3-、-(CH2)4-、-(CH2)5-、-(CH2)6-、-CH2CH(CH3)CH2-、-CH(CH3)(CH2)2-、-CH2CH(CH3)(CH2)2-、-(CH2)2CH(CH3)(CH2)-、-CH2CH(CH3)CH(CH3)(CH 2)2-、-(CH2)2CH(CH3)(CH2)3-、-(CH2)2CH(CH3)CH(CH3)(CH2)2-、-CH2-O-CH2-、-CH2-O-(CH2)2-、-(CH2)2-O-(CH2)2-、-CH=CH-、-CH2-CH=CH-、-CH2-C(CH3)=CH-、-CH2-CH=C (CH3)-、-CH2-CH=CH-CH2-、-CH2-C(CH3)=CH-CH2-、-(CH2)2C(CH3)=CH-、-(CH2)2CH=CH CH2-、-(CH2)2C(CH3)=CHCH2-、-(CH2)2CH=C(CH3)CH2-、-(CH2)2C(CH3)=C(CH3)CH2-、- (CH2)2C(CH3)=CH(CH2)2-、-(CH2)2C(CH3)=C(CH3)(CH2)2-、-C≡C-、-C≡CCH2-、-C≡CCH(CH3)-、-CH2CH2CH2-NH-CH2CH2-、-CH2CH2CH2-N(CH3)-CH2CH2-、-CH2-C(O)NH-CH2CH2-、 L 2 CH2-、-(CH2)2-、-(CH2)3-、-(CH2)4-、-(CH2)5-、-(CH2)6-、-CH2CH(CH3)CH2-、-CH(CH3)(CH2)2-、-CH2CH(CH3)(CH2)2-、-(CH2)2CH(CH3)(CH2)-、-CH2CH(CH3)CH(CH3)(CH2)2-、-(CH2)2CH(CH3)(CH2)3-、-(CH2)2CH(CH3)CH(CH3)(CH2)2-、-CH2-O-CH2-、-CH2-O-(CH2)2-、-(CH2)2-O-(CH2)2-、-(CH2)2-O-(CH2)2-、-CH=CH- 、 -CH2-CH=CH-、-CH2-C(CH3)=CH-、-CH2-CH=C(CH3)-、-CH2-CH=CH-CH2-、-CH2-C(CH3)=CH-CH2-、-(CH2 )2C(CH3)=CH-、-(CH2)2CH=CHCH2-、-(CH2)2C(CH3)=CHCH2-、-(CH2)2CH=C(CH3)CH2-、-(CH2)2C(CH3) =C(CH3)CH2-、-(CH2)2C(CH3)=CH(CH2)2-、-(CH2)2C(CH3)=C(CH3)(CH2)2-、-C≡C-、-C≡CCH2-、-C≡C-CH(CH3)-、-CH2-C(O)NH-CH2-、-CH2-C(O)N(CH3)-CH2-、-CH2-C(O)NH-C(CH3)-、-CH2-C(O)NH-CH2CH2-、 Among them, L 1 and L 2 Optionally substituted with one or more substituents independently selected from halogen, OH, oxo, CN, NH2.

7. The compound according to claim 1, wherein The compound has formula (A-1): or a pharmaceutically acceptable salt, stereoisomer, solvate or tautomer thereof.

8. The compound according to claim 7, wherein The compound has the formula (A-1-a): or a pharmaceutically acceptable salt, stereoisomer, solvate or tautomer thereof.

9. The compound according to claim 7, wherein The compound has the formula (A-1-b): or a pharmaceutically acceptable salt, stereoisomer, solvate or tautomer thereof.

10. The compound according to claim 2, wherein The compound has formula (IA): or a pharmaceutically acceptable salt, stereoisomer, solvate or tautomer thereof.

11. The compound according to claim 10, wherein The compound has the formula (IAI): or a pharmaceutically acceptable salt, stereoisomer, solvate or tautomer thereof.

12. The compound according to claim 11, wherein The compound has the formula: or a pharmaceutically acceptable salt, stereoisomer, solvate or tautomer thereof, wherein t is an integer selected from 0, 1 and 2 and all other variables are as defined herein.

13. The compound according to claim 4, wherein The compound has formula (II-A): or a pharmaceutically acceptable salt, stereoisomer, solvate or tautomer thereof.

14. The compound according to claim 13, wherein The compound has the formula (II-AI): or a pharmaceutically acceptable salt, stereoisomer, solvate or tautomer thereof.

15. The compound according to claim 14, wherein The compound has the formula: or a pharmaceutically acceptable salt, stereoisomer, solvate or tautomer thereof, wherein t is an integer selected from 0, 1 and 2, and all other variables are defined herein.

16. A compound of formula (AA): or a pharmaceutically acceptable salt, stereoisomer, solvate or tautomer thereof, wherein R a is selected from C1-C6 alkyl, H, C2-C6 alkenyl, C2-C6 alkynyl, C3-C 10 Cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally independently selected from halogen, OH, =O, NR 3 R 4 、CN、NO2、COOR 1 ,CONR 3 R 4 is substituted with one or more substituents; R b , R c , R d Each is independently selected from H, halogen, OH, NH2, CN, NO2, C1-C6 alkyl and C1-C6 alkoxy, wherein the alkyl or alkoxy is optionally substituted with one or more halogen, CN; X is selected from a bond, O, NR 1 , C(R 2 )2, S, S(O), S(O)2, C(O), C(O)O, C(O)NR 1 、OC(O)O、N(R 2 )C(O)NR 2 , aromatic diyl; R 1 Selected from H, C1-C6 alkyl, C3-C 10 Cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 acyl, heterocyclic, aryl, heteroaryl and S(O)2R 2 , wherein the alkyl, alkenyl, alkynyl, heterocycle, cycloalkyl, aryl or heteroaryl is optionally independently selected from halogen, OH, NH2, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10 Substituted by one or more substituents selected from cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocycle, aryl, heteroaryl; Each R 2 Independently selected from H, C1-C6 alkyl, C3-C 10 Cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocycle, aryl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, heterocycle, cycloalkyl, aryl or heteroaryl is optionally independently selected from halogen, OH, NH2, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10 Substituted by one or more substituents selected from cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocycle, aryl, heteroaryl; Y is selected from a bond, O, NR 1 , C(R 2 )2, S, S(O), S(O)2, C(O), C(O)O, C(O)NR 1 , OC(O)O, N(R 2 )C(O)NR 2 ; Z is selected from a bond, O, C(R 2 )2; Ring A is selected from C3-C 10 - Cycloalkanes, aromatics, heterocyclics, heteroaromatics; W is (CH2) w ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10; L 2 Selected from C1-C 10 Alkanediyl, C2-C 10 Alkenyl, C2-C 10 Alkynediyl, C3-C 10 -cycloalkanediyl, C3-C 10 -cycloalkanediyl-C1-C 10 -Alkanediyl, aryldiyl, aryldiyl-C1-C 10 -alkanediyl, heterocyclodiyl, heterocyclodiyl-C1-C 10 -alkanediyl, heterocyclodiyl-C(O), heteroaryldiyl, heteroaryldiyl-C1-C 10 Alkanediyl, C1-C6 alkanediyl-O-C1-C6 alkanediyl, C1-C6 alkanediyl-NR 1 -C1-C6 alkanediyl, C1-C6 alkanediyl-C(O)NR 1 -C1-C6 alkanediyl, wherein alkanediyl, alkenediyl, alkynyl, aryldiyl, heterocyclodiyl or heteroaryldiylheteroaryl is optionally independently selected from halogen, OH, oxy, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 、-C(O)NR 3 R 4 、-S(O)C1-C6 alkyl、-S(O)2NR 3 R 4 , aryl and -S(O)2C1-C6 alkyl; R 3 and R 4 Each independently selected from H, C1-C6 alkyl, C1-C6 acyl and C3-C 10 Cycloalkyl; or R 3 and R 4 Together with the atoms to which they are attached and any intervening atoms, they form a 5-14 membered heterocyclic ring, wherein the heterocyclic ring is optionally substituted with one or more substituents independently selected from halogen, OH, =O, CN, NO2, C1-C6 alkyl, C1-C6 alkoxy; R 5 Selected from H, halogen, OH, oxy, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 、-C(O)NR 3 R 4 、-S(O)C1-C6 alkyl、-S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl.

17. A compound of formula (AB): or a pharmaceutically acceptable salt, stereoisomer, solvate or tautomer thereof, wherein R a is selected from C1-C6 alkyl, H, C2-C6 alkenyl, C2-C6 alkynyl, C3-C 10 Cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally independently selected from halogen, OH, =O, NR 3 R 4 、CN、NO2、COOR 1 ,CONR 3 R 4 is substituted with one or more substituents; R b , R c , R d Each is independently selected from H, halogen, OH, NH2, CN, NO2, C1-C6 alkyl and C1-C6 alkoxy, wherein the alkyl or alkoxy is optionally substituted with one or more halogen, CN; X is selected from a bond, O, NR 1 , C(R 2 )2, S, S(O), S(O)2, C(O), C(O)O, C(O)NR 1 、OC(O)O、N(R 2 )C(O)NR 2 , aromatic diyl; R 1 Selected from H, C1-C6 alkyl, C3-C 10 Cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 acyl, heterocyclic, aryl, heteroaryl and S(O)2R 2 , wherein the alkyl, alkenyl, alkynyl, heterocycle, cycloalkyl, aryl or heteroaryl is optionally independently selected from halogen, OH, NH2, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10 Substituted by one or more substituents selected from cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocycle, aryl, heteroaryl; Each R 2 Independently selected from H, C1-C6 alkyl, C3-C 10 Cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocycle, aryl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, heterocycle, cycloalkyl, aryl or heteroaryl is optionally independently selected from halogen, OH, NH2, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10 Substituted by one or more substituents selected from cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, heterocycle, aryl, heteroaryl; L 1 Selected from C1-C 10 Alkanediyl, C2-C 10 Alkenyl, C2-C 10 Alkynediyl, C3-C 10 -cycloalkanediyl, C3-C 10 -cycloalkanediyl-C1-C 10 -Alkanediyl, aryldiyl, aryldiyl-C1-C 10 -alkanediyl, heterocyclodiyl, heterocyclodiyl-C1-C 10 -alkanediyl, heterocyclodiyl-C(O), heteroaryldiyl, heteroaryldiyl-C1-C 10 Alkanediyl, C1-C6 alkanediyl-O-C1-C6 alkanediyl, C1-C6 alkanediyl-NR 1 -C1-C6 alkanediyl, C1-C6 alkanediyl-C(O)NR 1 -C1-C6 alkanediyl, wherein alkanediyl, alkenediyl, alkynyl, aryldiyl, heterocyclodiyl or heteroaryldiylheteroaryl is optionally independently selected from halogen, OH, oxy, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 、-C(O)NR 3 R 4 、-S(O)C1-C6 alkyl、-S(O)2NR 3 R 4 , aryl and -S(O)2C1-C6 alkyl; Y is selected from a bond, O, NR 1 , C(R 2 )2, S, S(O), S(O)2, C(O), C(O)O, C(O)NR 1 , OC(O)O, N(R 2 )C(O)NR 2 ; Z is selected from a bond, O, C(R 2 )2; Ring A is selected from C3-C 10 - Cycloalkanes, aromatics, heterocyclics, heteroaromatics; W is (CH2) W ; w is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10; u is an integer selected from 0 and 1; R 3 and R 4 Each independently selected from H, C1-C6 alkyl, C1-C6 acyl and C3-C 10 Cycloalkyl; or R 3 and R 4 Together with the atoms to which they are attached and any intervening atoms, they form a 5-14 membered heterocyclic ring, wherein the heterocyclic ring is optionally substituted with one or more substituents independently selected from halogen, OH, =O, CN, NO2, C1-C6 alkyl, C1-C6 alkoxy; R 5 Selected from H, halogen, OH, oxy, CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl-C1-C6 alkoxy, C1-C6 alkyl-NR 1 -C1-C6 alkyl, NR 3 R 4 、-C(O)NR 3 R 4 、-S(O)C1-C6 alkyl、-S(O)2NR 3 R 4 and -S(O)2C1-C6 alkyl.

18. A compound selected from the group consisting of: or a pharmaceutically acceptable salt, stereoisomer, solvate or tautomer thereof.

19. The compound according to claim 16, wherein The compound is selected from: or a pharmaceutically acceptable salt, stereoisomer, solvate or tautomer thereof.

20. A pharmaceutical composition comprising the compound according to any one of claims 1 to 19 or a pharmaceutically acceptable salt, stereoisomer, solvate or tautomer thereof, and a pharmaceutically acceptable carrier.

21. The pharmaceutical composition of claim 20, further comprising one or more additional pharmaceutically active agents.

22. A method for inhibiting EGFR kinase activity in a cell, comprising contacting the cell with a compound according to any one of claims 1 to 19 or a pharmaceutical composition according to claim 20 or 21.

23. The method according to claim 22, wherein: The contacting is in vitro or in vivo.

24. A method for treating, alleviating or preventing a disease or condition associated with EGFR kinase activity, comprising administering the compound of any one of claims 1 to 19 or the pharmaceutical composition of claim 20 or 21 to a subject in need thereof.

25. The method according to claim 24, wherein: The disease is a hyperproliferative disease and / or disorder responsive to the induction of cell death.

26. The method according to claim 24, wherein: The disease or condition is selected from lung cancer; lung cancer susceptibility 3 (LNCR3); squamous cell carcinoma of the lung; gliosarcoma; brain stem glioma; adenocarcinoma; colorectal cancer; glioblastoma; breast cancer; squamous cell carcinoma; small cell carcinoma of the lung; squamous cell carcinoma of the lung; inflammatory skin and intestinal disease of the newborn 2; gastric cancer; prostate cancer; squamous cell carcinoma of the head and neck; pancreatic cancer; brain cancer; ovarian cancer; esophageal cancer; giant cell glioblastoma; gliosarcoma; benign tumor of the lung; glioma; exanthema; endometrial carcinoma; adenoid cystic carcinoma; bladder cancer; Cowden syndrome 1; bronchioloalveolar adenocarcinoma; oligodendroglioma; hepatocellular carcinoma; nonsquamous non-small cell lung carcinoma; high-grade glioma; glial tumors; squamous cell carcinoma of the larynx; nonpapillary renal cell carcinoma; chronic kidney disease; nasopharyngeal carcinoma; oral squamous cell carcinoma; lung disease; interstitial lung disease; adenosquamous lung cancer; bile duct carcinoma; familial meningioma; small cell carcinoma; tumor predisposition syndrome; pancreatic adenocarcinoma; diarrhea; breast ductal carcinoma.

27. The method according to claim 26, wherein: The disease or condition is lung cancer.

28. The method according to any one of claims 23 to 27, wherein: The subject is a mammal.

29. The method according to claim 28, wherein: The subject is a human.

Images